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The prophylactic benefit of aspirin in the prevention of preeclampsia is now widely 
recognized and increasingly utilized. However, its mechanism of action and optimal 
clinical utility in the prevention of preeclampsia remains a subject of ongoing research.  
 
This thesis examined the mechanism of action of aspirin in preventing preeclampsia with 
specific focus on its anti-inflammatory role, through the 15-epilipoxin-A4, aspirin 
triggered lipoxin (ATL), pathway. This thesis also examined for the influence of dose of 
aspirin in pregnancy through a pharmacokinetic assessment, and the influence of 
inadequate adherence to aspirin on the desired clinical outcomes in high-risk pregnancy. 
Additionally, this thesis also examined for factors that influenced women’s adherence to 
aspirin in pregnancy.  
 
A non-interventional, multi-centre, longitudinal cohort study was prospectively 
undertaken to achieve the aims of this thesis. In keeping with recent data, this thesis 
demonstrated that aspirin is an effective prophylactic intervention for preeclampsia 
amongst high-risk women when adequate adherence is observed. In addition to its 
known anti-platelet effect, the outcomes of this thesis suggest that aspirin is likely to play 
a role in placental development through its ATL mediated anti-inflammatory effect in 
high-risk pregnant women. Additionally, the studies in this thesis also suggest the 
potential need for aspirin dose adjustment in pregnancy given its altered 
pharmacokinetic in pregnancy. Importantly, this thesis also demonstrates the 
importance of adequate adherence with aspirin and emphasizes on the importance of 
assessment of adherence to aspirin in pregnancy, both in clinical and research settings.  
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1.1 Preeclampsia and its pathophysiology 
Preeclampsia is a hypertensive disorder of pregnancy that affects 8 – 10% of all 
pregnancies globally and is the indication for 20% of labour inductions and 15% of 
caesarean sections annually (2). It is defined as the onset of maternal hypertension after 
20 weeks of gestation with clinical and/or biochemical features of end organ impairment 
(Figure 1). Whilst the general incidence of preeclampsia remains static, the incidence of 
maternal and fetal morbidity and mortality, particularly in developing countries, is 
increasing and remains the second commonest cause of maternal mortality 
internationally (2-4).  
 
Figure 1: Clinical and biochemical features of Preeclampsia.   
Adapted from: Shanmugalingam et al. Tackling Preeclampsia – A three stage management 
strategy. How To Treat Edition of Australian Doctors (2019). 
SBP: systolic blood pressure, DBP: diastolic blood pressure 
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The understanding of the pathophysiology of preeclampsia continues to grow, however, 
at the time of this thesis, it remains a condition of heterogenous theories. The most 
commonly cited theory  describes impaired placental development in the first trimester 
that later results in the clinical syndrome (5, 6)– this is best simplified into a two-stage 
model (Figure 2).  
 
 
Figure 2: Two stage pathophysiology of preeclampsia.  
Adapted from: Shanmugalingam R et al, Aspirin in the prevention of preeclampsia: the 
conundrum of how, who and when. Journal of Human Hypertension 33, 1–9 (2019). 
PlGF: placental growth factor, sFlt-1: soluble fms-like tyrosine kinase -1, HELLP: Haemolysis, 
Elevated Liver enzymes, Low Platelet count, IUGR: intrauterine growth restriction. 
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1.1.1 Stage 1: Impaired placentation 
Stage one of the pathophysiology describes impaired cytotrophoblast invasion and 
pseudovasculogensis of the maternal uterine arteries. In normal pregnancy, the maternal 
spiral arteries are invaded by placental cytotrophoblast cells that replaces the endothelial 
lining of the spiral arteries and initiates pseudovasculogenesis, resulting in remodelling 
of the vessel wall (7). These alterations result in vasodilatation of the spiral arteries, 
allowing for an increase in placental blood flow with reduced resistance (8, 9). In 
preeclampsia, the cytotrophoblastic invasion of maternal spiral arteries is impaired, 
resulting in narrow spiral arteries that perfuses the placental bed with higher resistance 
(5). 
 
Cellular control of cytotrophoblast invasion depends on interactions between maternal 
decidua and fetal trophoblast, and is determined by local oxygen tension and immune-
mediated interactions (10). In-vitro studies have demonstrated that increased oxygen 
tension inhibits cytotrophoblasts from differentiating into cells with “invasive” 
phenotype and reduces expression of vascular endothelial (VE)-cadherin, an endothelial 
junction molecule, that helps regulate cytotrophoblast invasion (11).   
 
In addition to oxygen tension, immune mechanisms are also thought to play a role in 
cytotrophoblast invasion and pseudovasculogenesis. Redman et al described 
placentation as nature's transplant, drawing parallel to a semi-allogenic transplant, 
except, it is the placenta, and not the fetus that constitutes the 'transplant' in pregnancy 
(11). The placenta plays an important role in maintaining a balance; allowing for 
trophoblast invasion and adequate pseudovasculogenesis, whilst also preventing 
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uncontrolled trophoblast invasion (12). The maternal immune system maintains this 
balance by preventing overly robust trophoblast invasion whilst also preventing an 
exaggerated immune response in reaction to the trophoblastic invasion. In normal 
pregnancy, there is a predominance of a Th2 cytokine profile that consists of anti-
inflammatory properties. The Th2-type cells secrete interleukin-4 (IL-4), interleukin-5 
(IL-5), interleukin-6 (IL-6), interleukin-10 (IL-10) and has been shown to contribute 
towards trophoblast invasion and differentiation along with placental proliferation and 
angiogenesis (20, 21). Additionally, IL-10 has been shown to be a strong suppressor of 
pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-α) and 
interferon-gamma (IFN-ɣ) with additional anti-apoptotic features (22). In women at risk 
of preeclampsia, there is a predominance of Th1 pro-inflammatory cytokine profile, often 
from the first trimester, resulting in an abnormal Th1/Th2 balance (23-25). Cytokines 
interleukin-1 (1L-1), interleukin-1β (1L-1β), interleukin-2 (IL-2), interleukin-8 (IL-8), 
TNF-α and IFN-ɣ are characteristic of Th1-type immunity and are associated with cell-
mediated cytotoxic and inflammatory response. Therefore, the abnormal Th1/Th2 
maternal cytokine balance in the first trimester is thought to play a role in impaired 
placentation and angiogenesis (11). 
 
Genetic studies suggest that the susceptibility to preeclampsia may be influenced by 
polymorphic human leukocyte antigen-C (HLA-C) ligands and killer immunoglobulin 
receptors (KIRs) present on natural killer (NK) cells (5, 7). These data suggest that 
alterations in NK cell signalling may mediate the abnormal placentation noted in 
preeclampsia (12). It is hypothesized that the shallow placentation and inadequate 
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transformation of spiral arteries that occurs in Stage 1 of the disease subsequently leads 
to  placental ischemia and the maternal syndrome of preeclampsia (Stage two) (7, 13). 
 
1.1.2 Stage 2: Clinical manifestation of the syndrome 
Two endogenous anti-angiogenic proteins of placental origin—circulating soluble fms-
like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng) have a role in contributing 
towards the pathogenesis of preeclampsia in response to placental ischemia in stage two 
of the disease process (14, 15). sFlt-1 is a splice variant protein of vascular endothelial 
growth factor (VEGF) receptor Flt-1 and acts as a potent antagonist to VEGF and placental 
growth factor (PlGF). Plasma sFlt-1 concentrations have been found to be increased in 
women with preeclampsia approximately 2-5 week preceding the onset of clinical 
symptoms (6, 14, 16) along with a decrease in plasma PlGF concentrations (6, 16). In 
animal models, increasing circulating sFlt-1 resulted in a syndrome of hypertension, 
proteinuria, and glomerular endotheliosis, resembling preeclampsia (Figure 1) (5, 14, 
15). The increased understanding of the sFlt-1/PlGF imbalance in the second stage of the 
disease process has led to the clinical utility of this ratio in predicting preeclampsia in 
women with suspicious clinical features (17-20). 
 
Whilst the role of sFlt-1 and PlGF imbalance in the second stage of preeclampsia is well 
recognized, PlGF’s additional role in the first stage of the disease process is continuing to 
strengthen. PlGF is a member of the VEGF family and is predominantly expressed in the 
placenta, although it is also expressed at low levels in many other tissues. Like VEGF, PlGF 
is pro-angiogenic as it enhances the activity of VEGF by competitively binding to VEGFR-
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1 receptors. The role of PlGF in placental development is likely to be in the promotion of 
development and maturation of the placental vascular system through its influence on 
differentiation of uterine NK cells and proliferation of trophoblast cells (20, 21). In 
normal pregnancy, maternal plasma concentration of PlGF increases throughout 
gestation, peaking at approximately 26–30 weeks gestation with some variation due to 
smoking status, ethnicity, and pre-existing diabetes (20, 22). However, women at risk of 
developing preeclampsia and intrauterine growth restriction (IUGR) have low first 
trimester plasma PlGF concentration with this now being recognized as a biomarker of 
poor placentation (23-25). Consequently, PlGF is now used as a validated, commercially 
available, maternal biomarker as part of the first trimester screening algorithm to 
identify women who are at risk of developing preeclampsia (25, 26). 
 
1.2 The use of aspirin in the prevention of preeclampsia 
The understanding of the thromboxane-2 (TXA2) and prostaglandin-2 (PGI2) imbalance 
in preeclampsia led to the trial use of aspirin in managing preeclampsia in 1978 (21-23). 
Subsequently, aspirin was observed to have a prophylactic role in preventing 
preeclampsia in 1985, when Beaufils et al used a combination of aspirin (150 mg) and 
dipyridamole (300 mg) in first trimester and demonstrated a reduction in the rate of 
preeclampsia in the treatment group (0/48 vs 6/45; p<0.05) (24). Similarly, in 1991, the 
EPREDA trial proposed an added benefit of aspirin (150 mg daily) in reducing the rate of 
IUGR in comparison to placebo (20/156 [13%] vs 19/73 [26%]; p<0.02) (25).  However, 
subsequent studies on prophylactic aspirin were contradictory, with equivocal or 
absence of benefit in preventing preeclampsia (26-28). These studies, however, were 
confounded by varying doses of aspirin, heterogenous inclusion criteria and varied 
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timing of aspirin initiation. In the 2000s, aspirin re-emerged as a promising prophylactic 
agent (29-31). Between 2007 and 2010, Bujold et al and Askie et al demonstrated a 
benefit in the use of aspirin (RR 0.47: 95% CI 0.34-0.65) (30, 31). In 2017, Rolnik et at 
demonstrated a significant risk reduction of up to 70% when 150mg of aspirin is 
commenced prior to 16 weeks of gestation through a landmark multicentre, placebo 
controlled, randomized control trial (29). Whilst these studies have demonstrated 
variable outcomes, collectively, they provide useful safety data in demonstrating a lack of 
aspirin related complications in both the mother and fetus (26, 27, 30, 32).  
 
Risk stratifying women for preeclampsia is challenging. Current clinical guidelines 
suggest risk stratification based on clinical history (22, 23), however, a meta-analysis 
demonstrated that clinical history alone has a detection rate of 37% for early-onset 
preeclampsia and 28.9% for late-onset preeclampsia (33). In nulliparous women, clinical 
history alone detects 37% of preeclampsia for a false positive rate of 5% (34). Prior 
history of preeclampsia was the second strongest predictor factor, which is not applicable 
to nulliparous women (35). Mean arterial pressure (MAP), compared to systolic or 
diastolic reading alone has been discussed as a clinical predictor of preeclampsia. A 
prospective screening study utilising MAP (expressed as log multiple of the median) 
measured between 11+0 and 13+6 weeks gestation and maternal variables demonstrated 
a preeclampsia detection rate of 62.5% for a false-positive rate of 10% (36, 37). A 
predictive testing model incorporating maternal factors and second trimester uterine 
artery pulsaltility index (PI) demonstrated a detection rate for early and late 
preeclampsia of 100% and 56.4%, respectively for a false positive rate of 10% (36). More 
recently, the combination of maternal placental biomarkers; pregnancy associated 
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plasma protein A (PAPP-A) and PlGF along with MAP and clinical history has been shown 
to be sensitive, detecting 96% of cases of preeclampsia requiring delivery before 34 
weeks and 54% of all cases of preeclampsia with a false-positive rate of 10% (38). Whilst 
screening algorithms have been shown to effectively identify women at risk, particularly 
nulliparous women, its use is often limited by accessibility to the required resources. 
Therefore, many centres rely on clinical history for risk assessment. In keeping with this, 
the current guidelines recommend the use of clinical history in risk stratifying women 
(39-41).  This, however, may change based on the accessibility and cost- benefit analysis 
of the new screening markers.  
 
The importance of timing of initiation of aspirin is now recognized (30, 42). Bujold et al’s 
meta-analysis demonstrated that commencing low-dose aspirin prior to 16 weeks of 
gestation significantly reduced the rate of preeclampsia (RR 0.47: 95% CI 0.34-0.65) and 
IUGR (RR 0.44: 95% CI 0.30-0.65)(30). The observed benefit was lost when aspirin was 
commenced after 16 weeks of gestation (preeclampsia: RR 0.81: 95% CI 0.63-1.03 and 
IUGR: RR 0.98: 95% CI 0.87-1.10) (30). Contrary to this, another meta-analysis suggested 
that the 16 weeks gestation cut-off was not significant (43). Meher et al conducted an 
individual participant dataset analysis of the PARIS (Perinatal Antiplatelet Review of 
International Studies) Collaboration dataset and suggested that the outcomes with low-
dose aspirin were consistent when commenced before or after 16 weeks of gestation (RR 
0.90: 95% CI 0.79 - 1.03) for <16 weeks and for ≥16 weeks (RR 0.90: 95% CI 0.83 - 0.98)  
(interaction test p = 0.98)(31, 43). The analysis of the PARIS Collaboration  data, however, 
only demonstrated a modest overall preeclampsia reduction of ~10% with the use of 
prophylactic aspirin (43). The current guidelines suggest initiating aspirin before 16 
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weeks of gestation (39-41), however, recent studies suggest earlier initiation of aspirin 
(29, 44, 45). This, however, has not been assessed with a prospective randomised trial at 
the time of this thesis. 
 
1.3 The gaps in the literature 
1.3.1 Mechanism of action of aspirin 
Aspirin is a non-selective, irreversible cyclooxygenase-1 (COX-1) inhibitor (Figure 3). It 
prevents the production of TXA2 in platelets by acetylating a serine residue at position 
529 of the COX-1 isoform. This  results in an anti-thrombotic effect with a decrease in the 
TXA2/PGI2 ratio (46). 
 
Figure 3: Mechanisms of action of aspirin in the prevention of preeclampsia.  
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Adapted from Shanmugalingam R et al, Aspirin in the prevention of preeclampsia: the 
conundrum of how, who and when. Journal of Human Hypertension 33, 1–9 (2019). 
15R-HETE: 15R-hydroxyeicosatetraenoic acid, ATL: Aspirin triggered lipoxin/15-
epilipoxin-A4, COX-1: Cyclooxygenase-1, COX-2: Cyclooxygenase-2, ERK: Extracellular-
signal-regulated kinase, IL-1β: Interleukin 1-beta, IL 6: Interleukin 6, IL 8: Interleukin 8, IL 
10: Interleukin 10, MMP3: Matrix Metallopeptidase 3, TNF-α: Tumour Necrosis Factor Alpha 
 
Early studies on the mechanism of aspirin’s action in preeclampsia demonstrated an 
aspirin-induced decrease of TXA2 concentration and alteration of the TXA2/PGI2 ratio 
(47, 48). Roberts et al noted a dose mediated response with TXB2 (inactive metabolite of 
TXA2) and prostacyclin production in both non-pregnant female and male volunteers 
(49). Their study demonstrated that 50 mg of aspirin daily reduced TXB2 plasma 
concentration in almost 95% of their volunteers without an alteration in prostacyclin 
concentration. The use of 100-300 mg of aspirin a day, however, completely reduced 
TXB2 concentration and partially reduced prostacyclin concentration by 27% (49). When 
examined in pregnant women,  Sibai et al demonstrated a dose response reduction in 
TXA2 plasma concentration (of up to 98%) after 1 week of 80 mg aspirin therapy (50).  It 
was then hypothesized that aspirin improves placental blood flow and minimizes risk of 
placental thrombosis by reducing TXA2 and PGI2 concentrations. Studies that examined 
the correlation between TXA2/PGI2 concentration and maternal uterine artery pulsatile 
indexes (PI) demonstrated that aspirin reduced platelet aggregation and inhibited 
vasoconstriction with enhanced uterine blood flow (51). At that point, clinically, however, 
aspirin, had only demonstrated a modest benefit in the prevention of preeclampsia, with 
a risk reduction of 10- 20% despite the postulated modulation of the TXA2/PGI2 
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imbalance (52, 53). One explanation for this variation is that the TXA2/PGI2 imbalance is 
not the only pathogenic pathway for preeclampsia. There may also be a wide inter-patient 
variation in the degree of aspirin effect in addition to a gestation specific effect. This is 
partially answered in the observations that the preventative effect of aspirin is greater 
with early onset preeclampsia than late onset preeclampsia (29) and that the 
prophylactic benefit of aspirin is most evident when commenced prior to 16 weeks of 
gestation; with 16 weeks corresponding with the time at which placentation is complete 
(42). This suggests that aspirin potentially, has greater influence on placental 
development and less so on maternal biochemical dysregulation (42, 44).  
 
In 1989, Claria et al described the generation of endogenous 15-epilipoxin A4, better 
known as aspirin-triggered lipoxins (ATL) with the use of aspirin (54). The biosynthesis 
of ATL occurs through the cyclooxygenase-2 (COX-2) pathway (Figure 3).  Aspirin 
acetylates COX-2, switching its catalytic activity and enabling the conversion of 
endogenous arachidonic acid to 15R-hydroxyeicosatetraenoic acid (15R-HETE) (54, 55). 
The acetylated form of COX-2 remains active in vascular endothelial cells and mucosal 
epithelial cells to produce 15R-HETE. The 15R-HETE generated by endothelial and 
epithelial cells is then transformed by leukocyte 5-lipoxygenase into 15-epilipoxin-A4 and 
15-epilipoxin-B4. Given that ATL is the endogenous 15R enantiomers of endogenous 
Lipoxin-A4 (En-Lipoxin-A4), it shares many bioactivities with En-Lipoxin-A4, including 
downregulation of polymorphonuclear neutrophils (PMN) dependent acute 
inflammation (56, 57).  ATL is 50% less effectively enzymatically converted to its 
biologically inactive group of 15-oxo-metabolites in comparison to En-Lipoxin-A4. 
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Therefore, consequently, ATL is found to have a 2-fold greater half-life compared to En-
Lipoxin-A4 (57). 
 
Given its anti-inflammatory properties, ATL has been shown to block the generation of 
reactive oxygen species in endothelial cells, inhibit nuclear factor kappa-light-chain- 
enhancer of activated B cells (NF-Kb) activation and tumour necrosis factor alpha (TNF-
α) secretion in activated T cells (Figure 3) (55, 58-60). This is supported by studies where 
the use of exogenous ATL have demonstrated positive outcomes in experimental models 
of inflammatory conditions such as peritonitis (61), colitis (62), ischemic reperfusion 
injury (61) and angiogenesis (56). The endogenous generation of ATL with aspirin 
consumption was first confirmed by Fiorucci et al in 2003 (63). This was further 
demonstrated by Chiang et al who showed a rise in ATL concentration with low dose 
aspirin (81 mg) (0.25 ± 0.63 ng/ml, p = 0.04).  
 
More recently, En-Lipoxin-A4 and ATL have been shown to have a role in reproductive 
medicine. Xu et al’s described a two-fold reduction En-Lipoxin-A4 in women with 
established preeclampsia (64). This was also demonstrated in a lipopolysaccharide (LPS) 
induced preeclampsia rat model (64, 65). Furthermore, low first trimester plasma En-
Lipoxin-A4  concentration has also been proposed as a potential screening biomarker in 
identifying women who are at risk of intrauterine growth dysregulation (66). Cell culture 
studies have demonstrated that exogenous ATL has the potential to reverse the 
inflammatory process observed in preeclampsia by upregulating IL-10 and nitric oxide 
(NO) whilst downregulating the generation of TNF -α (67, 68). Given this, the role of ATL  
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production with aspirin, in high-risk women with En-Lipoxin-A4 dysregulation is of 
growing interest, however, remains unclear (69). 
 
1.3.2 Clinical use of aspirin – influence of dose, adherence, and 
resistance 
The relatively modest benefit of prophylactic aspirin in some obstetric studies have 
raised questions on optimal aspirin dosing, aspirin resistance and non-adherence 
amongst high-risk pregnant women. Initial studies that demonstrated prophylactic 
benefit of aspirin,  prescribed a daily dose of 150-300 mg (24). Subsequent studies, 
however, used lower dose ranging from 75 – 150 mg daily (30, 42), whilst more recent 
studies suggest better clinical outcomes with the use of 150 mg daily (44, 70). Most 
guidelines at the time of this thesis do not specify a recommended dose of aspirin but  
suggest a range of 75 – 150 mg with 100 mg being the most commonly recommended 
(39, 71). The use of 150 mg in recent studies, however, has resulted in a shift towards the 
use of 150 mg in some guidelines (72). Nevertheless, there remains a significant paucity 
in clinical and pharmacokinetic data that directly compares the use of 100 mg to 150 mg 
of aspirin in pregnant women to support such a change in clinical practice. It, therefore, 
remains unclear if the use of 150 mg daily results in better bioavailability of aspirin and 
consequently, better clinical outcomes.  
 
Aspirin non-responsiveness or resistance, refers to a lack of anti-platelet action or 
desired clinical effect with the use of aspirin (73). Multiple factors such as platelet 
turnover, dose of aspirin and patient's weight have been shown to contribute towards 
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aspirin non-responsiveness in the non-pregnant population (Figure 4) (73, 74). Non-
obstetric cardiology studies have demonstrated a 2 to 3 fold higher incidence of 
morbidity and mortality with aspirin non-responsiveness, suggesting the need to further 
examine its actual prevalence (75, 76). Subsequent studies, however, attributed 50% of 
aspirin non-responsiveness to inadequate adherence, suggesting inadequate adherence 
as the strongest confounder in aspirin non-responsiveness (77, 78). 
 
 
Figure 4: Factors thought to contribute toward towards aspirin non-responsiveness. 
Adapted from Shanmugalingam R et al, Aspirin in the prevention of preeclampsia: the 
conundrum of how, who and when. Journal Human Hypertension 33, 1–9 (2019). 
COX 1: Cyclooxygenase-1, COX 2: Cyclooxygenase-2, GP IIB/IIIA: Glyocprotein IIB/IIIA, 
mRNA: messenger ribonucleic acid, vWF: von Willebrand factor 
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In obstetrics, the actual prevalence of clinical aspirin resistance or non-responsiveness in 
the pregnant cohort is unknown. Caron et al’s study showed that approximately 30% of 
pregnant women demonstrated a lack of laboratory response to aspirin at 81 mg, based 
on platelet function analyzer (PFA-100) assessment (79).  The lack of PFA-100 response 
was overcome with a higher dose of aspirin (162 mg daily) (79).  It was, however, unclear 
if the observed lack of biochemical response with 81mg of aspirin was a result of true 
aspirin resistance or lack of adherence as demonstrated by non-obstetric aspirin studies. 
Non-adherence with prescribed medications amongst pregnant women is reported to 
vary between 20-80% (83-85). Yet, only 30% of all obstetric aspirin studies over the last 
45 years have assessed for adherence with aspirin. Even so, adherence was inconsistently 
defined and assessed in these studies (80, 81). Recent data suggests that high-risk women 
will have to be at least 90% adherent with their prescribed aspirin to benefit from it (81). 
Most studies have utilised indirect, qualitative measure of adherence through self-
reporting questionnaires to assess adherence (80, 81). Whilst qualitative assessment 
provides a convenient and cost effect method of assessment, its reliability is highly 
questionable, given the potential for reporting and recall bias (82). The use of 
quantitative assessment of adherence with aspirin, through platelet aggregation makers 
or metabolite markers of aspirin are more reliable methods of  assessment of adherence 
(83, 84). However, its use is limited by the cost and need for laboratory expertise. Given 
the variability in the current literature, the actual prevalence of aspirin non-adherence 
amongst high-risk pregnant women and its influence on their desired clinical outcome 
remains undetermined. 
 
CLINICAL AND PROTEIN CORRELATIONS OF PROPHYLACTIC TREATMENTS FOR PREECLAMPSIA 
 
  Page 40 of 137 
 
Other factors that may contribute towards aspirin non-responsiveness includes 
difference in aspirin preparation: enteric coated (EC) vs non-enteric coated (Non-EC), 
effect of smoking and presence of gene polymorphism or cellular dysregulation (Figure 
4) (85-87). The consensus on the recommended preparation of aspirin in pregnancy 
remains unclear. Enteric coated (EC) aspirin delays and reduces systemic absorption by 
~ 20% in healthy non-pregnant volunteers (88-90). These factors, however, have not 
been examined in pregnancy and its influence on the clinical efficacy of aspirin in high-
risk pregnancies remains unknown. 
 
1.4 The rationale of this thesis: Aims and Objectives 
This thesis was aimed at answering the research questions relating to an alternative 
mechanism by which aspirin reduces the risk of preeclampsia and to examine factors 
(aspirin dose, adherence, and resistance) that influences the desired obstetric outcomes. 
 
 Chapter 4 (Scholarly Research Paper 1): Mechanism of action of aspirin 
This chapter examines the difference in longitudinal En-Lipoxin-A4 concentration 
in normal pregnancy compared to high-risk pregnancy and the influence of aspirin 
on maternal plasma concentration of ATL, PlGF and selected cytokine profile of 
high-risk pregnancy. 
 
  Chapter 5 (Scholarly Research Paper 2): Pharmacokinetics of aspirin in 
pregnancy 
The chapter examines the pharmacokinetics of aspirin in pregnancy.  
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 Chapter 6 (Scholarly Research Paper 3): Aspirin resistance and non-
adherence in pregnancy 
This chapter examines the prevalence of aspirin resistance and non-adherence 
amongst high-risk pregnant women and its influence on obstetric outcomes. 
 
 Chapter 7 (Scholarly Research Paper 4): Factors that influence adherence to 
aspirin in pregnancy 
This chapter examines patient reported factors that influences adherence with 
aspirin in pregnancy. 
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2.1 Longitudinal cohort study  
2.1.1 Participant recruitment  
This study was conducted as a non-interventional, observational, longitudinal cohort 
study. Pregnant women were opportunistically recruited from three outpatient high-risk 
pregnancy clinics across the South Western Sydney Local Health District (SWSLHD), 
Australia. The three hospitals were Liverpool, Bankstown, and Campbelltown Hospitals 
(Figure 5). Ethics approval was obtained (South Western Sydney Local Health District 
(SWSLDH) human ethics committee) (HE 16/184) and participants provided written 
informed consent to participate in this study. 
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Figure 5: Area map of the South Western Sydney Local Health District 
Adapted from SWSLHD planning unit 
https://www.swslhd.health.nsw.gov.au/planning/swslhdcommunities.html 
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Liverpool Hospital is a tertiary referral unit with an annual delivery rate of 4000 women.  
Bankstown and Campbelltown Hospitals are both outer metropolitan centres with an 
annual delivery rate of 2500 and 3500 respectively (91) .  All pregnant women at the 
high-risk clinics were risk stratified by their treating clinicians based on the National 
Institute for Health and Care Excellence, UK (NICE) clinical guidelines or the Fetal 
Medicine Foundation (FMF) first trimester screening algorithm (Table 1). Based on the 
NICE guidelines, the clinicians commenced aspirin in women who were found to have 1 
major risk factor or at least 2 moderate risk factors (35). The FMF screening scans were 
performed in private medical imaging facilities external to the hospital. The treating 
clinicians commenced women on aspirin based on their risk as identified by the FMF 
algorithm. Women were advised to take either 100 mg or 150 mg of aspirin by their 
clinicians based on the centre specific practise. A large study favouring the use of 150 mg 
of aspirin (29) was published mid-way through the recruitment of this longitudinal study, 
however, given the lack of strong recommendation from clinical guidelines, some centres 
within the SWSLHD continued to prescribe 100 mg of aspirin. There were no alteration 
to the initial prescribed dose of aspirin (no cross over between 100 mg and 150 mg of 
aspirin). All women who participated in this study underwent their antenatal care at a 
SWSLHD public hospital. 
 
The inclusion and exclusion criteria were as below: 
Inclusion criteria: 
 Risk stratified as high- risk for preeclampsia by treating clinician  
 ≤ 20 weeks gestation at time of recruitment (estimated gestation as verified by 
dating scan) 
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 ≥ 20+1 weeks of gestation at time of recruitment 
 Non-English-speaking  
 Unable to provide written informed consent 
  < 16 years of age 
 Commenced on aspirin prior to recruitment 
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Table 1: Risk stratification criteria. 
NICE: National Institute for Health and Care Excellence, FMF: Fetal-Maternal Medicine, 
BMI: Body mass index, MoMs: Multiple of the Median, MAP: Mean arterial pressure, PI: 
pulsatility index, PlGF: placental growth factor, PAPP-A: pregnancy-associated plasma 
protein-A  
NICE Guidelines (35) FMF First trimester screening (92) 
Major risk factors 
• Chronic hypertension 
• Autoimmune conditions 
• Chronic kidney disease  
• Previous preeclampsia 
• Type 1 or type 2 diabetes 
Moderate risk factors 
• First pregnancy 
• Age 40 years or older 
• Pregnancy interval of more than 10 years 
• BMI of ≥ 35 kg/m2  
• Family history of preeclampsia 
• Multi-fetal pregnancy. 
FMF first trimester screening with 
combined MoMs of maternal MAP, 
uterine artery PI, PlGF and PAPP-A into 
an algorithm with a cut off of 1:100. 
CLINICAL AND PROTEIN CORRELATIONS OF PROPHYLACTIC TREATMENTS FOR PREECLAMPSIA 
 
  Page 48 of 137 
 
2.1.2 Sample size  
Sample size was calculated based on the assumption that the untreated high-risk 
pregnant women have a preeclampsia-risk rate of 40% and that aspirin treated high-risk 
pregnant women will have a 50% reduction in preeclampsia-risk compared to the 
untreated group (93). Thus, approximately 60 women in each group (aspirin and non-
aspirin) group would be needed to have 80% power assuming an alpha (two tailed) of 
0.05. The target recruitment number was inflated to 220 women in total to allow for a 
predicted 20% dropout in both groups and a high prevalence (50%) of inadequate 
adherence.  
 
2.1.3 Study protocol  
Blood samples and clinical data were collected prospectively at baseline (prior to first 
dose of aspirin). Subsequently, serial blood samples, clinical data and self-reported 
adherence assessment was conducted at 16, 20, 24, 28, 32 and 36 weeks of gestation 
(Figure 6). High-risk pregnant women who were not prescribed aspirin, either due to 
aspirin intolerance or delayed presentation (between 16+1-20 weeks of gestation) 
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Figure 6: Illustrative representation of study protocol. 
 
Blood samples were collected via a 21FG Vacutainer Push Button needle (Becton, 
Dickinson and Company USA) into 3 x 4 ml VACUETTE® K2EDTA tubes (Greiner Bio-One 
International) and 2 x 3.8 ml tubes containing 0.38 ml of 0.129 mol/l buffered sodium 
citrate (pH 5.5) for PFA-100 analysis. Samples in two of the three VACUETTE® K2EDTA 
tubes were centrifuged immediately at 3000 rpm for 10 minutes, plasma was aliquoted 
(220 µL) and stored at -80⁰C until analysis. The third VACUETTE® K2EDTA tube and both 
sodium citrate tubes were sent to the South Western Sydney pathology service at 
Liverpool Hospital, NSW, Australia (National Association of Testing Authorities, Australia 
(NATA) accredited) at room temperature for a full blood count and PFA-100 assessment 
within 4 hours of collection. The investigators were blinded to the PFA-100 results till 
after study completion. Clinical data were collected in real time at each time point. Details 
on assessment of self-reported adherence is as elaborated under Chapter 2.4.1 
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2.2 Biochemical analysis 
2.2.1 Magnetic Luminex® analysis  
Simultaneous quantitative analysis of plasma IL-1β, TNF-α, IL-8, IL-10 and IFN-γ were 
performed with the use of the Magnetic Luminex® Performance multiplex human high 
sensitivity cytokine premixed kit A (R&D Systems, Minnesota, USA). Standards, reagents 
and undiluted plasma samples were prepared and assayed in duplicates based on the 
manufacturer’s manual with the use of HydroFlex® microplate washer (Tecan Trading 
AG, Switzerland) (94).  Briefly, cytokine-specific antibodies were pre-coated on the 
magnetic microplates followed by the addition of 100 µL of undiluted plasma sample into 
each well. Biotin-antibody cocktails, specific to the cytokines, were added to each well. 
Streptavidin-Phycoerythrin conjugated secondary antibody was used for detection. 
Prepared microplates were analysed with Luminex® 100/200® system (Luminex 
Corporation, Texas, USA).  
 
Quantitative data for each cytokine was derived based on the microparticle regions 
specified by the manufacturer (94) and the respective standard curves by utilizing 
xPONENT® software (Luminex Corporation, Texas, USA) and presented in pg/mL. 
Samples with intra and inter-assay variation of more than 10% were repeated.  
 
2.2.2 Platelet Function Analyzer (PFA-100) analysis 
PFA-100 analysis refers to the assessment of primary haemostasis under sheer stress 
with a benchtop automated instrument, PFA-100 analyzer®. The PFA-100® (Dade 
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Behring, Düdingen, Switzerland) instrument is composed of a microprocessor-controlled 
device and single-use test cartridges. The test cartridges consist of a sample reservoir, a 
capillary and a membrane coated with 2 µg equine type I collagen and either 10 µg epi-
nephrine bitartrate (EPI cartridge) or 50 µg adenosine 5’-diphosphate (ADP cartridge). 
Blood samples were analysed in duplicates within 4 hours of collection. Women’s platelet 
count was assessed prior to PFA-100 analysis. Samples from women with platelet count 
of <100 x 109/L were not assessed to minimize erroneous results. 
 
Prior to sample analysis, test cartridges were left in room temperate for 5 minutes 
following which, test cartridges were placed into the cassette one at a time. Blood samples 
were mixed by gentle inversion (3-4 times by hand) prior to pipetting 800 µL of blood 
into the reservoir of the cartridge. The sample is then aspirated through a capillary with 
a diameter of 200 mm with constant negative pressure resulting in high shear forces 
(5000–6000s-1). The capillary ends in a membrane aperture with a diameter of 150 mm. 
Platelets adhere at the aperture where they are activated by collagen and aggregates. The 
two agonists, epinephrine and ADP enhances aggregation. Finally, a platelet plug occludes 
the aperture and blood flow stops. The time measured in seconds from the beginning of 
the test until formation of an occluding platelet plug is called closure time (CT). If an 
occluding platelet plug does not form after 300 seconds, the analysis is stopped. Samples 
were tested in duplicates with both reagents (EPI and ADP). Samples with an inter- and 
intra-assay variation of more than 10% were not reported and were repeated by the 
investigators. CT reference ranges of 80-170 seconds for COL/EPI and 60-120 seconds 
for COL/ADP were used based on the manufacture’s and the SWSLHD pathology internal 
validation (Figure 7). 
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Figure 7: Flow chart of Platelet Function Analyzer (PFA-100) closure time (CT) analysis.  
Adapted from SWSLHD pathology laboratory manual (95).  
PFA 100: Platelet Function Analyzer 100, PCV: packed cell volume, PLT: platelet, COL/ADP: 
collagen/adenosine, COL/EPI: collagen/epinephrine 
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2.2.3 Placental growth factor (PlGF) analysis 
Enzyme linked immunosorbent assay (ELISA) were performed using commercial kits for 
PlGF (R&D Systems, MN, USA).   Lyophilised human PlGF standard provided by the 
manufacturer was reconstituted using proprietary calibrator diluent RD5K. This was 
used to produce a dilution series (in duplicates) for a standard curve ranging from 0 to 
1000 pg/mL. Pre-coated 96-well plates were then filled with 100 µL of proprietary assay 
diluent RD1-22 followed by duplicates of 100 µL of prepared standard or plasma sample. 
Plate were then covered with plastic film and incubated for 2 hours at room temperature 
on an orbital shaker. The plates were then washed 3 times in an auto washer using 400 
µL of proprietary wash buffer solution per well, following which,  200 µL of conjugate 
(horseradish peroxidase linked polyclonal antibody specific for human PlGF, included in 
the kit) was added to each well. The plates were then covered with plastic film again and 
incubated for 1 hour at room temperature on an orbital shaker. Following which, the 
plates were washed for a final time (as specified above). Subsequently, 200 µL of 
substrate (hydrogen peroxide and tetramethylbenzidine, included in the kit) was added 
to each well and incubated for 30 minutes in a darkened environment, in room 
temperature.  As a final step, 50 µL of an acid stop solution (2N sulphuric acid, included 
in the kit) was added to each well.  The plates were then shaken for 5 seconds within the 
spectrophotometer (Sunrise, Tecan, Germany) prior to being read at 450 nm with 
wavelength correction at 540 nm. Samples with an inter and intra-assay variation of more 
than 10% were repeated. 
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2.3 Liquid chromatography mass spectrometry (LCMS) 
2.3.1 Plasma salicylic acid (SA) detection 
2.3.1.1. Sample preparation for analysis  
Standards were prepared in duplicates using 100 µL of blank human plasma with known 
concentrations of salicylic acid (SA) (Sigma Aldrich, Castle Hill, NSW, Australia). Diluted 
SA (in 100% methanol) was added to blank plasma in standard concentrations of 0 
ng/mL, 10 ng/mL, 25 ng/mL, 50 ng/mL, 100 ng/mL, 200 ng/mL and 500 ng/mL. All 
standard preparation were spiked with a fixed concentration of 125 ng deuterated 
salicylic acid (D4-SA) (Santa Cruz Biotechnology, CA, USA) as internal control and 
vortexed for 1 minute. Samples from participants, from each time points, were prepared 
in duplicates of 100 µL in Eppendorf tubes and spiked with a fixed concentration of 125 
ng of D4-SA as internal control. 
 
To precipitate protein, 400 µL of 100% of acetonitrile (ACN) (Lichrosolv, Merck Milipore, 
Baywater VIC, Australia) was added to standards and samples and vortexed for 30 
seconds. Samples and standards were then centrifuged at 3000 rpm for 10 minutes 
(Eppendorf Microcentrifuge Model 5415R, Hamburg Germany) following which,  
supernatant was transferred into glass culture tubes (12 X 75 mm disposable culture 
tubes, Kimble, USA) and evaporated over N2 at 60°C (Eppendorf Concentrator plus Model 
22331 Hamburg) for approximately 90 minutes. Samples and standards were then 
reconstituted and acidified with 1 mL of 0.1% v/v formic acid (FA) (Lichrosolv, Merck 
Milipore, Baywater VIC, Australia) prior to solid phase extraction (SPE) with Discovery 
DSC-18 1 mL cartridges (Supelco, Bellefonte, PA, USA) and a vacuum manifold. Cartridges 
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were preconditioned with 1 mL of 100% methanol and washed with 2 mL of 0.1% v/v 
trifluoroacetic acid (TFA) (Lichrosolv, Merck Milipore, Baywater VIC, Australia). The 
sample and standards were applied to the column, washed with 1 mL of water, and eluted 
with 1 mL of 100% methanol. Following which, Methanol was evaporated over N2 at 60oC 
for 90 minutes. Samples were then reconstituted with 100 µL of 0.1% v/v FA and spun at 
3000 rpm for 5 minutes prior to transfer into high performance liquid chromatography 
(HPLC) inserts. 
 
2.3.1.2. Liquid chromatography mass spectrometry (LCMS) 
methodology  
Analysis of samples were performed with Agilent 6460 LCMS (Agilent Technologies, 
Santa Clara, CA, USA). Standards and samples (5 µL) were injected onto a Zorbax Eclipse 
XDB-C18 column (4.6 X 50 mm, 1.8 µm particle size, 600 bar; Agilent Technologies, Santa 
Clara, CA, USA) and eluted with the gradient consisting of 0.1% v/v FA in water (mobile 
phase (MP A)) and 0.1% v/v FA and 90% v/v ACN in water (Mobile phase B (MP B)). The 
gradient was commenced at 30% of MP B, subsequently increased to 90% at 2 minutes 
and maintained at 90% for another 2 minutes. Gradient was then increased to 100% of 
MP B within 0.5 minute, maintained at 100% for another minute, decreased to 30% by 6 
minutes and equilibrated for another minute. Following which, gradient was maintained 
at a flow rate of 0.5 ml/min. Electrospray ionization, in negative mode, was performed 
using the following parameters: capillary spray voltage of 3500v, drying gas flow of 10 
L/min at 325°C and nebuliser pressure of 45 psi. Optimal fragmentor voltage (90v) and 
collision energy voltage (15v) were obtained by flow injection analysis in MS2-product 
ion scan mode. The following MRM ion transitions were monitored 136.9 ->93.10 (SA) 
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and 141.00 -> 97.00 (D4-SA). Peak areas for SA, relative to internal standard D4-SA, was 
used to interpolate a standard curve and calculate SA concentration in standards and 
samples. Duplicates with a variation of more than 10% were repeated. 
 
2.3.2 Plasma Lipoxin-A4 and 15-epilipoxin-A4 detection 
2.3.2.1. Sample preparation  
Standards were prepared in duplicates using 100 µg/mL of 15-epilipoxin-A4 (Sapphire 
Bioscience Pty Ltd, Australia) and 100 µg/mL of Lipoxin-A4 (Sapphire Bioscience Pty Ltd, 
Australia). Briefly, 2 µL of each standards were added to 196 µL of 100% methanol to 
constitute a stock solution containing 1 µg/mL of 15-epilipoxin-A4 and Lipoxin-A4 
respectively. Stock solution was then diluted with varying volumes of 50% methanol to 
obtain series of standard concentrations ranging from 0 ng/mL to 200 ng/mL. Deuterated 
(D5) Lipoxin-A4 (Lipoxin A4-d5) (Sapphire Bioscience Pty Ltd, Australia) was utilized as 
internal standard, in a fixed concentration of 20 ng/mL, across all standard 
concentrations. 
 
Plasma samples, collected at all time points, were prepared, and analysed in duplicates. 
Plasma sample preparation involved protein precipitation of 50 µL of plasma with 200 
µL of 100% of ACN (1:4, v/v) containing 2 ng Lipoxin A4-d5 in Eppendorf tubes. The tubes 
were vortexed for 30 seconds and subsequently submerged in ice for 15 minutes prior to 
being centrifuged at 3000 rpm for 10 minutes. Supernatant were then transferred into 
glass culture tubes (12 x 75 mm disposable culture tubes, Kimble, USA) and evaporated 
at 45°C (Eppendorf Concentrator Model 22331 Hamburg) for approximately 90 minutes.  
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Standards were then reconstituted and acidified with 1 mL of 0.1% FA prior to SPE using 
Discovery DSC-18 1 mL cartridges (Supelco, Bellefonte, PA, USA) on a vacuum manifold. 
SPE cartridges were preconditioned with 1 mL of 100% Methanol and washed with 2 mL 
of 0.1% FA. Following which, samples were applied to the column and washed with 1 mL 
of 0.1% FA prior to elution with 600 µL of 100% Methanol twice. Methanol eluate were 
then evaporated at 45°C for 90 minutes. Samples were then reconstituted with 100 µL of 
20% Methanol containing 0.05% Acetic Acid (AA) followed by a final spin at 1400 rpm 
for 10 minutes prior to transfer into HPLC vial inserts. 
 
2.3.2.2. Liquid chromatography mass spectrometry (LCMS) 
methodology  
LCMS analysis were performed with Shimadzu triple quadrupole mass spectrometer 
LCMS8050 coupled with UHPLC Nexera X2 series (Shimadzu Corp. Kyoto, Kyoto 
Prefecture, Japan). Separation of En-Lipoxin-A4 and ATL in plasma were achieved with a 
Phenomenax Kinetex® C18 (150 x 2.1 mm, 1.7 µm) (Phenomenax Pty Ltd, NSW, 
Australia) column fitted with a SecurityGuard™ ULTRA Cartridges UHPLC C18 (2.1 mm) 
(Phenomenax Pty Ltd, NSW, Australia), with MP A containing 0.05% AA in water and MP 
B consisting of 100% Methanol. Injection volume of 5 µL was used with a total run of 24 
minutes at a flow rate of 0.5 mL/min. The gradient was started at 59% of MP B and 
maintained isocratic for 20 minutes. Gradient was subsequently increased to 95% within 
0.5 minutes and maintained for 2 minutes before returning to 59% in the next half 
minute. Tandem MS was performed using electrospray ionization, in negative mode, with 
the following parameters: Nebulizing gas flow of 3 L/min and heating gas flow of 10 
L/min at 300°C.   Drying gas flow was set at 10 L/min with heat block temperature of 
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400°C.  The optimal fragmentor voltage and respective collision energy voltage for each 
molecule were obtained by flow injection analysis using Optimizer. The following MRM 
ion transitions were monitored m/z 351->217 and 351->115 for En-Lipoxin-A4 and ATL 
with additional channels of m/z 315->135 for En-Lipoxin-A4 and m/z 315->59 for ATL, 
respectively. Lipoxin-A4- d5 peak was used as an internal standard to identify the 
corresponding peak of En-Lipoxin-A4 and quantify both molecules by fitting their peak 
area ratios to the standard curve. Linear regression curves were constructed using the 
ratios of peak areas for En-Lipoxin-A4 and ATL relative to the internal standard and 
presented in pg/mL. Data acquisition was performed using LabSolutions software 
(version 5.91) and qualitative and quantitative analysis of data was conducted using 
accompanied browser software. Duplicates with a variation of more than 10% were 
repeated. 
 
2.4 Assessment of adherence 
2.4.1 Self-reported adherence with aspirin  
Qualitative assessment of adherence was conducted through a questionnaire generated 
based on the Simplified Medication Adherence Questionnaire (SMAQ) (Table 2) (96-98). 
Women undertook this assessment at each time point for the duration of aspirin therapy 
(Figure 6). The investigators (research midwives) verbally questioned women at each 
time point. Adherence through qualitative assessment was defined as a negative response 
to questions 2 and 3 in the qualitative questionnaire in ≥90% of the time points. 
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Questions Response 
1) Are you on aspirin? Yes/No 
2) Have you missed any of your regular aspirin? Yes/No 
3) Have you missed your regular aspirin in the last 7 
days 
Yes/No 
4) In the last 7 days, how many doses of aspirin have 
you missed? 
Number: 
5) When was your last dose of aspirin 
Date……………… 
Time………………… 
Table 2: Self-reported adherence questionnaire used at every time point of follow-up 
 
2.4.2 Biochemical assessment of adherence with aspirin  
Biochemical evidence of adequate adherence with aspirin was defined as an appropriate 
PFA-100 CT (CT reference ranges of 80-170 seconds for COL/EPI and 60-120 seconds for 
COL/ADP))(95) with detectable plasma SA in ≥90% of the time points. The cut-off of 
≥90% was based on published literature (81). Biochemical evidence of intermittent 
adherence was defined as appropriate PFA-100 response and detectable plasma SA in 
<90% of the time points. Women were defined as aspirin resistant if there was a lack of 
appropriate PFA-100 response despite detectable plasma SA (Figure 8). 
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Figure 8: Illustrative representation of assessment of biochemical adherence. 
Adapted from Shanmugalingam et al. The clinical influence of non-adherence with 
prophylactic aspirin in preventing preeclampsia in high-risk pregnancies. Hypertension, 
75,1125–1132 (2020). 
PFA-100 = Platelet function analyzer 100, *SA: Salicyclic acid 
 
2.5 Mixed methods analysis: Quantitative and qualitative study 
High-risk pregnant women from the longitudinal study who were prescribed aspirin 
(n=154) were invited to participate in a sequential-exploratory designed mixed methods 
study. Women in the non-aspirin group were excluded. Electronic invitations, via email, 
were sent out to women from October 2018 – June 2019, to participate in this 
anonymous, non-compulsory survey that consisted mainly of multiple-choice responses 
with free text boxes for additional responses.  
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Anonymous response was utilized to facilitate honest and non-biased responses. 
Questions for the quantitative study were generated based on factors that are known to 
influence adherence with medications in pregnancy (Table 3) (99, 100).  
 
Question Question type 
How do you rate your understanding of why you were 
asked to take aspirin in your recent pregnancy? 
Graded response 
(Scale of 1-5) 
Who first advised you to take aspirin in your pregnancy? 
5 Multi-choice, single-
response option with 
free text for additional 
response  
How satisfied were you with your doctor’s/midwife’s 
explanation on the need for aspirin in your pregnancy? 
Graded response 
(Scale of 1-4) 
Can you please elaborate on what could have been done 
better with the explanation provided to you? 
Free text response 
Were you worried about taking aspirin in your pregnancy? Yes/No response 
What were your concerns with taking aspirin in pregnancy 
9 Multi-choice, multi- 
response option with 
free text for additional 
response 
Did you feel comfortable discussing your concerns with 
your doctor/midwife? 
Yes/No response 
If no, why did you not feel comfortable discussing your 
concerns? 
Free text response 
How satisfied were you with the discussion with your 
pharmacist on the use of aspirin in pregnancy? 
Graded response  
(Scale of 1-4) 
How satisfied were you with your discussion with your 
obstetrician on the use of aspirin in pregnancy? 
Graded response  
(Scale of 1-4) 
Did you do your own research to understand the need for 
aspirin in pregnancy? 
Yes/No response 
What was/were your source(s) of information? 
4 Multi-choice, multi-
response option with 
CLINICAL AND PROTEIN CORRELATIONS OF PROPHYLACTIC TREATMENTS FOR PREECLAMPSIA 
 
  Page 62 of 137 
 
free text for additional 
response 
Did your research change your decision on taking aspirin in 
pregnancy? 
Yes/No response 
How often did you miss your aspirin in your pregnancy? 
1 of 7 Multi-choice, 
single-response option 
What was/were the reason(s) you missed your aspirin? 
8 Multi-choice, multi-
response option with 
additional free text 
response 
What strategies might have helped you take your aspirin 
consistently without missing it? 
5 Multi-choice, multi-
response option with 
additional free text 
response. 
Did you have to take other medications/vitamins in your 
recent pregnancy and if so, how many medications were 
you taking? 
4 Multi-choice, single-
response option with 
additional free text 
response 
Did you have difficulty taking other medications (other 
than aspirin)? 
Yes/No response 
How often did you miss your other medications (besides 
aspirin) in your pregnancy? 
1 of 7 Multi-choice, 
single-response option 
Table 3: Questions used in quantitative study 
 
At the end of the questionnaire (quantitative assessment), women were invited to 
participate in a one-to-one, face-to-face interview for the qualitative assessment. Women 
were advised to express their interest by sending an email to the primary investigator. 
Purposeful selection of interview participants, based on participant’s obstetric history 
and biochemically observed adherence to aspirin (101) , was done to gain maximum and 
balanced variation in the sample. Open ended questions for the qualitative interview 
were generated based on current literature and the data obtained from the quantitative 
survey (Table 4)(80, 102-104).  
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Theme 1: Knowledge (probing questions in italic) 
1) What is your understanding of preeclampsia  
2) What is your understanding on why you were asked to take aspirin? 
3) How did you feel about taking aspirin in your pregnancy? 
        - Were you worried? If so, what were your concerns? 
        - Did you talk to anyone about your concern? 
        - What did your family and friends think about you being on aspirin? 
        - Did you know anyone else on aspirin? Did this reassure you? 
4) Did you do your own research about using aspirin in pregnancy? 
      - What was your source? 
      - Was your source helpful? Did it scare you?  
      - What you have preferred as a source of information? 
      - What is your take on the information available on the internet? 
       - Did your research change your decision on taking aspirin? if so, how and why? 
 
Theme 2: Compliance 
1) How many medications did you have to take during your pregnancy? 
2) How did you feel about taking medications in pregnancy? 
        - Did you feel safe taking medications in pregnancy? 
        - Did you feel like you knew enough about why you needed the medications? 
3) How often would you have missed medications  
      - What was the reason you missed them? 
      - How often would you have missed aspirin? 
      - What was the reason for this? 
      - Did you experience any side effects? 
      - Were there any restrictions that made it difficult? 
         (Ie: taking it at a particular time/specific instructions / tablet size or             
          configuration) 
4) What would have helped you take your medications without missing them? 
      - What strategies have you tried to use to minimize the times you missed your    
        pills? Was this effective? IF no, why? 
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Theme 3: Quality improvement 
1) Were you happy with the explanation your doctor provided with need for aspirin in 
your pregnancy? 
      - Did you discuss the use of aspirin in pregnancy with your renal doctors? Were  
        you satisfied with this interaction?  
      - Did you discuss the use of aspirin with your obstetrician? Were you satisfied             
        with this interaction? 
      - Did you discuss the use of aspirin with your GP? Were you satisfied with this            
        interaction? 
      - Did you discuss the use of aspirin with your pharmacist? Were you satisfied with  
        this interaction? 
Table 4: Questions used in qualitative study 
 
Semi-structured interviews were conducted by a single experienced co-investigator who 
was not involved with the clinical care of the women. Interviews were audio-recorded 
with short key notes taken during interviews to allow for member checking at the end of 
the interview. Duration of the interviews ranged from 45 to 75 minutes. Participants 
were provided with a verbal summary of the interview and the opportunity to request 
amendments to the interpretations. Interviews were ceased at the point of data 
saturation, which was set at the point at which no new data emerged from interviews. 
 
2.5.1 Data analysis 
Audio recorded interviews were transcribed verbatim. No preconceived codes or 
categories were used. A six-stage sequential qualitative analysis was undertaken in 
analysing the transcription with the use of NVivo® (v.12 QRS International Pty Ltd) 
(105).  The six stage analysis was based on Braun and Clarke’s thematic analysis which 
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involved (a) familiarity with data set, (b) generating initial codes, (c) formation of themes, 
(d) review of themes, (e) defining themes and (f) data reporting (106). 
 
Transcripts were re-analysed through the six-stage analysis process by a second 
investigator to ensure agreement of codes and themes. Results of the quantitative and 
qualitative studies were combined through a process of triangulation that enabled the 
investigators to connect and interpret both data sets simultaneously through 
convergence and corroboration with the use of NVivo® (107, 108). Phi correlation (φ) of 
data was done through SPSS (v.25 Chicago,IL, USA). Statistical significance was set at 0.05. 
A φ value of 0.7 – 1 was representative of a strong correlation, 0.3 – 0.69 of a moderate 
correlation and values of <0.3 were representative of a weak correlation. 
 
2.6 Definitions used 
Clinical definitions and outcomes assessed were based on the Society of Obstetric 
Medicine, Australia and New Zealand (SOMANZ) and International Society of Study of 
Hypertension in Pregnancy (ISSHP) clinical guidelines (39, 71, 72) and are as elaborated 
in Table 5. Both international (ISSHP 2018) and national (SOMANZ 2014) level guidelines 





CLINICAL AND PROTEIN CORRELATIONS OF PROPHYLACTIC TREATMENTS FOR PREECLAMPSIA 
 





Onset of hypertension after 20 weeks of gestation 
accompanied by one or more of the following features of 
end organ impairment: 
Renal  
 Significant proteinuria – a spot urine 
protein/creatinine ratio ≥ 30 mg/mmol  
 Serum or plasma creatinine > 90 μmol/L 
 Oliguria: urine output <80 mL/4 hr  
Haematological  
 Thrombocytopenia <100,000 /µL  
 Haemolysis: schistocytes or red cell fragments on 
blood film, raised bilirubin, raised lactate 
dehydrogenase >600 mIU/L, decreased 
haptoglobin 
 Disseminated intravascular coagulation  
Liver  
 Raised serum transaminases 
 Severe epigastric and/or right upper quadrant 
pain. 
Neurological 
 Convulsion (eclampsia) 
 Hypereflexia with sustained clonus 
 Persistent, new headache 
 Persistent visual disturbances (photopsia, 
scotomata, cortical blindness, posterior 
reversible encephalopathy syndrome, retinal 
vasospasm) 
 Stroke 
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Pulmonary oedema 
Intrauterine growth restriction (IUGR) 
Early onset-
preeclampsia 
The onset of preeclampsia (as described above) ≤ 34 
weeks of gestation 
Late onset-
preeclampsia 
The onset of preeclampsia (as described above) >34 
weeks of gestation 
Intrauterine growth 
restriction (IUGR) 
Intra-uterine estimated fetal weight of <10th centile 
Preterm delivery Delivery prior to 37 weeks of gestation 
Increase in antenatal 
antihypertensives 
A cumulative increase of ≥50% (through the duration of 
study) in the dose of antenatal antihypertensive or the 
addition of additional antihypertensive agents to 
maintain antenatal BP target of ≤140/90mmHg 
Decrease in antenatal 
antihypertensives 
A cumulative reduction of ≥50% (through the duration of 
study) in the dose of antenatal antihypertensives or the 
cessation of one or more antihypertensive agents. 
Average SBP 
Mean of all systolic blood pressure readings recorded 
through the duration of study 
Average DBP 
Mean of all diastolic blood pressure readings recorded 
through the duration of study 
Primigravida Woman who conceived for the first time 
Table 5: Definition of clinical outcomes used 
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2.7 Statistical analysis 
Data were analysed using statistical tests through Statistical Package for Social Sciences 
(SPSS®) v25 (IBM, Armonk, New York, United States) and GraphPad® Prism v8.4.1 
(GraphPad Software, La Jolla, California, United States). 
 
For the longitudinal biochemical data (Chapter 4), repeated measures analysis of 
variance (ANOVA) was used to analyse difference in longitudinal En-Lipoxin-A4, ATL, 
PlGF and cytokine concentrations. For the pharmacokinetic data (Chapter 5), one-way 
ANOVA (post hoc testing with Tukey’s test), four-way ANOVA (post hoc testing with 
Tukey’s test) and T-tests were utilised for analysis of mean values. For clinical data 
(Chapter 6), unadjusted Chi-square analysis was used to examine for difference between 
characteristics and obstetric outcomes. An adjusted analysis using a binary logistic-
regression analysis (stepwise backward) was undertaken to assess group differences 
(expressed as the odds ratio (OR) and 95% confidence interval). Repeated measure 
ANOVA was used to examine differences between average systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) over time and between groups. Comparison of 
outcomes in women with varying degree of intermittent adherence with non-aspirin 
control group was done through a Pearson χ2 analysis. A Kaplan-Meier analysis was 
undertaken to assess pregnancy continuation (survival) between ≥90% adherent group 
and <90% adherent group. Agreement between self-reported and biochemical adherence 
was assessed with Cohen’s kappa coefficient. For mixed methods data (Chapter 7), Phi 
correlation(φ) was utilized to correlate the combined quantitative and qualitative data 
to women’s adherence with aspirin. Statistical significance was set at p <0.05. 
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Pregnant women who were risk stratified as high-risk for preeclampsia were recruited 
from 3 high-risk pregnancy clinics across SWSLHD from December 2016 – January 2019. 
A total of 248 women were approached for enrolment into this study, of whom, 220 
women consented to participate (Figure 9). Of the 220 women, 119 (54%) were from 










































































































CLINICAL AND PROTEIN CORRELATIONS OF PROPHYLACTIC TREATMENTS FOR PREECLAMPSIA 
 
  Page 71 of 137 
 
Of the 220 high-risk pregnant women recruited, data from 196 high-risk women were 
available for analysis (Figure 10). Of the 196 high-risk women, 154 high-risk women were 
prescribed aspirin and 42 high-risk women were not prescribed aspirin by their treating 
clinician. High-risk women who were not prescribed aspirin were used as the control 
group and are referred to, hereafter, as the ‘non-aspirin group’.  
 
Figure 10: Outcome of recruitment of high-risk pregnant women in the longitudinal 
cohort study 
* Patient reported difficulty to attend follow up reviews. 
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Figure 11 describes the reasons women in the non-aspirin group were not prescribed 
aspirin by their treating clinician. The average gestation at which women were 
commenced on aspirin was 12 weeks (± 2 weeks). Aspirin was ceased at 34-36weeks of 
gestation based on centre specific practise. 
 
                                        
Figure 11: Reasons for non-aspirin prescription in the non-aspirin group 
*Presentation to hospital between 16+1 and 20 weeks of gestation. # Known pre-existing 




CLINICAL AND PROTEIN CORRELATIONS OF PROPHYLACTIC TREATMENTS FOR PREECLAMPSIA 
 
  Page 73 of 137 
 
Comparison of clinical characteristics of the participants are described in Table 6. The 
only statistically significant difference between the two groups was the proportion of 
women with previous preeclampsia (higher in the aspirin group (40%) in comparison to 
the non-aspirin group (26%)). 
        Characteristics 





Age (years) * 32 (± 6.5) 31 (± 5.2) 0.4 
Primigravity 18(12%) 8(19%) 0.07 
Pre-pregnancy Body Mass 
Index (BMI) of ≥ 30 
64(42%) 24(57%) 0.4 
Multi-fetal pregnancy 7(4%) 1(2%) 0.7 
Smoking in pregnancy 9(9%) 3(7%) 0.6 
Conception through artificial 
reproductive therapy 
14(9%) 4(10%) 0.9 
§Booking systolic BP * 118 (±3) 120 (±4.1) 0.3 
§Booking diastolic BP* 77 (±2.4) 74 (±3.1) 0.2 
Use antihypertensives at 
booking§ 






























Indication for aspirin in 
pregnancy ** 









Renal disease 35(23%) 7(17%) 0.3 
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Type 1 or Type 2 Diabetes 12(8%) 3(7%) 0.8 
Based on first trimester  
screening only † 




         0.9 
 
Table 6: Characteristics of participating high-risk pregnant women 
*mean with standard deviation (±SD). † Analysis based on Fisher’s exact test. ** Added percentages 
exceed 100% as some women had more than 1 medical condition. § Booking refers to the first 
antenatal review. BP: Blood Pressure. 
 
Given the growing evidence on the optimal timing of initiation of aspirin in effective 
prevention of preeclampsia (109), data from women who were commenced on aspirin 
after 16 weeks of gestation (n=9) were excluded from the final analysis.  
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4.1 Study overview 
The prophylactic benefit of aspirin in the prevention of preeclampsia is increasingly 
recognised, however, its mechanism of action remains unclear. Given the variable clinical 
outcomes observed, an understanding of the mechanism of action of aspirin in preventing 
preeclampsia may play a role in understanding its optimal clinical utility.  
 
Recent non-obstetric aspirin mechanistic studies have demonstrated an anti-
inflammatory role of aspirin through the 15-epilipoxin-A4 (ATL) pathway (57, 110, 111). 
ATL is an epimer of endogenous Lipoxin-A4 (En-Lipoxin-A4), a potent endogenous anti-
inflammatory lipoxin, and has been shown to downregulate pro-inflammatory Th1 
cytokines and upregulate anti-inflammatory Th2 cytokines in cell-culture and animal 
models (112-114). Recent obstetric studies identified a possible association between low 
first trimester maternal En-Lipoxin-A4 and subsequent features of placental dysfunction 
(65, 66) and given that ATL is an epimer of En-Lipoxin-A4, cell studies have examined the 
role ATL on placental development through its proposed anti-inflammatory properties 
(67, 68). Gil-Villa et al demonstrated that when exogenous ATL treated plasma from 
women with preeclampsia was added to human umbilical vein endothelial cells (HUVEC), 
adhesion of polymorphonuclear neutrophils (PMN) to HUVEC was reduced compared to 
the non-ATL treated plasma (68). Similarly, Alvarez et al demonstrated that ATL reversed 
antiphospholipid antibody (aPL)-induced decrease in trophoblast migration in aPL 
treated human trophoblast cell line (HTR8) cells. This effect appeared to be regulated 
through restoration of IL-6 production. However, clinical data on this remains sparse. 
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This chapter of the thesis aimed to examine for; (1) differences in maternal En-Lipoxin-
A4 concentration in low-risk (LR) and high-risk (HR) pregnancy; (2) effect of aspirin on 
plasma ATL concentration in high-risk (HR) women; (3) effect of aspirin on selected 
circulating cytokine (specific to the pathophysiology of preeclampsia) concentration in 
HR women; (4) difference in ATL and cytokines with differing doses of aspirin (100 mg 
vs 150 mg) and (5) the observed relationship in longitudinal maternal ATL and cytokines 
with obstetric outcomes. Given the pro-angiogenic effect of PlGF and recent data on 
raised endogenous maternal PlGF concentration in relation to aspirin ingestion (115), 
this chapter also examined the difference in maternal PlGF concentration in relation to 
aspirin use and the observed effect on clinical outcomes.  
 
Plasma samples collected from HR women recruited in the longitudinal cohort study 
(Chapter 2.1) were analysed for En-Lipoxin-A4,  ATL,  IL-8,  IL-10,  TNF-α,  IFN-γ,  IL-1β and 
PlGF (Chapters 2.2 and 2.3). Samples were assessed for adequate adherence with aspirin 
with a two-point biochemical assessment (Chapter 2.4.2) prior to analysis. Only data from 
HR women with ≥90% adherence and the non-aspirin group were analysed, therefore, 
data presented consist of two groups: aspirin-adherent high-risk women (HR-AA) and 
non-aspirin control high-risk women (HR-NA). Data from women with inadequate 
adherence were excluded from the analysis in this chapter. 
 
Plasma samples of LR women with normal pregnancy outcomes (n=20) were obtained 
from frozen plasma collection of a historic longitudinal cohort where samples were 
collected at 12, 20, 28 and 36 weeks of gestation between September 2003 – March 2005. 
LR women from the historic cohort had no clinical risk factors for preeclampsia. Given 
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the prolonged storage duration of the frozen plasma sample from the historic cohort, an 
internal control sub-analysis of En-Lipoxin-A4 plasma concentration from 5 HR women 
from the historic cohort (September 2003- March 2005) (total of 20 samples) were 
analysed against the En-Lipoxin-A4  plasma concentration of HR women from the 
longitudinal cohort (December 2016-January 2019). There were no statistically 
significant differences in all samples analysed, therefore, minimising any potential 
storage time related difference in plasma En-Lipoxin-A4 concentration from the historic 
cohort. 
 
4.2 Summary of key findings 
HR women were observed to have up to 70% lower plasma concentration of En-Lipoxin-
A4 (p<0.001) compared to LR women (116). HR-AA (n=82) had significantly higher 
concentration of plasma ATL (p<0.001) with lower plasma concentration of IL-8 from 12-
36 weeks of gestation (p <0.001), TNF-α from 24-36 weeks of gestation (P=0.02) and an 
increase in plasma concentration of IL-10 from 16 – 28 weeks of gestation (p=0.03) 
compared to the HR-NA group (116). Additionally, a statistically significant rise in 
maternal PlGF plasma concentration by 61% at 12 weeks, 108% at 16 weeks, 116% at 20 
weeks, 121% at 24 weeks, 141% at 28 weeks, 143% at 32 weeks and 160% at 36 weeks 
of gestation was observed in the HR-AA group compared to the HR-NA group 
(p<0.001)(Figure 12)(Table 7).  
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Figure 12: Plasma concentration of PlGF in aspirin adherent (HR-AA) and non aspirin 
high-risk (HR-NA) groups. 
HR-AA: Aspirin adherent high-risk pregnant women group, HR-NA: Non-aspirin high-risk 
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8 weeks 13.5(±6) 11.4(±4) 18 0.4 
12 weeks 80.8(±32) 49.8(±23) 61 <0.001 
16 weeks 232.7(±52) 111.6(±63) 108 <0.001 
20 weeks 348.7(±122) 161.1(±79) 116 <0.001 
24 weeks 473.2(±124) 214.6(±113) 121 <0.001 
28 weeks 742.7(±140) 307.9(±133) 141 <0.001 
32 weeks 640.2(±167) 262.7(±134) 143 <0.001 
36 weeks 634.7(±97) 244.1(±82) 160 <0.001 
Table 7: Comparison of plasma PlGF between the aspirin adherent high-risk pregnant 
women group (HR-AA) and non-aspirin high-risk pregnant women group (HR-NA). 
HR-AA: Aspirin adherent high-risk pregnant women group, HR-NA: Non-aspirin high-risk 
pregnant women group. PlGF: placental growth factor 
 
HR-AA women who were on  150 mg of aspirin were observed to have 35% higher plasma 
concentration of ATL (p=0.02) and IL-10 (by 18% at 16 and 20 weeks of gestation 
(p=0.01)) compared to HR-AA women who were on 100 mg of aspirin. There were no 
statistically significant differences in plasma PlGF, IL-8, TNF-α, IL-1β and IFN-γ 
concentrations between 100 mg and 150 mg of aspirin (116). However, this study was 
underpowered for a statistically significant comparison between 100 mg and 150 mg of 
aspirin. 
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HR women who developed preeclampsia were observed to have lower En-Lipoxin-A4, 
ATL, and IL-10 plasma concentration with higher IL-8 plasma concentration compared to 
HR women who did not develop preeclampsia (116). There were no statistically 
significant differences in IL-1β and IFN-ϒ plasma concentration (116). HR women who 
developed preeclampsia were also observed to have lower plasma PlGF concentration 
compared to HR women who did not develop preeclampsia (Figure 13). 
        
 
Figure 13: Comparison of plasma PlGF concentration of high-risk women (both HR-AA and 
HR-NA) based on clinical outcome (preeclampsia and no preeclampsia). 
HR-AA: Aspirin adherent high-risk pregnant women group, HR-NA: Non-aspirin high-risk 
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4.3 Strengths and limitations of this study 
The study is novel as the variation in plasma En-Lipoxin-A4, detection of plasma ATL in 
relation to aspirin ingestion, and its corresponding alterations in selected pro-
inflammatory and anti-inflammatory cytokines have not been previously examined in HR 
pregnant women. Additionally, stringent measures were undertaken to ensure that the 
observed changes were in relation to aspirin ingestion (Chapter 2.4.2). The LCMS 
methodology used to detect plasma En-Lipoxin-A4 and ATL were optimized and validated 
internally to increase the sensitivity of detection. The comprehensive description of the 
methodology is detailed in Chapter 2.3.2.  
 
The study’s main limitation is that it is observational.  It is hypothesized that the observed 
changes in the maternal plasma concentration of IL-10 and IL-8 are as a result of 
endogenous ATL production with adequate aspirin ingestion, however, the study does 
not demonstrate a direct relationship, only an association. Given the limited sample size 
(limited by number women who did not need adherence criteria), comparison analysis 
between the effects of 100 mg and 150 mg aspirin on endogenous cytokine and PlGF 
concentration were underpowered.  
 
4.4 Conclusions 
Plasma En-Lipoxin-A4 concentration was observed to be lower in HR women compared 
to LR controls. Adequate ingestion of aspirin resulted in significant elevation of 
endogenous ATL concentration and an observed reduction of pro-inflammatory cytokine 
IL-8, with an increase in anti-inflammatory cytokine IL-10. A rise in maternal plasma PlGF 
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concentration was also observed in relation to adequate aspirin adherence. The ongoing 
raise in maternal plasma PlGF concentration even after aspirin cessation suggest that the 
observed elevation in PlGF concentration is potentially a surrogate marker of better 
placentation with early initiation of aspirin.  
 
The findings of this study suggest that aspirin potentially improves placentation, as 
demonstrated through the observed rise in PlGF, through its anti-inflammatory 
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Introduction: The benefit of aspirin in preventing preeclampsia is increasingly recognised, however, 42 
its mechanism of action remains unclear. Non-obstetric studies have described an anti-inflammatory 43 
effect of aspirin through 15-epilipoxin-A4(ATL). However, the anti-inflammatory mechanism of aspirin 44 
in the prevention of preeclampsia remains unknown. 45 
Objective/Hypothesis: To examine the (1) difference in longitudinal endogenous lipoxin-A4(En-46 
Lipoxin-A4) concentration in low-risk(LR) and high-risk(HR) pregnancies, (2)effect of aspirin on 47 
endogenous ATL concentration and the associated effect on  cytokine profile of HR women. 48 
Methods: Plasma from 220 HR women were collected at 12,16,20,24,28,32 and 36 weeks of gestation. 49 
Adherence to aspirin was biochemically verified. Plasma En-Lipoxin-A4 and ATL concentrations were 50 
analysed through liquid-chromatography mass-spectrometry(LC-MS/MS) and cytokines;IL-10, TNF-α, 51 
IFN-ɣ, IL-8 and IL-1β with high-sensitivity multi-bead Luminex® assay.  52 
Results: HR women have up to 70% lower plasma concentration of En-Lipoxin-A4(p<0.001) compared 53 
to LR women.  HR women with adequate aspirin adherence(HR-AA)(n=82)  had higher plasma 54 
concentration of ATL(p<0.001),  lower concentration  of IL-8 from 16-36 weeks of gestation(p 55 
<0.001)and increased IL-10 concentration from 16 – 28 weeks of gestation (p=0.03) in comparison to 56 
high-risk women who were not on aspirin(HR-NA). HR-AA who did not develop preeclampsia had 57 
higher plasma En-lipoxin-A4(p<0.001), ATL(p=0.02) and IL-10 concentrations(p<0.001) with lower IL-8 58 
concentration(p=0.004) compared to HR who developed preeclampsia.  59 
Discussion: Plasma concentration of En-Lipoxin-A4 is lower in HR women compared to LR controls. 60 
Adequate adherence with aspirin results in an increase in ATL and IL-10 with reduced IL-8 plasma 61 
concentration. This study suggests a potential anti-inflammatory role of aspirin, through the ATL 62 


















The prophylactic benefit of aspirin in preventing preeclampsia amongst high-risk pregnant(HR) women 78 
is increasingly recognized with a risk reduction of 50-68% when commenced prior to 16 weeks of 79 
gestation and with optimal adherence(1-5). Recent meta-analysis and pharmacokinetic studies suggest 80 
potential higher risk reduction with the use of 150mgs of aspirin given its altered pharmacokinetics in 81 
pregnancy, however, the clinical data for this remains lacking(6, 7). Whilst there is growing evidence to 82 
support its clinical utility, the mechanism by which aspirin acts as a prophylactic agent in reducing the 83 
risk of preeclampsia remains unclear and is of ongoing interest. 84 
  85 
Early studies investigating the mechanism of aspirin in the prevention of preeclampsia demonstrated 86 
an aspirin-induced decrease in maternal thromboxane-A2(TXA2) and mediation of the unbalanced 87 
thromboxane/prostacyclin(TXA2/PGI2) ratio, in favour of prostacyclin(8-11).  It was, therefore, 88 
hypothesized that aspirin improved placental blood flow and minimized risk of placental thrombosis 89 
by mediating TXA2 and PGI2. However, current data demonstrates a gestation specific effect of aspirin 90 
with minimal prophylactic benefit when commenced after 16 weeks of gestation; a timing that 91 
correlates with completion of placental development(6). This, therefore, suggests the possibility of 92 
additional mechanisms by which aspirin influences placentation in reducing the risk of preeclampsia. 93 
 94 
Recent non-obstetric aspirin mechanistic studies have demonstrated an anti-inflammatory role of 95 
aspirin through the 15-epilipoxin-A4 pathway, also known as the aspirin-triggered-lipoxin(ATL) 96 
pathway(12-14). ATL is an epimer of endogenous lipoxin-A4(En-Lipoxin-A4), a potent endogenous anti-97 
inflammatory lipoxin, and has been shown to regulate Th1/Th2 cytokine imbalance in cell-culture and 98 
animal models(15-17). Lipoxin-A4 has been shown to mediate inhibition of neutrophil and eosinophil 99 
chemotaxis  and decreases inflammatory infiltrates in-vivo with downregulation of interleukin 6 (IL-6), 100 
tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), whilst upregulating interleukin 101 
10 (IL-10) expression(16, 18). Given that a pro-inflammatory maternal state is known to impair 102 
cytotrophoblast implantation and placentation (19-23), an increase in maternal En-lipoxin-A4 could 103 
potentially play a role in improving the placental environment. Recent obstetric studies identified a 104 
possible association between low first trimester maternal En-Lipoxin-A4 and subsequent features of 105 
placental dysfunction(24, 25) and given that ATL is an epimer of En-Lipoxin-A4, studies have focused on 106 
examining the role ATL on placental development(26, 27). However, clinical data on this remains sparse. 107 
 108 
Given the paucity in the current literature, this study aimed to examine the; (1) differences in maternal 109 
En-Lipoxin-A4 concentration in low-risk(LR) and high-risk(HR) pregnancy; (2) effect of aspirin on 110 
plasma ATL concentration in HR women; (3) effect of aspirin on selected circulating cytokine 111 
concentration in HR women; (4) difference in ATL and cytokines with differing doses of aspirin (100mgs 112 
vs 150mgs) and (5) the observed relationship in longitudinal maternal ATL and cytokines with obstetric 113 
outcome. 114 
 115 
Materials and Methods 116 
 117 
Participant recruitment and sample collection 118 
 119 
High-risk pregnant (HR) women were recruited over 25 months (December 2016-January 2019) from 120 
clinics across three hospitals within the South Western Sydney Local Health District (SWSLHD) as part 121 
of a longitudinal observational cohort study. Ethics approval was obtained (SWSLDH Ethics Committee 122 
HE 16/184) and women provided written informed consent. Women were assessed as high-risk for 123 
preeclampsia by their treating clinicians using the NICE clinical guidelines or the Fetal Medicine 124 
Foundation (FMF) high-risk screening program (Table 1). Inclusion criteria included (1) risk-stratified 125 
high-risk for preeclampsia by the treating clinician (2) < 20+1 weeks of gestation at time of enrolment. 126 




time of recruitment (3) women of non-English speaking background (4) unable to provide written 128 
informed consent (5) > 20+0 weeks gestation at time of enrolment. Women were recruited at time of 129 
commencement of aspirin and were followed through to the end of their pregnancy. Blood samples 130 
and clinical data were collected at baseline (prior to first dose of aspirin) and at 16,20,24,28,32 and 36 131 
weeks of gestation. Aspirin was ceased between 34+1-35+6 weeks of gestation in accordance with local 132 
practice. HR women who were not prescribed aspirin either due to aspirin intolerance or delayed 133 
presentation (between 16+1-20+0 weeks of gestation) were followed identically to the aspirin 134 
prescribed group and served as the control high-risk pregnancy (High risk- no aspirin: HR-NA) group. 135 
Frozen plasma samples of low-risk women (LR) with normal pregnancy outcomes (n=20) were 136 
obtained from a historic longitudinal cohort where samples were collected at 12, 20, 28 and 36 weeks 137 
of gestation between September 2003 – March 2005. Women from the historic LR cohort had no 138 
clinical risk factors for preeclampsia. 139 
 140 
Blood samples were collected via a 21G BD Vacutainer Push Button needle(Becton, Dickinson and 141 
Company USA) into 3 x 4mls VACUETTE® K2EDTA tubes(Greiner Bio-One International) and 2 x 3.8ml 142 
tubes containing 0.38ml of 0.129mol/l buffered sodium citrate (pH 5.5) for platelet function 143 
analyser(PFA-100) analysis. Samples in two of the three VACUETTE® K2EDTA tubes were centrifuged 144 
immediately at 3000rpm for 10mins following which, plasma was aliquoted in 220µL volumes and 145 
stored at -80⁰C until analysis. The third VACUETTE® K2EDTA tube and both sodium citrate tubes were 146 
sent to the SWSLHD pathology service at Liverpool Hospital (NATA accredited) at room temperature 147 
for full blood count and platelet function analyzer (PFA-100) assessment respectively within 4 hours 148 
of collection. 149 
 150 
Assessment of adherence with aspirin 151 
 152 
Biochemical evidence of adherence with aspirin was verified through a two-point biochemical 153 
assessment with the use of PFA-100 and plasma salicylate acid (SA) detection(5, 28)at all time points of 154 
the study. Adherence was defined as simultaneously prolonged PFA-100 with detectable plasma SA, 155 
at ≥90% of timepoints(5). A value of ≥90% adherence was based on published data(1, 29).Only data from 156 
HR women with ≥90% adherence and the control group were analysed, therefore, final data presented 157 
consist of two groups: aspirin-adherent high risk women(HR-AA) and non-aspirin control high-risk 158 
women(HR-NA). 159 
 160 
LC-MS/MS analysis of En-Lipoxin-A4 and ATL   161 
 162 
Standards were prepared in duplicates in Eppendorf tubes using 100µg/mL of 15-epilipoxin-A4 163 
(Sapphire Bioscience Pty.Ltd, Australia) and 100µg/mL of Lipoxin-A4 (Sapphire Bioscience Pty.Ltd, 164 
Australia). Briefly, 2µL of each standard were added into 196µL of 100% Methanol (Lichrosolv, Merck 165 
Milipore, Baywater VIC, Australia) to constitute a stock solution of 1µg/mL of 15-epilipoxin-A4 and 166 
Lipoxin-A4. Stock solution was then diluted with varying volumes of 50% methanol to obtain series of 167 
standard concentrations ranging from 0ng/mL to 200ng/mL. Deuterated lipoxin-A4(Lipoxin-A4-D5) 168 
(Sapphire Bioscience Pty.Ltd, Australia), as an internal standard, was spiked at a fixed concentration 169 
of 20ng/mL across all standards and vortexed for 30secs prior to transfer into HPLC vial inserts. 170 
 171 
Plasma preparation, in duplicates, involved protein precipitation of 50µL of plasma with 200µL of 172 
100% of acetonitrile (ACN)(1:4, vol:vol)(Lichrosolv, Merck Milipore, Baywater VIC, Australia) 173 
containing 2ng Lipoxin-A4-D5 in Eppendorf tubes. The tubes were vortexed for 30secs and submerged 174 
in ice for 15mins prior to being centrifuged at 16,168g for 10mins (Eppendorf Microcentrifuge Model 175 
5415R, Hamburg Germany). The supernatant were then transferred into glass culture tubes (12 x 176 
75mm disposable culture tubes, Kimble, USA) and evaporated at 45°C using an Eppendorf 177 




with 1mL of 0.1% formic acid(FA)(Lichrosolv, Merck Milipore, Baywater VIC, Australia) prior to solid 179 
phase extraction using Discovery DSC-18 1mL (SPE) cartridges (Supelco, Bellefonte, PA, USA) on a 180 
vacuum manifold. SPE cartridges were preconditioned with 1mL of 100% methanol, then washed with 181 
2mL of 0.1% FA. Following which, samples were applied to the cartridge and washed with 1mL of 0.1% 182 
FA prior to elution with 600µL of 100% methanol twice. The methanol eluate were then evaporated 183 
at 45°C for 90mins. Dried samples were then reconstituted with 100µL of 20% Methanol containing 184 
0.05% Acetic Acid (AA) followed with a final spin at 1.4 x104rpm for 10mins prior to transfer into HPLC 185 
vial inserts. 186 
 187 
LC-MS/MS analysis were performed on Shimadzu triple quadrupole mass spectrometer LCMS8050 188 
coupled with UHPLC Nexera X2 series (Shimadzu Corp. Kyoto, Kyoto Prefecture, Japan). Separation of 189 
En-lipoxin-A4 and ATL in plasma was achieved with a Phenomenax Kinetex® C18 (150 x 2.1mm, 190 
1.7µm)(Phenomenax Pty Ltd, NSW, Australia) column fitted with a SecurityGuard™ ULTRA Cartridges 191 
UHPLC C18 (2.1mm)(Phenomenax Pty Ltd, NSW, Australia), with mobile phase A containing 0.05% AA 192 
in water and mobile phase B consisting of 100% Methanol. Injection volume of 5µL was used with a 193 
total run of 24mins at a flow rate of 0.5mL/min. The gradient was commenced at 59% of mobile phase 194 
B and maintained isocratic for 20min. Following which the gradient was increased to 95% within 195 
0.5mins and maintained for 2 mins before returning to 59% in the next half minute. Tandem MS was 196 
performed using  the following parameters; negative electrospray ionization, nebulizing gas flow of 197 
3L/min with heating gas flow of 10L/min and interface temperature of 300°CThe optimal fragmentor 198 
voltage and respective collision energy voltage for each molecule were obtained by flow injection 199 
analysis using Optimizer. The following MRM ion transitions were monitored; m/z 351->217 for En-200 
Lipoxin-A4 and 351->115 for ATL with additional channels of m/z 315->135 for En-Lipoxin-A4 and m/z 201 
315->59 for ATL. Epimers of ATL and En-Lipoxin-A4 were separated on LC at different retention times, 202 
though they share the same MRM ion transitions.  The Lipoxin-A4-D5 peak was used as internal 203 
standard to identify the corresponding peak of En-Lipoxin-A4 and quantify levels of both molecules by 204 
fitting their peak area ratios to the standard curve. Linear regression curve was constructed using the 205 
ratios of peak areas for En-Lipoxin-A4 and ATL relative to the internal standard and presented in 206 
pg/mLs. Data acquisition was performed using LabSolutions software (version 5.91) and qualitative 207 
and quantitative analysis of data was conducted using accompanied browser software.  Duplicates 208 
with a variation of more than 10% were repeated. 209 
 210 
 211 
Cytokine analysis with Magnetic Luminex® Performance Assay multiplex kits. 212 
 213 
Simultaneous quantitative analysis of interleukin-1β(IL-1β), TNF-α, Interleukin-8(IL-8), IL-10 and IFN-γ 214 
concentrations were measured with the use of the Magnetic Luminex® Performance multiplex human 215 
high sensitivity cytokine premixed kit A(R&D Systems, Minnesota, USA). Standards, reagents and 216 
undiluted 100µL of plasma were prepared and assayed in duplicate based on the manufacturer’s 217 
manual with the use of HydroFlex® microplate washer(Tecan Trading AG, Switzerland)(30). Prepared 218 
microplates were analysed with the Luminex® 100/200® system (Luminex Corporation, Texas, USA). 219 
Quantitative data for each cytokine were derived based on the microparticle regions specified by the 220 
manufacturer(30) and the respective standard curves with the use of the xPONENT® software(Luminex 221 
Corporation, Texas, USA) and presented in pg/ml. Samples with intra and inter-assay variation of more 222 
than 10% were repeated. 223 
 224 
Definition of preeclampsia 225 
 226 
Clinical diagnosis of preeclampsia was defined as the onset of hypertension (≥140/90mmHg) after 20 227 
weeks of gestation with clinical and/or biochemical features of end organ impairment in keeping with 228 





Statistical analysis 231 
 232 
Sample size was calculated based on the assumption that untreated HR women have a preeclampsia-233 
risk rate of 40% and that aspirin treated HR women will have a 50% reduction in preeclampsia-risk 234 
compared to the HR-NA group. The initial total recruitment target number of 120 was inflated to 220 235 
women (in total) to allow for a predicted 20% dropout and a high prevalence (50%) of intermittent 236 
adherence with aspirin. 237 
 238 
Repeated measures ANOVA was used to analyse difference in longitudinal En-Lipoxin-A4, ATL and 239 
cytokine concentrations. Chi-square analysis and t-test were used for assessment of clinical 240 
characteristics. Statistical analysis was performed with SPSS v25 with data reported as mean (±SD 241 
standard deviation) and significance set at <0.05. Results were analysed per protocol based on 242 
adherence. Aspirin adherence analysis was undertaken to ensure adequate exposure to aspirin in 243 
analysing results obtained and clarify relationships where ingestion was verified.   244 
 245 
Results 246 
A total of 220 HR women were recruited, with complete data from 187 women available for analysis; 247 
of which 145 HR women were prescribed aspirin and 42 were not prescribed aspirin (HR-NA) (Figure 248 
1). Of the 145 HR women who were prescribed aspirin, data from 82 women who met adherence 249 
criteria were analysed (HR-AA) and within this group, 54(66%) were on 100mgs of aspirin and 28(34%) 250 
were on 150mgs of aspirin. Data from 63 HR women who did not meet aspirin adherence criteria were 251 
excluded. 252 
 253 
Samples from 20 women in the historic LR group were analysed for plasma En-Lipoxin-A4. Clinical 254 
characteristics of women in the historic LR group and all prospectively examined HR women (n=187) 255 
are as describe in Table2. There was a higher proportion of primigravids (65% vs 18%, p=0.001) and 256 
women who were smoking in pregnancy (25% vs 6%, p=0.003) in the historic LR cohort compared to 257 
the HR women cohort (Table 2). 258 
 259 
Comparison of clinical characteristics between HR-AA(n=82) and HR-NA(n=42) women demonstrated 260 
a higher percentage of women with previous preeclampsia in the HR-AA group compared to the HR-261 
NA group (48% vs 26%, p=0.03)(Table 3). There were no other significant clinical differences between 262 
both groups (Table 3).  263 
 264 
Plasma En-Lipoxin-A4 concentration in LR and HR groups 265 
Adjusted longitudinal analysis of plasma En-Lipoxin-A4 concentration between both groups of women 266 
demonstrated a 64-70% lower plasma En-Lipoxin-A4 concentration in the HR group compared to the 267 
LR group at all gestation time points of analysis (p<0.001)(Figure 2a)(Supplementary Table 1)(33).  268 
 269 
Plasma ATL concentration in HR-AA and HR-NA groups 270 
 271 
Baseline comparison of plasma ATL concentration between HR-AA and HR-NA groups (pre-aspirin 272 
therapy plasma concentration) did not demonstrate a statistically significant difference (Figure 2b). 273 
On initiation of aspirin, HR-AA women had up to a 19-fold elevation in plasma ATL concentration for 274 
the duration of aspirin therapy in comparison to the HR-NA women (p<0.001) (Figure 275 
2b)(Supplementary Table 2)(33). HR-AA women on 150mgs of aspirin had a 21±4% (p<0.001) higher 276 
plasma ATL concentration compared to HR-AA women on 100mgs of aspirin through the duration of 277 
aspirin therapy (Figure 2c)(Supplementary Table 3).  278 





Effect of aspirin on selected cytokine profile 281 
 282 
The cytokines examined were IL-8, TNF-α, IFN-γ and IL-1β and 1L-10. HR-AA women had lower plasma 283 
concentration of IL-8 by 43% at 16 weeks (p<0.001), 51% at 20 weeks (p<0.001), 48% at 24 weeks 284 
(p<0.001), 42% at 28 weeks (p<0.001), 51% at 32 weeks(p<0.001) and 47% at 36 weeks (p<0.001) 285 
compared to HR-NA women(Figure 3a)(Supplementary Table 4)(33). Lower plasma concentration of 286 
TNF-α; by 10% at 28 weeks(p=0.03), 11% at 32 weeks (p=0.02) and 9% at 36 weeks (p=0.04) were 287 
observed in the HR-AA group (Figure 3b) compared to the HR-NA group. There were no differences in 288 
plasma TNF-α concentration (p=0.08) between 16 – 24 weeks of gestation and in IL-1β and IFN-γ 289 
concentrations between both groups at all time points (Figure 3c). HR-AA women also demonstrated 290 
higher plasma concentration of IL-10; by 87% at 16 weeks (p<0.001), 58% at 20 weeks (p<0.001), 43% 291 
at 24 weeks (p<0.001) and 29% at 28 weeks (p<0.001)(p=0.02) (Figure 3d) compared to HR-NA group. 292 
 293 
HR-AA women on 150mgs of aspirin demonstrated higher IL-10 plasma concentration at 16 weeks (by 294 
15%, p=0.01) and 20 weeks of gestation (by 13%, p=0.02) compared to HR-AA women on 100mgs 295 
aspirin (Supplementary Figure 1c) (Supplementary Table 3)(33) . There was no difference in IL-10 plasma 296 
concentration between differing aspirin doses between 24-36 weeks of gestation. Furthermore, there 297 
were no aspirin dose related effect on the concentrations of IL-8 and TNF-α at all time points of 298 
assessment (Supplementary Table 5 and Supplementary Figure 1)(33). 299 
 300 
 301 
Obstetric outcome in relation to plasma En-lipoxin-A4, ATL and cytokine levels  302 
 303 
This sub-analysis examined for difference between the HR-AA and HR-NA groups only. 6 women in the 304 
HR-AA group and 15 women in the HR-NA women developed preeclampsia(5). They were observed to 305 
have significantly lower En-lipoxin-A4 concentration at all time points (p<0.001) and lower ATL 306 
concentration (in HR-AA group)(p=0.02) for the duration of aspirin therapy (Figures 4a and b).  307 
 308 
Plasma IL-8 concentration was noted to be lower in the HR-AA who did not develop preeclampsia (p= 309 
0.004) (Figure 4c) and similarly, plasma IL-10 concentration was higher in HR-AA women who did not 310 
develop preeclampsia(p<0.001)(Figure 4d). 311 
 312 
Discussion 313 
Our study demonstrates that HR women have up to 70% lower plasma En-lipoxin-A4 concentration 314 
compared to LR women through the duration of their pregnancy. In response to adequate aspirin 315 
therapy, HR-AA women were observed to have a significant increase in endogenous ATL concentration 316 
for the duration of aspirin therapy.  An assessment of the effect of aspirin on selected cytokines 317 
demonstrated a significant and sustained reduction in pro-inflammatory IL-8 and increased anti-318 
inflammatory IL-10 plasma concentration in the HR-AA group compared to the HR-NA group. A 319 
comparison between 100mgs and 150mgs of aspirin demonstrated that HR women who were on 320 
150mgs of aspirin had a 21±4% higher concentration of ATL through the duration of aspirin therapy 321 
with modestly increased plasma concentration of IL-10 (13-15%) between 16-20 weeks of gestation. 322 
The obstetric outcomes of the women in this observational cohort study have been published(5). We 323 
observed a lower rate of preeclampsia (7% vs 36%, p<0.001), intrauterine growth retardation (5% vs 324 
21%, p<0.001) and pre-term delivery (8% vs 26%, p<0.001) in the HR-AA group compared to the HR-325 
NA group. Based on our clinical data(5), whilst most women who developed preeclampsia were found 326 
to have late onset preeclampsia (onset ≥ 34 weeks of gestation), 2% of women from the HR-AA group 327 
and 7% of women from the HR-NA group developed early onset preeclampsia (onset < 34 weeks of 328 
gestation). Further analysis of plasma En-lipoxin-A4, endogenous ATL and cytokine concentrations in 329 




plasma En-lipoxin-A4, ATL and IL-10 concentrations with lower plasma concentration of IL-8 in 331 
comparison to HR women who developed preeclampsia, suggesting a potential anti-inflammatory 332 
effect of prophylactic aspirin (Figure 4). The increased TNF-α concentration in third trimester (24-36 333 
weeks of gestation) in HR-NA group is likely reflective of the higher rate of preeclampsia in this group 334 
in comparison to the HR-AA and less-likely due to an aspirin-related effect (Figure 3b)(5). 335 
 336 
Endogenous Lipoxin-A4 (En-Lipoxin-A4) is a lipid mediator that elicits anti-inflammatory actions via its 337 
receptor, formyl peptide receptor 2 (FPR2/ALX) and is thought to be the “ regulator” of 338 
inflammation(18, 34).  Human reproductive studies have shown that En-Lipoxin-A4 and its receptor 339 
FPR2/ALX regulates inflammatory events in the human endometrium and decidua of early 340 
pregnancy(34, 35). Clinical studies, however, have demonstrated contradictory findings and this is likely 341 
attributed to the variation in the gestation at which the maternal En-Lipoxin-A4 concentration were 342 
examined and the cohort of women studied. Lipa et al demonstrated that low maternal first-trimester 343 
En-Lipoxin-A4 concentration was associated with intrauterine fetal growth disturbance, in keeping 344 
with our results, suggesting that low first-trimester En-Lipoxin-A4 concentration played a role in 345 
placental dysregulation(24). In established preeclampsia (mainly third trimester), Perruci et al 346 
demonstrated elevated En-Lipoxin-A4 concentration suggesting a physiological anti-inflammatory 347 
response to the pro-inflammatory pathogenesis of established preeclampsia(36). Perruci et al, 348 
however, excluded women with chronic conditions, a group that is known to have lower plasma En-349 
Lipoxin-A4 concentration. In keeping with non-obstetric studies that have demonstrated lower En-350 
Lipoxin-A4  in patients with chronic conditions(37, 38), our study found lower En-Lipoxin-A4 351 
concentration in the HR group, in which 88% of women had pre-existing chronic conditions, through 352 
the duration of study (16-36 weeks of gestation) compared to the LR group in whom none had 353 
underlying chronic conditions. A sub-analysis of En-Lipoxin-A4 concentration in HR women who 354 
developed preeclampsia (both early and late onset preeclampsia) against HR women who didn’t 355 
develop preeclampsia demonstrated lower plasma concentration in the preeclampsia group at all 356 
times points (Figure 4a). Higher BMI has been suggested to influence plasma En-Lipoxin-A4 357 
concentration(36) however a comparison of characteristics between the low En-Lipoxin-A4 group (HR 358 
group) and high En-Lipoxin-A4 group (LR group) did not demonstrate any difference in our cohort 359 
(Table 2). Further sub-analysis of En-Lipoxin-A4 of all women (LR and HR) in relation to BMI did not 360 
demonstrate a difference in En-Lipoxin-A4 concentration between women with BMI of <30 and ≥30 361 
(Supplementary Table 6)(33) .The LR group used in our study had a higher number of women who 362 
smoked in their pregnancy in comparison to women in the HR group. The influence of smoking on En-363 
Lipoxin-A4 concentration remains unknown. 364 
 365 
ATL is an endogenous 15R-enantiomer of En-Lipoxin-A4 and shares many of the bioactivities evoked 366 
by En-lipoxin-A4 with a 2-fold greater half-life. Chiang et al demonstrated that ingestion of 81mgs of 367 
aspirin in a male predominant cohort, resulted in plasma ATL concentration of approximately 3ng/mls 368 
(3000pg/mls)(39). Our study observed plasma ATL concentration of up to 7000pg/mls with 100mgs of 369 
aspirin and up to 8500pg/mls with 150mgs of aspirin. The difference in plasma ATL concentration 370 
identified is likely confounded by a dose-dependent response and method of plasma ATL detection 371 
used (ELISA in Chiang et al’s study and high sensitivity LC/LCMS in our study). Non-obstetric studies 372 
have demonstrated upregulation of IL-10 and down-regulation of TNF-α and 1L-8 with the use of 373 
exogenous ATL(40-42). Similarly, reproductive cell culture studies have demonstrated ATL related 374 
reversal in the inflammatory process observed in preeclampsia by upregulating IL-10 and nitric oxide 375 
(NO) whilst downregulating TNF-α(27). However, knowledge on the influence of endogenous ATL in HR 376 
obstetric subjects remains limited and the dose of exogenous ATL used to produce this effect is not 377 
parallel with the endogenous plasma ATL concentration observed with the use of aspirin. Our study 378 
demonstrated that endogenous ATL concentration in HR women with adequate aspirin ingestion was 379 
associated with a sustained increase in plasma concentration of IL-10 and reduced concentration of 380 





Dose-dependent effects of 100mgs and 150mgs of aspirin were examined in this study. Whilst we 383 
observed higher endogenous ATL concentration with the use of 150mgs of aspirin compared to 384 
100mgs of aspirin, we did not observe a meaningful difference in plasma IL-10 and IL-8 concentration 385 
between both doses of aspirin. The lack of difference may be attributable to the small sample size in 386 
both groups and the potential physiological longitudinal variation in IL-10(22, 23). More recent 387 
metanalysis and pharmacokinetic studies(6, 7) have demonstrated the need for >100mgs of aspirin in 388 
the prevention of preeclampsia, however, pharmacodynamic and clinical studies with a larger sample 389 
size and adequate power, are required in examining this. 390 
 391 
Strengths and limitations 392 
 393 
Our study is novel in that the variation of En-lipoxin-A4 and the detection of ATL with aspirin ingestion 394 
and its corresponding alteration in selected pro-inflammatory and anti-inflammatory cytokines have 395 
not been previously examined in women at risk of developing preeclampsia. Additionally, we verified 396 
adequate aspirin adherence and included only those women found to be adherent in our analysis to 397 
ensure that the observed ATL and cytokines changes were in relation to aspirin ingestion. The LC-398 
MS/MS methodology used to detect plasma En-lipoxin-A4 and ATL was optimized and validated by 399 
our group to increase the sensitivity of detection. Given the prolonged storage duration of the plasma 400 
sample used for the En-lipoxin-A4 level in the LR group, we conducted an internal control analysis of 401 
plasma En-lipoxin-A4 concentration in plasma samples of 5 HR women from the historic cohort (years 402 
2003-2005) against the plasma En-lipoxin-A4 concentration of the HR women in our cohort (years 403 
2016-2019).  There was no statistically significant difference in the plasma En-Lipoxin-A4 404 
concentration between samples analysed, therefore, minimising any potential storage time related 405 
difference in En-Lipoxin-A4 concentration from the historic cohort. 406 
 407 
Our study has several limitations.  We hypothesize that the observed changes in the maternal plasma 408 
IL-10 and IL-8 concentrations were a result of endogenous ATL production with adequate aspirin 409 
ingestion, however, our study does not demonstrate a causal relationship, only by association. The 410 
study was also not adequately powered for the post hoc analysis comparing differences in cytokine 411 
concentrations between different aspirin doses. Further cell culture studies (endothelial and 412 
trophoblast cells) examining the direct effect of aspirin on endogenous ATL and its effect on cytokines, 413 
endothelial nitric oxide (eNOS) and cell invasion may help better understand the relationship between 414 




Our study suggests that HR pregnant women have lower En-lipoxin-A4 concentration. Adequate 419 
adherence with prophylactic aspirin amongst these women demonstrated an increased plasma 420 
concentration of ATL and an observed increase in plasma IL-10 and reduction in IL-8 concentrations. 421 
This was clinically associated with a lower rate of preeclampsia(5). Therefore, suggesting a possible 422 
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Legends for Figures and Tables 550 
Figure 1: Recruitment of high-risk pregnant women. *due to difficulty in attending research follow-up 551 
appointments. HR: High-risk pregnancy, HR-AA: High-risk pregnancy aspirin adherent, HR-NA: High-552 
risk pregnancy not on aspirin 553 
 554 
Figure 2: (A)Difference in endogenous plasma Lipoxin-A4 (En-Lipoxin-A4) concentration between 555 
women in the low-risk pregnancy (LR) group (historic cohort) and high-risk pregnancy (HR) group. (B) 556 
A comparison of endogenous plasma 15-epilipoxin-A4 (ATL) concentration between high-risk 557 
pregnancy women who met aspirin adherence criteria (HR-AA) and high-risk pregnant women who 558 
were not on aspirin (HR-NA). (C) A sub-comparison of plasma ATL concentration between 100mg and 559 
150mg of aspirin in high-risk pregnant women who met aspirin adherence criteria (HR-AA). 560 
*statistically significant at <0.05. # High-risk women in the non-aspirin (HR-NA) group did not have 561 
plasma assessment at 12 weeks of gestation due to delayed presentation. ^ Pre-aspirin baseline 562 
plasma ATL concentration (HR-AA) comparison between the high- risk aspirin adherent group (at 12 563 
weeks of gestation) and baseline level in the high-risk non-aspirin group(HR-NA)(at 16 weeks of 564 
gestation) was not statistically significant.  565 
 566 
Figure 3: (A) Comparison of plasma IL-8 concentration between non-aspirin (HR-NA) and aspirin 567 
adherent (HR-AA) high-risk pregnancy groups. (B) Comparison of plasma TNF-α concentration 568 
between HR-NA and HR-AA groups. (C) Comparison of plasma IL-1β concentration between HR-NA 569 
and HR-AA groups. (D) Comparison between plasma IFN-γ concentration between HR-NA and HR-AA 570 
groups and (E) Comparison between plasma IL-10 concentration between HR-NA and HR-AA groups. 571 
*statistically significant at <0.05. # High-risk women in the non-aspirin group did not have plasma 572 





Figure 4: (A) Comparison of plasma En-Lipoxin-A4 concentration between preeclampsia and non-575 
preeclampsia groups. (B) Comparison of plasma 15-epilipoxin-A4 (ATL) concentration between 576 
preeclampsia and non-preeclampsia groups. (C) Comparison between plasma IL-8 concentration 577 
between preeclampsia and non-preeclampsia groups and (D) Comparison between plasma IL-10 levels 578 
between preeclampsia and non-preeclampsia groups.*statistically significant at <0.05. For Figures 4 579 
(B-D), HR-AA women with no preeclampsia is represented by the green solid line with solid dot. HR-580 
AA women with preeclampsia is represented by green dotted line with solid square. HR-NA women 581 
with no preeclampsia is represented by red solid line with solid dot. HR-NA women with preeclampsia 582 
is represented by red dotted line with solid square. 583 
 584 
 585 
Table 1: Screening methods used to by clinicians to risk-stratify pregnant women in this study. *NICE 586 
guidelines recommend the use of aspirin in women with 1 major risk factor or ≥2 moderate risk factors. 587 
# The FMF screening algorithm recommends the use of aspirin in women with a ratio of <1:100. 588 
 589 
Table 2: (A) Clinical characteristics comparison between women in the historic low-risk pregnancy (LR) 590 
group and prospectively examined all high-risk pregnancy (HR) group. (B) Subgroup analysis of aspirin-591 
adherent high-risk pregnant women (HR-AA) and non-aspirin high-risk pregnant women (HR-NA).‡ All 592 
high-risk (HR) group consist of all high-risk women from the longitudinal study (HR-AA, HR-NA and HR 593 
women who were prescribed aspirin but did not meet adherence criteria).  #HR group consist only of 594 
HR-AA and HR-NA with exclusion of HR women who did not meet adherence criteria. * mean with 595 
standard devia on (±SD). † Analysis based on Fisher’s exact test.** added percentages exceed 100% 596 
as some women had more than 1 medical conditions. ± First trimester screening were done in private 597 
screening units based on a combined MoMs algorithm of maternal mean arterial pressure (MAP), 598 
uterine artery pulsatility index (PI) and maternal serum placental growth factor (PlGF) and pregnancy-599 
associated plasma protein A (PAPP-A) with a cut off of 1:100. N/A (not applicable) as no women in the 600 














NICE Guidelines* Fetal-Maternal Medicine (FMF) First 
trimester screening# 
 
Major risk factors 
 
 Chronic hypertension 
 Autoimmune conditions 
 Chronic kidney disease  
 Previous preeclampsia 
 Type 1 or type 2 diabetes 
 
Moderate risk factors 
 
• first pregnancy 
• age 40 years or older 
• pregnancy interval of more than 10 years 
• body mass index (BMI) of 35 kg/m2 or  
               more at first visit 
• family history of pre-eclampsia 
• multi-fetal pregnancy. 
 
 
FMF first trimester screening 
combined multiple of median 
(MoMs) of maternal mean arterial 
pressure (MAP), uterine artery 
pulsatility index (PI) and maternal 
serum placental growth factor 
(PlGF) and pregnancy-associated 
plasma protein A (PAPP-A) into an 
algorithm with a cut off of 1:100. 
Table 1: Screening methods used to by clinicians to risk-stratify pregnant women in this study. *NICE guidelines recommend the use of aspirin in women 









                (A) Total Study Group (n=207) (B) HR Groups (n=124)# 
Characteristics LR group 
 (n=20) 
 All HR group 
(n=187)‡ 
p-value 










Age (years) * 32 (±5.3) 33 (±5.5) 0.9 32 (± 5.5) 31 (± 5.2) 0.4 
 
Primigravity 13(65%) 33(18%) 0.001 14(17%) 8(19%) 0.8 
Pre-pregnancy Body Mass Index (BMI) of ≥ 30 8(40%) 86(46%) 0.5 34(41%) 24(57%) 0.06 
Multifetal Pregnancy  1(5%) 8(4%) 0.8 6(7%) 1(2%) 0.7 
Smoking in pregnancy 5(25%) 7(4%) 0.003 4(5%) 3(7%) 0.6 
Conception through artificial reproductive therapy 2(10%) 16(9%) 0.08 9(11%) 4(10%) 0.9 
Ethnicity 
                       Caucasian 
                       Middle Eastern 
                       South Asian 
                       South East Asian 
                       African† 
                       Polynesians† 
                       Australian Aboriginals† 




































Indication for aspirin in pregnancy ** 
                      Chronic hypertension 
                      Previous preeclampsia 
                      Renal disease 
                      Type 1 or Type 2 Diabetes 
                      Based on first trimester  
                      screening only± †                 





































Table 2: (A) Clinical characteristics comparison between women in the historic low-risk pregnancy (LR) group and prospectively examined all high-risk 




‡ All high-risk (HR) group consist of all high-risk women from the longitudinal study (HR-AA, HR-NA and HR women who were prescribed aspirin but did not 
meet adherence criteria).  #HR group consist only of HR-AA and HR-NA with exclusion of HR women who did not meet adherence criteria. * mean with 
standard deviation (±SD). † Analysis based on Fisher’s exact test.** added percentages exceed 100% as some women had more than 1 medical conditions. ± 
First trimester screening were done in private screening units based on a combined MoMs algorithm of maternal mean arterial pressure (MAP), uterine 
artery pulsatility index (PI) and maternal serum placental growth factor (PlGF) and pregnancy-associated plasma protein A (PAPP-A) with a cut off of 1:100. 

































                    Figure 1: Recruitment of high-risk pregnant women . *due to difficulty in attending research follow-up appointments.  




• 4 moved out of area 
• 1 elective drop out* 
• 1 medical termination 
• 18 early miscarriages (before 20 
weeks of gestation) 
• 9 commenced on aspirin >16 
weeks of gestation 
187 HR 
women 






















Figure 2: (A) Difference in endogenous plasma Lipoxin-A4 (En-Lipoxin-A4) 
concentration between women in the low-risk pregnancy (LR) group 
(historic cohort) and high-risk pregnancy (HR) group. (B) A comparison of 
endogenous plasma 15-epilipoxin-A4 (ATL) concentration between high-
risk pregnancy women who met aspirin adherence criteria (HR-AA) and 
high-risk pregnant women who were not on aspirin (HR-NA). (C) A sub-
comparison of plasma ATL concentration between 100mg and 150mg of 
aspirin in high-risk pregnant women who met aspirin adherence criteria 
(HR-AA).  
*statistically significant at <0.05. # High-risk women in the non-aspirin 
(HR-NA) group did not have plasma assessment at 12 weeks of gestation 
due to delayed presentation. ^ Pre-aspirin baseline plasma ATL 
concentration (HR-AA) comparison between the high- risk aspirin 
adherent group (at 12 weeks of gestation) and baseline level in the high-
risk non-aspirin group(HR-NA)(at 16 weeks of gestation) was not 









   
 
 











Figure 3: (A) Comparison of plasma IL-8 concentration between non-aspirin 
(HR-NA) and aspirin adherent (HR-AA) high-risk pregnancy groups. (B) 
Comparison of plasma TNF-α concentration between HR-NA and HR-AA 
groups. (C) Comparison of plasma IL-1β concentration between HR-NA and 
HR-AA groups. (D) Comparison between plasma IFN-γ concentration 
between HR-NA and HR-AA groups and (E) Comparison between plasma IL-
10 concentration between HR-NA and HR-AA groups. 
*statistically significant at <0.05. # High-risk women in the non-aspirin group 


























Figure 4: (A) Comparison of plasma En-Lipoxin-A4 concentration between 
preeclampsia and non-preeclampsia groups. (B) Comparison of plasma 15-
epilipoxin-A4 (ATL) concentration between preeclampsia and non-preeclampsia 
groups. (C) Comparison between plasma IL-8 concentration between 
preeclampsia and non-preeclampsia groups and (D) Comparison between 
plasma IL-10 levels between preeclampsia and non-preeclampsia groups. 
*statistically significant at <0.05. For Figures 4 (B-D), HR-AA women with no 
preeclampsia is represented by the green solid line with solid dot. HR-AA 
women with preeclampsia is represented by green dotted line with solid 
square. HR-NA women with no preeclampsia is represented by red solid line 
with solid dot. HR-NA women with preeclampsia is represented by red dotted 
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5.1 Study overview 
The pharmacokinetics of medications in pregnancy is often altered and influenced by the 
physiological changes that occur throughout pregnancy.  The altered liver metabolism 
and renal excretion leads to varied absorption, distribution and elimination of commonly 
used medications in pregnancy (117, 118).  However, most pharmacokinetic data, 
including the pharmacokinetics of aspirin, have been extrapolated from healthy males 
(119, 120) and the data on its altered pharmacokinetics in pregnancy remains lacking. 
 
At the time of this study, the optimal dose of aspirin in pregnancy remains unclear, with 
some data suggesting the need for dose adjustment (>100 mg), to obtain better risk 
reduction of preeclampsia (29, 42, 121). Current guidelines do not specify a 
recommended dose of aspirin but suggest a range of 75 mg – 150 mg with 100 mg being 
the most commonly suggested (39, 71). However, the increasing use of 150 mg since 
recent studies (29) is likely to impact clinical guidelines in the future (72). Nonetheless, 
there remains a significant paucity in clinical and pharmacokinetic data that directly 
compares the use of 100 mg to 150 mg of aspirin in pregnant women to support a definite 
change in clinical practice.  
 
Additionally, pharmacology studies comparing varying preparations of aspirin in healthy 
male and female volunteers have demonstrated better platelet inhibition activity with 
non-EC aspirin compared to EC aspirin, which is often used for gastrointestinal protection 
(88). Once again, the pharmacokinetics of the various preparations of aspirin in pregnant 
women have not been examined and the influence on obstetric clinical outcomes remains 
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unknown. Another area of growing interest is the chronotherapy of daily aspirin. 
Hermida et al have demonstrated that ingestion of aspirin at bedtime results in better 
ambulatory blood pressure control and reduced incidence of hypertensive disorders of 
pregnancy amongst high-risk women (122, 123). However, the mechanism of this effect 
and the current definitive recommendation on this remains unclear. 
 
This chapter of the thesis aimed to examine for; (1) the difference in pharmacokinetics of 
aspirin, through its major active metabolite, plasma salicylic acid (SA), in pregnant 
women compared to non-pregnant women,  (2) the effect of dose (100 mg vs 150 mg), 
(3) preparation (EC vs non-EC) and, (4) chronotherapy of aspirin (morning vs night) 
between both groups. Plasma SA was intentionally used in place of plasma aspirin 
concentration given the short half-life of plasma aspirin (15 minutes) (119, 120). 
 
Twelve HR pregnant women (from the longitudinal cohort study) and 3 non-pregnant 
women were enrolled into this study. Pregnant women were in one of four groups (100 
mg EC, 100 mg non-EC, 150 mg non-EC morning dosing and 150 mg non-EC night dosing). 
Non-pregnant women undertook each of the four dosing schedules consecutively with a 
minimum 30-day washout period between each preparation. Blood samples were 
collected at baseline (pre-ingestion), 1, 2, 4, 6, 12 and 24-hours post-ingestion of aspirin 
(Figures 13 and 14).  
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Figure 14: Illustrative representation of allocation of participants in the pharmacokinetics 
study. 
Adapted from Shanmugalingam R. et al, A pharmacokinetic assessment of optimal dosing, 
preparation and chronotherapy of aspirin in pregnancy. American Journal of Obstetrics and 
Gynaecology (AJOG), 22, 255.E1-E9 (2019).  
*Three non-pregnant females were used for all 4 subgroups in a cross-over pattern with a 
washout period of at least 30 days between differing aspirin preparation. 
 
 
Figure 15: Time points for plasma sample collection 
Time points at which plasma samples were collected are representation by the blue arrows. 
Baseline sample was collected prior to ingestion of daily dose of aspirin.  
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Plasma samples were analysed for SA through LCMS (Chapter 2.3.1). Pharmacokinetic 
values of area under the curve (AUC(t-24)), point of maximum concentration (Cmax), 
time of maximum concentration (Tmax), volume of distribution (Vd), clearance (CL) and 
elimination half-life (t½) (Figure 16) were obtained through a validated PKSolver® 
software (124) and analysed for statistical significance with SPSSv25. 
 
Figure 16: Illustrative representation of pharmacokinetic values assessed 
AUC(t-24): area under the curve from 0-24 hours, Cmax: point of maximum concentration, 
Tmax: time point of maximum concentration, t ½: half life 
 
5.2 Summary of key findings 
Pregnant women were observed to have 40% ± 4% lower AUC(t-24) (p <0.01), 29% ± 
3% lower Cmax (p<0.01) and 44% ± 8% higher CL (p<0.01) in comparison to non-
pregnant women with both 100 mg and 150 mg of aspirin. Therefore, suggesting, altered 
aspirin pharmacokinetics in pregnancy. The reduced AUC(t-24), with 100 mg of aspirin, 
however, was minimized with the use of 150 mg of aspirin in pregnant women. The 
AUC(t-24) achieved with 150 mg of aspirin was similar to that achieved with the use of 
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100 mg aspirin in non-pregnant women (Figure 17), therefore, suggesting the need for 
dose adjustment of aspirin in pregnancy.  
 
 
Figure 17: Illustrative representation of pharmacokinetics of aspirin in pregnant and 
non-pregnant women. 
Adapted from Shanmugalingam R. et al, A pharmacokinetic assessment of optimal dosing, 
preparation and chronotherapy of aspirin in pregnancy. American Journal of Obstetrics and 
Gynaecology (AJOG), 22, 255.E1-E9 (2019). Pharmacokinetics of 100 mg of non-EC aspirin 
(green) compared to 150 mg of non-EC aspirin (blue) in pregnant (dotted lines) and non-
pregnant women (solid lines).* AUC(t-24) of 150 mg non-EC aspirin is 42% lower in 
pregnant women compared to non-pregnant women (p<0.01). # AUC of 100 mg non-EC 
aspirin is 38.6% lower in pregnant women compared to non-pregnant women (p<0.01). ^ 
The use of 150 mg of aspirin in pregnancy minimizes the pregnancy related reduction in 
AUC(t-24) and Cmax with the use of 100 mg of aspirin in pregnancy (125). 
CLINICAL AND PROTEIN CORRELATIONS OF PROPHYLACTIC TREATMENTS FOR PREECLAMPSIA 
 
  Page 92 of 137 
 
There was a 4-hour delay (p<0.01) in Tmax, 47% ± 3% reduction in Cmax (p<0.01) and a 
48% ± 1% increase in Vd (p<0.01) with the use of 100 mg EC aspirin compared to 100 
mg non-EC aspirin with no difference in the overall AUC. There were no differences in 
pharmacokinetic values of aspirin with the comparison of morning and night dosing.  
 
5.3 Strengths and limitations of this study 
This is the first pharmacokinetic study to examine the effect of varying dose of aspirin in 
pregnancy in comparison to non-pregnant control women, making this a novel study at 
the time of this thesis. Additionally, the LCMS methodology used to detect, and measure 
plasma SA is unique in that it was optimized and validated for use in obstetric studies 
(126). The pharmacokinetic findings of this study strengthens the current data on the 
potential need for aspirin dose adjustment in pregnancy (121). However, further 
correlation with pharmacodynamic and clinical studies comparing 100 mg to 150 mg of 
aspirin in pregnancy will be required to better understand the optimal dose of aspirin in 
pregnancy.  
 
This study has several limitations.  Pregnant women with renal disease were excluded 
from this pharmacokinetic study. Given that SA is renally excreted, women with renal 
disease may have higher drug exposure. Whilst this is out of the scope of this study, the 
pharmacokinetics of aspirin in women with renal disease and the optimal dose in these 
women will require further exploration. Another limitation in this study is the small 
number of participants which limits the ability to examine for further confounders such 
as inter-gestational variation of pharmacokinetics and ingestion of aspirin in relation to 
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intake of food. Whilst Rymark et al did not demonstrate an inter-gestation variation in 
the pharmacokinetics of aspirin in the second and third trimester (117), the potential 
difference in the first trimester remains unknown and will be worth exploring in future 
pharmacokinetic studies. Similarly, the optimal timing of ingestion of aspirin in relation 
to food intake remains unclear with a recent systematic review demonstrating a lack of 
difference in overall bioavailability (127).  
 
5.4 Conclusions 
There is lower total drug metabolite concentration of aspirin in pregnancy compared to 
the non-pregnant state. This suggest a potential need for aspirin dose adjustment in 
pregnant women. This is likely due to the altered pharmacokinetics of aspirin in 
pregnancy with an increase in clearance. There was no difference in total drug metabolite 
concentration of aspirin between EC and non-EC aspirin nor between morning and night 
dosing of aspirin. However, further pharmacodynamic and randomized clinical studies 




Original Research ajog.orgOBSTETRICSA pharmacokinetic assessment of optimal dosing,
preparation, and chronotherapy of aspirin in pregnancy
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BACKGROUND: The benefit of aspirin in preventing preeclampsia is 3% reduction in point of maximum concentration (P < .01) with a 44%
well established; however, studies over the years have demonstrated vari-
ability in outcomes with its use. Potential contributing factors to this variation
in efficacy include dosing, time of dosing, and preparation of aspirin.
OBJECTIVE:We aimed to compare the difference in pharmacokinetics
of aspirin, through its major active metabolite, salicylic acid, in pregnant
women and nonpregnant women, and to examine the effect of dose (100
mg vs 150 mg), preparation (enteric coated vs nonenteric-coated), and
chronotherapy of aspirin (morning vs evening) between the 2 groups.
MATERIALS AND METHODS: Twelve high-risk pregnant women
and 3 nonpregnant women were enrolled in this study. Pregnant women
were in 1 of 4 groups (100 mg enteric coated, 100 mg nonenteric-
coated, 150 mg nonenteric-coated morning dosing, and 150 mg
nonenteric-coated evening dosing), whereas nonpregnant women un-
dertook each of the 4 dosing schedules with at least a 30-day washout
period. Blood samples were collected at baseline (before ingestion) and at
1, 2, 4, 6, 12, and 24 hours after ingestion of aspirin. Plasma obtained was
analyzed for salicylic acid levels by means of liquid
chromatographymass spectrometry. Pharmacokinetic values of area
under the curve from time point 0 to 24 hours point of maximum con-
centration, time of maximum concentration, volume of distribution,
clearance, and elimination half-life were analyzed for statistical signifi-
cance with SPSS v25 software.
RESULTS: Pregnant women had a 40%  4% reduction in area
under the curve from time point 0 to 24 hours (P < .01) and 29% Cite this article as: Shanmugalingam R, Wang XS,
Münch G, et al. A pharmacokinetic assessment of optimal
dosing, preparation, and chronotherapy of aspirin in
pregnancy. Am J Obstet Gynecol 2019;221:255.e1-9.
0002-9378/$36.00
Crown Copyrightª 2019 Published by Elsevier Inc. All rights
reserved.
https://doi.org/10.1016/j.ajog.2019.04.027 8% increase in clearance (P < .01) in comparison to that in
nonpregnant women when 100 mg aspirin was administered. The
reduction in the area under the curve from time point 0 to 24 hours,
however, was minimized with the use of 150 mg aspirin in pregnant
women, with which the area under the curve from time point 0 to 24
hours was closer to that achieved with the use of 100 mg aspirin in
nonpregnant women. There was a 4-hour delay (P < .01) in the time of
maximum concentration, a 47%  3% reduction in point of maximum
concentration (P < .01) and a 48%  1% increase in volume of dis-
tribution (P < .01) with the use of 100 mg enteric-coated aspirin
compared to nonenteric-coated aspirin, with no difference in the
overall area under the curve. There was no difference in the pharma-
cokinetics of aspirin between morning and evening dosing.
CONCLUSION: There is a reduction in the total drug metabolite con-
centration of aspirin in pregnancy, and therefore a dose adjustment is
potentially required in pregnant women. This is likely due to the altered
pharmacokinetics of aspirin in pregnancy, with an increase in clearance.
There was no difference in the total drug metabolite concentration of
aspirin between enteric-coated and nonenteric-coated aspirin and be-
tween morning and evening dosing of aspirin. Further pharmacodynamic
and clinical studies are required to examine the clinical relevance of these
pharmacokinetic findings.
Key words: aspirin, dose, pharmacokinetics, preeclampsia, pregnancyhe pharmacokinetics of medica-T tions in pregnancy is influenced by
the maternal physiological changes that
occurs through all three trimesters of
pregnancy. These changes lead to an
alteration in the absorption, distribu-
tion, and elimination of commonly used
medications in pregnancy.1,2 However,
most pharmacokinetic studies of medi-
cations commonly used in pregnancy,such as aspirin, have been conducted in
healthy males.3,4
The prophylactic use of aspirin to
prevent preeclampsia has been studied
over the last 40 years, but results are
contradictory because of unanswered
questions relating to its optimal
application. The varying risk reduc-
tion of between 10% and 60%
observed in previous studies has been
largely attributed to the heterogeneity
of studies for dosing, timing of
ingestion, gestation at initiation of
therapy, and type of aspirin
preparation.5e7
Initial studies that demonstrated a
prophylactic benefit of aspirin pre-
scribed a daily dose of 150e300 mg.8
Subsequent studies, however, argued
for the use of low-dose therapy ranging
from 75 to 150mg daily,5,9 whereasmoreSEPTEMBER 2019 Amerirecent studies suggest better clinical
outcomes with the use of a 150-mg
dose.10,11 Current guidelines do not
specify a recommended dose of aspirin
but suggest a range of 75e150 mg, with
100 mg being the most commonly sug-
gested dose.12,13 The use of 150 mg in
recent studies is likely to have an impact
on clinical guidelines in the future14;
however, there remains a significant
paucity in clinical and pharmacokinetic
data that directly compares the use of
100 mg to 150 mg aspirin in pregnant
women to support such a change in
clinical practice. It therefore remains
unclear whether the use of 150 mg daily
results in better bioavailability of aspirin
and consequently better clinical
outcomes.
Pharmacology studies comparing
varying preparations of aspirin incan Journal of Obstetrics & Gynecology 255.e1
AJOG at a Glance
Why was this study conducted?
To address the lack of data and understanding on the pharmacokinetics of aspirin
in pregnancy and its impact on the variable outcomes observed with its pro-
phylactic role in preventing preeclampsia.
Key findings
The total drug exposure of aspirin is reduced in pregnancy compared to that in
nonpregnant women and suggests the need for dose adjustment in pregnancy.
What does this add to what is known?
The physiological changes in pregnancy alters the pharmacokinetic of medication
in pregnancy. Aspirin in now commonly used in high-risk pregnant women, and
this finding will provide more insight into the potential need for dose adjustment
in pregnancy.
Original Research OBSTETRICS ajog.orghealthy male and female volunteers
have demonstrated better platelet in-
hibition activity with nonenteric-
coated aspirin (non-EC) compared to
enteric-coated aspirin (EC), which is
often used for gastrointestinal protec-
tion.15 Bhatt et al demonstrated a lack
of platelet inhibition activity with EC
aspirin in patients with diabetes,
whereas others have demonstrated a
lack of difference in platelet inhibition
activity between the 2 preparations in
healthy volunteers.16,17 Once again, the
pharmacokinetics of the various prep-
arations of aspirin in pregnant women
have not been examined, and the in-
fluence on obstetric clinical outcomes
remains unknown.
Another area of growing interest is the
chronotherapy of daily aspirin. Recent
studies demonstrated that ingestion of
aspirin at bedtime results in better
ambulatory blood pressure control and
reduced incidence of hypertensive dis-
orders of pregnancy among high-risk
women.18 However, the mechanism of
this effect is not understood, and the
current recommendation on this re-
mains unclear.
Based on the current gaps in the
literature and clinical practice, we aimed
to compare the pharmacokinetics of
aspirin in pregnant vs nonpregnant
women, and to examine the effect of
dose (100 mg vs 150 mg), preparation
(EC vs non-EC), and chronotherapy of
aspirin (morning vs evening dosing)
between the 2 groups.255.e2 American Journal of Obstetrics & GynecolMaterials and Methods
Sample collection
Twelve pregnant women from high-risk
pregnancy clinics within the South
Western Sydney Local Health District
(SWSLHD), NSW, Australia, gave writ-
ten informed consent to participate in
this study. Women were in 1 of 4 groups
(100 mg EC, 100 mg non-EC, 150 mg
non-EC morning dosing, and 150 mg
non-EC evening dosing). Three
nonpregnant women undertook each of
the 4 dosing schedules with at least a 30-
day washout period (Figure 1). Baseline
clinical characteristics of the participants
included age, ethnicity, body mass index
(BMI), weight, gestation at time of study,
and smoking status (Table 1). The type
of aspirin consumed by healthy
nonpregnant women was standardized.
The aspirin consumed by pregnant par-
ticipants was unaltered from their pre-
scribed aspirin. At the time of
publication, 150 mg EC aspirin was not
commercially available for clinical use in
Australia. Patients who were prescribed
150 mg aspirin by their clinicians were
therefore advised to use half a tablet of
300 mg non-EC aspirin or one-and-a-
half tablets of 100 mg non-EC aspirin.
The pregnant and nonpregnant women
in our study used half a tablet of 300 mg
non-EC aspirin. Morning dosing of
aspirin was set at 8 am  0.5 hour, and
evening dosing was set at 2000 1 hour.
Ingestion and time of ingestion of
aspirin were witnessed and verified by
the attending investigator. Participantsogy SEPTEMBER 2019in this study took their aspirin right after
consuming food. Women with underly-
ing renal and liver dysfunction were
excluded from this study.
Blood samples (4 mL) were collected
via a 23G BD Vacutainer Push Button
needle (Becton Dickinson, Franklin
Lakes, NJ) at baseline (before ingestion)
and 1, 2, 4, 6, 12, and 24 hours after
ingestion of aspirin. Blood samples were
collected into VACUETTE K2EDTA
tubes (Greiner Bio-One International)
and were centrifuged immediately at
3000 rpm for 10 minutes. Plasma was
then aliquoted and stored at80Cuntil
analysis.
Ethics approval for this study was
obtained from the SWSLDH ethics
committee (HE 16/184).
Sample preparation for liquid
chromatographyLmass
spectrometry analysis
Standards were prepared using 100 mL
blank human plasma with known con-
centrations of salicylic acid (SA) (Sigma
Aldrich, Castle Hill, NSW, Australia).
Salicylic acid was dissolved and diluted
with 100% methanol before spiking
blank plasma with known concentra-
tions of 0 ng/mL, 10 ng/mL, 25 ng/mL,
50 ng/mL, 100 ng/mL, 200 ng/mL, and
500 ng/mL. The standards were then
spiked with a fixed concentration of 125
ng deuterated salicylic acid (D4-SA)
(Santa Cruz Biotechnology, Santa Cruz,
CA) as an internal control and vortexed
for 1 minute. Similarly, 100 mL of plasma
at each time point was transferred into
Eppendorf tubes and spiked with a fixed
concentration of 125 ng D4-SA as in-
ternal control.
To precipitate protein, 400 mL of
100% of acetonitrile (ACN) (Lichrosolv;
Merck Milipore, Baywater, VIC,
Australia) was added to standards and
samples and vortexed for 30 seconds.
Samples and standards were then
centrifuged at 16,168 g for 10 minutes
(Eppendorf Microcentrifuge Model
5415R, Hamburg Germany), after which
the supernatant was transferred into
glass culture tubes (12  75-mm
disposable culture tubes) and evapo-
rated at 45C using an Eppendorf
Concentrator (Model 22331) for
FIGURE 1
Patient distribution. A total of 12 pregnant volunteers were subdivided into 4
groups as above
*Three nonpregnant women were used for all 4 subgroups in a crossover pattern with a washout
period of at least 30 days between varying aspirin exposures.
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standards were then reconstituted and
acidified with 1 mL of 0.1% formic acid
(FA) (Lichrosolv; Merck Milipore, Bay-
water, VIC, Australia).
Samples and standards underwent
solid phase extraction using Discovery
DSC-18 1 mL solid phase extraction
cartridges (Supelco, Bellefonte, PA) with
a vacuum manifold. Cartridges were
preconditioned with 1 mL of 100%
methanol, then washed with 2 mL of
0.1% trifluoroacetic acid (TFA)
(Lichrosolv; Merck Milipore, Baywater
VIC, Australia). The sample and stan-
dards were applied to the column and
then washed with 1 mL of water, after
which they were eluted with 1 mL of
100% methanol. The methanol eluate
was then evaporated at 45C for 90 mi-
nutes. Samples were then reconstituted
with 100mL of 0.1% FA and spun at 1.4
104 RPM for 5 minutes before transfer
into high-performance liquid chroma-
tography (HPLC) vial inserts.
Liquid chromatographyLmass
spectrometry methodology
Analysis was performed on an Agilent
1290 series UHPLC system coupled with
6460A triple quadrupole mass spec-
trometers (Agilent Technologies, Santa
Clara, CA). The separation of SA inplasma was achieved by using an Agilent
Zorbax Eclipse XDB-C18 (4.6 50 mm,
1.8 mm) column fitted with a UHPLC
Zorbax Eclipse XDB-C18 (4.6  5 mm,
1.8 mm) guard column, with mobile
phase A containing 0.1% formic acid in
water and mobile phase B consisting of
0.1% formic acid in 90% acetonitrile in
water. The injection volume was 5 mL
with a total run of 7 minutes at flow rate
of 0.5 mL/min. The gradient was started
at 30% of B and increased to 90% at 2
minutes and was then maintained at
90% for another 2 minutes. It then
increased to 100% in the next 0.5 min-
ute, maintained at 100% for another
minute, decreased to 30% by 6 minutes,
and re-equilibrated for another minute
at 30% before the next injection. Tan-
dem mass spectrometry was performed
using electrospray ionization equipped
with jet stream technology in the nega-
tive mode using the following parame-
ters: capillary spray voltage was held at
3500 V, drying gas flow of 10 L/min with
temperature set at 325C and nebulizer
pressure at 45 psi. The optimal frag-
mentor voltage (90 V) and collision en-
ergy voltage (15 V) was obtained by flow
injection analysis in MS2-product ion
scan mode. The following MRM ion
transitions were monitored: 136.9
->93.10 (SA) and 141.00 -> 97.00SEPTEMBER 2019 Ameri(D4-SA). Peak areas for SA relative to the
internal standard D4-SA was used to
interpolate a standard curve and then to
calculate the SA present in standard and
sample.
Data analysis
Data acquisition was performed using
MassHunter B.07.01, and data analysis
was conducted using MassHunter qual-
itative and quantitative software (version
B.07.00; Agilent Technologies). The
pharmacokinetic parameters of
maximum concentration (Cmax), time
point of maximum concentration
(Tmax), area under the curve from time
point 0 to 24 hours [AUC(t-24)], volume
of distribution (Vd), clearance (CL), and
elimination half-life (t½) were deter-
mined through a 2-compartmental
analysis using PKSolver.19 One-way
analysis of variance (post hoc testing
with Tukey test), 4-way analysis of vari-
ance (post hoc testing with Tukey test),
and t tests were used for analysis of mean
values with SPSS v25 software.
Results
The characteristics of the participants
are described in Table 1. There was no
statistically significant difference in the
clinically relevant characteristic between
the participants. This included age,
weight, BMI, and gestation in pregnant
women. None of the participants were
smokers, and none were on a proton
pump inhibitor or histamine H2 recep-
tor antagonist.
Effect of varying dose of aspirin
The 150-mg non-EC group had a 40%
6% higher AUC(t-24) (P ¼ .01) and 31%
 2% higher Cmax (P¼.02) compared to
100-mg non-EC group for both preg-
nant and nonpregnant women (Figure 2
and Table 2). There was no difference in
the t½ and Tmax in pregnant and
nonpregnant women regardless of
dosage. However, the mean AUC(t-24)
was 41%  2% and 34%  4% lower in
pregnant women in both the 100-mg
non-EC and 150-mg non-EC aspirin
groups, respectively (P < .01), with a
43%  8% increase in CL, in compari-
son to that in nonpregnant women.
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255.e4 American Journal of Obstetrics & Gynecology SEPTEMBER 201931%  3% lower in pregnant women in
both the 100-mg non-EC and 150-mg
non-EC aspirin groups, respectively (P
< .01).
When comparing 150 mg in preg-
nancy against a regular dose of aspirin in
nonpregnant women (100 mg), the dif-
ference in the pharmacokinetics between
groups was minimal, with a difference of
5% in the AUC(t-24) and 2.3% in the
Cmax. This suggests that a higher dose of
aspirin (150 mg) minimizes the
pregnancy-related reduction in total
drug exposure of 100 mg aspirin
(Figure 2 and Table 2).
Effect of varying preparation of
aspirin
There was no difference in the AUCt-24
and t½ between the 100-mg EC and non-
EC dosing. There was, however, a 4-hour
delay (P < .01) in the Tmax and a 47% 
2% reduction in Cmax (P< .01) as well as
a 48%  1% increase in Vd (P < .01)
with the use of 100 mg EC aspirin
compared to non-EC aspirin (Figure 3
and Table 3).
Once again, pregnant women had a
43% 2% lower AUCt-24 (P¼.03) and a
27%  1% lower Cmax (P ¼ .01)
respectively, with a 44%  1% increase
in CL (P < .01) in both the EC and non-
EC preparations of 100 mg aspirin
compared to that in nonpregnant
women (Figure 3 and Table 3).
Effect of chronotherapy of aspirin
In examining the influence of chrono-
therapy on the pharmacokinetics of
aspirin, we compared morning (8 am 
0.5 hour) and evening (8 pm  1 hour)
dosing of 150mg aspirin in pregnant and
nonpregnant women. There was no
difference in the AUC(t-24), Cmax, Tmax,
and t½ half between the 2 dosing regi-
mens, indicating a lack of influence of
chronotherapy on the pharmacokinetics
of aspirin (Figure 4 and Table 4). We
once again found that pregnant women
had a 35%  4% lower AUC(t-24) (P ¼
.01) and 24%1% lower Cmax (P¼ .02)
with a 46%  4% increase in CL
compared to that in nonpregnant
women in both morning and evening
dosing of 150 mg non-EC aspirin groups
(Figure 4 and Table 4).
TABLE 2
Comparison of mean pharmacokinetic values between pregnant and nonpregna
nonLenteric-coated (non-EC) aspirin
100 mg Non-EC aspirin
P valuea







AUC(t-24) (ng/mL*h) 12187.3  100 21096.6  532 <.01 19993.3  240
Tmax (h) 2 2 NS 2
Cmax (ng/mL) 2417.2  71 3214.7  98 <.01 3289.3  117
t½ (h) 2.5  0.3 2.7  0.2 NS 2.6  0.2
Vd mg/(ng/mL) 0.08  0.005 0.06  0.005 NS 0.09  0.002
CL mg/(ng/mL)/h 0.006  0.001 0.003  0.001 <.01 0.009  0.001
Data are mean  standard deviation.
AUC(t-24), area under the curve from time point 0 to 24 hours; CL, clearance; Cmax, point of maximum concentration; NS, not significant; T
Vd, volume of distribution.
a P value represents the comparison between pregnant and nonpregnant women in the 100 mg non-EC aspirin group and the 150 mg
comparison between 100 mg non-EC aspirin and 150 mg non-EC aspirin.
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FIGURE 2
Pharmacokinetics of 100 mg nonLenteric-coated (non-EC) aspirin (green)
compared to 150 mg non-EC aspirin (blue) in pregnant (dotted lines) and
nonpregnant women (solid lines)
*Area under the curve from time point 0 to 24 hours [AUC(t-24)] of 150 mg non-EC aspirin is 42%
lower in pregnant women compared to nonpregnant women (P< .01). #Area under the curve of 100
mg non-EC aspirin is 38.6% lower in pregnant women compared to nonpregnant women (P< .01).ˇ
Use of 150 mg aspirin in pregnancy minimizes the pregnancy-related reduction in the area under
the curve (AUC) and the point of maximum concentration (Cmax) with the use of 100 mg aspirin in
pregnancy.
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SEPTEMBER 2019 AmeriA 4-way analysis of variance exam-
ining formultifactor relationship did not
demonstrate a statistically significant 4-
way interaction among dose, chrono-
therapy, pregnancy, and preparation
(F3,16 ¼ 0.773, P ¼ .5).
Comment
Our study demonstrated a consistent
reduction in total drug metabolite con-
centration of aspirin (measured through
SA) in pregnancy, with an average 40%
 4% reduction in AUC(t-24) and 29%
3% reduction in Cmax with a 44%  8%
increase in CL in comparison to that in
nonpregnant women when 100 mg
aspirin was administered. The reduced
AUC with the use of 100 mg, however,
was minimized with the use of 150 mg
aspirin in pregnant women. Use of the
150-mg dose in pregnant women ach-
ieved total drug metabolite concentra-
tion similar to that from 100 mg aspirin
in nonpregnant women. This therefore
suggests that the physiological changes,
such as increase in clearance, that occur
in pregnancy highlight the potential
need for aspirin dose adjustment in
pregnancy. The only pharmacokinetic
study of aspirin in pregnancy to date was
conducted in 1994 by Rymark et al, who
demonstrated that 75 mg aspirin in
pregnant women in the second and third
trimesters had a lower SA plasma peaknt women with both doses of
irin
P valuea P valueb
Nonpregnant women
(n¼3)
29288.3  430 <.01 .01
2 NS NS
4797.5  182 <.01 .02
2.6  0.4 NS NS
0.07  0.003 NS NS
0.005  0.001 <.01 NS
max, time of maximum concentration; t½, elimination half-life;
non-EC aspirin groups, respectively; b P value represents the
can Journal of Obstetrics & Gynecology 255.e5
FIGURE 3
Pharmacokinetics of 100 mg enteric-coated (EC) aspirin (red) and 100 mg
nonLenteric-coated (non-EC) aspirin (green) in both pregnant (dotted lines)
and nonpregnant (solid lines) women
*EC aspirin demonstrated a 4-hour delay in time of maximum concentration (Tmax) (P < .01) and a
47% reduction in point of maximum concentration (Cmax) (P< .01) compared to non-EC aspirin, with
no difference in area under the curve from time point 0 to 24 hours [AUC(t-24)] (P¼ not significant).
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Original Research OBSTETRICS ajog.orgcompared to that in nonpregnant
women, with no intertrimester varia-
tion.1 Despite the widespread use of
aspirin in pregnancy, its altered phar-
macokinetics in pregnancy and theTABLE 3
Comparison of mean pharmacokinetic
nonLenteric-coated (non-EC) 100-mg





AUC t-24 (ng/mL*h) 12187.3  100 2109
Tmax (h) 2
Cmax (ng/mL) 2417.2  71 321
t½ (h) 2.5  0.3
Vd mg/(ng/mL) 0.08  0.005
CL mg/(ng/mL)/h 0.006  0.001
Data are mean  standard deviation.
AUC(t-24), area under the curve from time point 0 to 24 hours; CL, c
Vd, volume of distribution.
a P value represents the comparison between pregnant and nonpr
represents the comparison between 100 mg EC and non-EC a
Shanmugalingam et al. Altered pharmacokinetics of aspirin
255.e6 American Journal of Obstetrics & Gynecolimpact of this on optimal dosing and
clinical outcomes have not been
adequately examined and remain
unclear. This evidence suggests
that we should stop extrapolatingvalues between pregnant and nonpregna
aspirin
P valuea





6.6  532 .03 11927.3  104
2 NS 6
4.7  98 .01 1275  97
2.7  0.2 NS 2.6  0.1
0.06  0.005 NS 0.16  0.01
0.003  0.001 <.01 0.007  0.001
learance; Cmax, point of maximum concentration; NS, not significant; T
egnant women in the 100-mg enteric-coated (EC) aspirin group and th
spirin.
in pregnancy. Am J Obstet Gynecol 2019.
ogy SEPTEMBER 2019pharmacokinetic data from nonpreg-
nant women and should undertake the
relevant studies in pregnant women.
Aspirin is absorbed rapidly from the
stomach and intestine by passive
diffusion and is rapidly hydrolyzed,
with a short half-life of 15 minutes, into
salicylic acid.3,4 Salicylic acid is
responsible for aspirin’s anti-
inflammatory effects.20 With repeated
dosing, salicylic acid has been found to
be the principal substance in plasma,
with a half-life of 2 hours.21 For these
reasons, we chose to examine the
pharmacokinetics of aspirin through
detection of its hydrolyzed product,
salicylic acid, as did Rymark et al. About
50e70% of salicylic acid in the blood is
bound to albumin, whereas the rest
remains in the active, ionized state.3,20
The protein binding of salicylic acid is
concentration dependent, and therefore
saturation of binding sites leads to more
free salicylic acid and eventually to
toxicity.20 The volume of distribution
(Vd) of salicylic acid is low, at 0.1e0.2
L/kg, indicating that the majority of
salicylic acid is confined to the plasma.4
This is consistent with what we
demonstrate in this study. As for its
metabolism, 80% of salicylic acid is
metabolized in the liver through
conjugation with glycine to form sali-
cyluric acid and with glucuronic acid to
form 2 different glucuronide esters.20nt women in enteric-coated (EC) and
P valuea P valueb
Nonpregnant women
(n ¼ 3)
22007.3  118 .03 NS
6 NS <.01
1808.3  154 .01 <.01
2.5  0.3 NS NS
0.13  0.01 NS <.01
0.004  0.001 <.01 NS
max, time of maximum concentration; t½, elimination half-life;
e nonenteric-coated (non-EC) group, respectively; b P value
FIGURE 4
Pharmacokinetics of morning (blue) and evening (purple) dosing of 150 mg
nonLenteric coated (non-EC) aspirin in pregnant (dotted line) and
nonpregnant (solid line) women
*There was no difference in the pharmacokinetics of morning and evening dosing of 150 mg aspirin.
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ajog.org OBSTETRICS Original ResearchSalicylic acid is excreted mainly by the
kidneys as salicyluric acid (75%), free
salicylic acid (10%), salicylic phenol
(10%), and acyl glucuronides (5%).3,4
In pregnancy, there is a progesterone-
driven delay in gastrointestinal motility
which results in a 30% increase in gastric
emptying time and an approximatelyTABLE 4
Comparison of mean pharmacokinetic v
dosing of 150 mg nonLenteric-coated





AUC t-24 (ng/mL*h) 19993.3  240 2928
Tmax (h) 2
Cmax (ng/mL) 3289.3  117 479
t½ (h) 2.6  0.2
Vd mg/(ng/mL) 0.09  0.002
CL mg/(ng/mL)/h 0.009  0.001
Data are mean standard deviation. AUC(t-24), area under the cu
concentration; t½, elimination half-life; Vd, volume of distributio
a P value represents the comparison between pregnant and nonp
evening dosing of aspirin.
Shanmugalingam et al. Altered pharmacokinetics of aspirin40% reduction in gastric acidity.22,23
These changes can result in ionization
of weak acids such as aspirin and could
potentially affect its absorption. Simi-
larly, there have been arguments that the
use of enteric-coated aspirin can also
reduce its absorption.15 Evidence to









8.3  430 .01 21417.7  428
2 NS 2
7.5  182 .02 3439.6  256
2.6  0.4 NS 2.8  0.5
0.07  0.003 NS 0.08  0.01
0.005  0.001 <.01 0.008  0.001
rve from time point 0 to 24 hours; CL, clearance; Cmax, point of maxim
n.
regnant women in the morning and evening dosing groups, respectivel
in pregnancy. Am J Obstet Gynecol 2019.
SEPTEMBER 2019 Ameribeen contradictory. Our assessment on
the influence of enteric coating demon-
strated an expected delay in Tmax with
reduced Cmax and an increase in Vd with
no overall difference in AUC(t-24) be-
tween EC and non-EC aspirin. However,
the influence of EC aspirin on the
pharmacodynamic of aspirin in preg-
nancy remains unknown and is subject
to further research.
A stronger influence on the alteration
of pharmacokinetics in pregnancy is the
variation in drug distribution and elim-
ination. The physiological plasma
expansion of 50% in pregnancy often
results in altered drug volume of distri-
bution (Vd) and is most prominent to-
ward the end of the first trimester.24,25
The total mean increase in the maternal
body volume is approximately 8 L, and
the resulting volume expansion results in
a decrease in peak serum concentration
(Cmax), particularly of hydrophilic
agents such as salicylate acid. The
increased circulating estrogen and pro-
gesterone in pregnancy can either in-
crease or decrease hepatic metabolism of
drugs based on its stimulatory or inhib-
itory influence on the cytochrome P450
isoenzymes and uridine 5’-diphospho-
glucuronosyltransferase isoenzyme ac-
tivity.24,26,27 Glucuronidation activity
may be a critical determinant of aspirin
efficacy; however, the enzymes respon-
sible for this conjugation have yet to bewomen in bothmorning and evening
rin, evening dosing
P valuea P valueb
Nonpregnant women
(n ¼ 3)
30048.2  296 .01 NS
2 NS NS
4276.5  238 .02 NS
2.5  0.5 NS NS
0.07  0.01 NS NS
0.003  0.001 <.01 NS
um concentration; NS, not significant; Tmax, time of maximum
y; b P value represents the comparison between morning and
can Journal of Obstetrics & Gynecology 255.e7
Original Research OBSTETRICS ajog.orgidentified and characterized.28 There-
fore, the influence of pregnancy on the
hepatic metabolism of salicylic acid re-
mains subject to further research.
The relationship between increased
creatinine clearance and drug excretion in
pregnancy is well recognized and has been
demonstrated through various studies,
including ours, which demonstrated a
45% increase in clearance of SA.24,29,30
Renal drug excretion is dependent on the
glomerular filtration rate (GFR), tubular
secretion, and resorption. In pregnancy,
GFR is increased by 50% from the first
trimester and continues to increase until
the last week of pregnancy.24,31 Therefore,
the clearance of drugs and metabolites
that are excreted renally, such as salicyluric
acid and salicylic acid, is thought to par-
allel the change in GFR in pregnancy,
leading to lower Cmax and AUC(t-24) as
demonstrated in our study.32 Plasma
protein binding of drugs is known to
reduce in pregnancy because of reduced
albumin concentration and estrogen-
induced reduced protein-binding of
drugs.29,33 Decreased protein binding in-
creases the concentration of free drug and
consequently increases the clearance of
drugs and metabolites such as salicylates
via the increased renal clearance in preg-
nancy. The net effect of reduced protein
binding, however, is counterbalanced by
the increased renal clearance of drugs and
metabolites such as salicylates.
Although our study did demonstrate a
reduced total drug metabolite concen-
tration of aspirin in pregnancy with a
potential need for dose adjustment in
pregnancy, the clinical relevance of this
will need to be examined through a ran-
domized clinical study in pregnancy that
directly compares the clinical outcomes
with the use of 100 mg and 150 mg
aspirin. In addition, more data on the
safety of 150 mg aspirin in pregnancy is
required. Our study did not demonstrate
a difference in the pharmacokinetics be-
tween EC and non-EC aspirin in the
pregnant and nonpregnant states. Simi-
larly, we did not demonstrate a difference
in the pharmacokinetics of aspirin in
relation to chronotherapy. The current
thought on the mechanism of aspirin in
the prevention of preeclampsia focuses
on 2 pathways that potentially influence255.e8 American Journal of Obstetrics & Gynecolplacentation. This involves aspirin’s in-
fluence on platelet aggregation (through
the cyclooxygenase [COX]1 pathway)
and its immunomodulatory effect
through the COX-2 pathway.34,35 Given
this, in translating our pharmacokinetic
findings to clinical studies, there is a need
to further examine a dose-dependent
response to platelet aggregation and the
immune pathway of preeclampsia. In
addition to this, there is a need to
examine its overall effect on the pertinent
end-point—namely, the clinical out-
comes of these women and their infants.
Our study has a few limitations. The
study excluded pregnant women with
renal disease. Given that salicylate acid is
renally excreted, women with renal dis-
ease can potentially have higher drug
exposure. Although this is beyond the
scope of our study, the pharmacokinetics
of aspirin in women with renal disease
and the optimal dose in these women
will require further exploration. Another
limitation to our study is the small
number of participants. Although our
post hoc power analysis was close to
100% to address the main aim of this
study, the sample size limited our ability
to examine for further confounders such
as intergestational variation of pharma-
cokinetics and ingestion of aspirin in
relation to intake of food. Although
Rymark et al did not demonstrate an
intergestational variation in the phar-
macokinetics of aspirin in the second
and third trimesters,1 the potential dif-
ference in the first trimester remains
unknown and will be worth exploring in
future pharmacokinetic studies. Simi-
larly, the optimal timing of aspirin
ingestion in relation to food intake re-
mains unclear, with a recent systematic
review demonstrating a lack of difference
in overall bioavailability.36 This, again, is
worth exploring in future pharmacoki-
netic studies.
In conclusion, the physiological
changes that occur in pregnancy alter the
pharmacokinetics of aspirin in preg-
nancy, suggesting the need for aspirin
dose adjustment in pregnancy. n
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6.1 Study overview 
Whilst the understanding on the prophylactic use of aspirin in preeclampsia prevention 
continues to improve, there remains the need to optimize the prescription and uptake of 
aspirin to maximize the observed risk reduction. The variable risk reduction with 
obstetric aspirin studies historically have been attributed to study heterogeneity with 
inconsistent dose, gestation of initiation of aspirin and risk stratification. Recent studies 
have better addressed these factors (38, 42, 70, 121, 125), however, the clinical burden 
of non-adherence with aspirin in pregnancy and its influence on the expected 
preeclampsia risk-reduction remains unclear. This is particularly important given that 
non-adherence to medications in pregnancy is reported to occur in 60-70% of women 
and is associated with poorer maternal and fetal outcomes (128, 129). 
 
This chapter of the thesis aimed to examine for; (1) the prevalence of aspirin non-
adherence amongst high-risk pregnant women and its influence on obstetric outcomes 
and (2) the correlation between quantitative and qualitative assessment of adherence 
with aspirin. HR women who were recruited into the longitudinal observational cohort 
study (Chapter 2.1) underwent both quantitative and qualitative assessment of 
adherence, in the form of PFA-100 and plasma SA assessment (Chapter 2.4.2) and self-
reported assessment (Chapter 2.4.1) respectively.  
 
6.2 Summary of key findings 
Of the 220 high-risk women recruited, no women were aspirin resistant and 63 (44%) 
women demonstrated inadequate adherence of <90% (101). Adjusted logistic regression 
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analysis demonstrated that women with inadequate adherence (<90% adherence) had 
higher incidence of early-onset preeclampsia (17% vs 2%) (OR=1.9; 95% CI 1.1-
8.7;p=0.04), late-onset preeclampsia (41% vs 5%)(OR=4.2; 95% CI 1.4-19.8;p=0.04), 
IUGR (29% vs 5%)(OR=5.8; 95% CI 1.2-8.3;p=0.001), preterm delivery (27% vs 
10%)(OR=5.2; 95% CI 1.5-8.7;p=0.008) and higher likelihood of increase in 
antihypertensives antenatally (60% vs 10%)(OR=4.6; 95% CI 1.2-10.5;p=0.003)(101). 
Kaplan-Meier analysis demonstrated a lower incidence of premature delivery with a 
longer duration pregnancy (HR=0.3; 95% CI 0.2-0.5;p<0.001)( Figure 18)  in the adherent 
group (101).  
 
 
Figure 18: Kaplan-Meier analysis of preterm delivery between all three groups of 
analysis. 
Adapted from Shanmugalingam et al. Clinical influence of nonadherence with prophylactic 
aspirin in preventing preeclampsia in high-risk pregnancies: a multicenter, prospective, 
observational cohort study. Hypertension, 75, 1125–1132 (2020). 
CLINICAL AND PROTEIN CORRELATIONS OF PROPHYLACTIC TREATMENTS FOR PREECLAMPSIA 
 
  Page 98 of 137 
 
 
Obstetric outcomes were also compared between the non-aspirin control group (non-
aspirin group) and the group with inadequate adherence, where adherence was treated 
as an ordinal (<30% vs 31-60% vs 61-89% adherence) rather than dichotomous variable. 
Analysis comparing the four groups did not demonstrate any difference in the examined 
obstetric outcomes (101). An analysis between both methods of adherence assessment 
(quantitative; biochemical assessment and qualitative; self-reported adherence) 
demonstrated only a moderate agreement with ƙ=0.48, SE=0.029, p<0.0001(101).  
 
Nine women who were commenced on aspirin after 16 weeks of gestation (between 16+1 
and 20+0 weeks of gestation) were excluded for the purpose of the main analysis. 
However, a descriptive sub-analysis of these women demonstrated that 6 women (67%) 
met adherence criteria and of these 6 women, 2 developed late onset preeclampsia and 3 
developed early onset preeclampsia despite being adherent, indicating the importance of 




Aspirin commenced after 
16 weeks gestation & 
adherence criteria met 
(n=6) 
Aspirin commenced 
before 16 weeks of 
gestation & adherence 
criteria met (n=82) 
Early onset preeclampsia 3 (50%) 2(2%) 




Preterm delivery  3(50%) 8(10%) 
Table 8: Clinical outcomes in high-risk women who were commenced on aspirin after 16 
weeks of gestation (between 16+1 and 20+0 weeks of gestation) 
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6.3 Strengths and limitations of this study 
This study is novel in assessing for obstetric outcomes in a multi-centre, demographically 
diverse, cohort of high-risk pregnant women based on a reliable quantitative assessment 
of adherence with aspirin. Additionally, this study also assessed the clinical impact of 
intermittent adherence on obstetric outcome and agreement between quantitative and 
self-reported adherence with aspirin.  
 
Limitations of this study include the variation in aspirin doses. In the aspirin adherent 
group, 72% of women were on 100 mg and 28% were on 150 mg of aspirin. This variation 
is due to the change in evidence during the period of this study (29). There was no cross 
over in dose taken by any woman. Given the small numbers of women in each subgroup, 
an analysis to compare obstetric outcomes between the two doses was underpowered 
and could not be performed. There was, however, no observed difference in maternal or 
fetal complications with both doses of aspirin (101) . This study did not assess for 
reliability of semi-qualitative method of adherence which is occasionally used in obstetric 
and non-obstetric studies. Another limitation is the exclusion of women of non-English 
speaking background. Language barrier has been shown to influence adherence with 
medications in non-obstetric studies (130)  and, therefore, further studies examining the 
relationship between language and adherence as assessed by semi-qualitative and 
quantitative methods in obstetric studies would be beneficial. 
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6.4 Conclusions 
The data observed is in keeping with the current literature in supporting the prophylactic 
effect of aspirin with an absolute risk reduction of preeclampsia of 51%(NNT=2) in a 
high-risk cohort, but only where adherence was ≥90%. Women who were prescribed but 
<90% aspirin adherent, had a higher rate of preeclampsia, IUGR, delivery before 37 
weeks of gestation and increase in antihypertensive requirements in pregnancy. This 
study also demonstrates that self-reported adherence does not accurately reflect actual 
adherence with only moderate agreement between both methods of assessment. Recent 
obstetric aspirin meta-analyses have shown the importance of initiating aspirin before 
16 weeks of gestation. The sub-analysis described in section 6.2 demonstrated similar 
findings despite adequate adherence with aspirin (Table 8). 
 
This study demonstrated the high, and often underrecognized prevalence of aspirin non-
adherence amongst high-risk women and the significance of inadequate adherence on the 
desired preeclampsia risk reduction. This, therefore, highlights the importance of 
assessing for adherence to aspirin through a validated and reliable method in both 
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CHAPTER 7. SCHOLARLY RESEARCH PAPER 4: FACTORS THAT INFLUENCE ADHERENCE WITH ASPIRIN AMONG HIGH-
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7.1 Study overview 
Non-adherence to medications in pregnancy is increasingly recognized and results in 
higher rates of potentially preventable maternal and fetal morbidity and mortality (129). 
The study described in Chapter 6 demonstrated that 44% of the high-risk pregnant 
women in the longitudinal cohort study were not adequately adherent with prophylactic 
aspirin. Consequently, this was associated with a higher incidence of preeclampsia, 
preterm delivery and intrauterine growth restriction (101). The factors that influences 
adherence to aspirin in pregnancy, from the women’s perspective, remain poorly studied 
and understood.  
 
This chapter of the thesis aimed to examine for the factors, from the women’s perspective, 
that influenced adherence with prophylactic aspirin in their pregnancy. A sequential-
exploratory designed mixed methods study involving a quantitative (n=122) and 
qualitative (n=6) survey was conducted. Women recruited in the longitudinal cohort 
study (Chapter 3 and Chapter 6) (101) were invited to participate in an electronic 
anonymous quantitative study and face-to-face  qualitative interview as described in 
Chapter 2.5. 
 
7.2 Summary of key findings 
The study identified factors that both positively and negatively influenced adherence to 
aspirin amongst high-risk pregnant women. Two key themes, from the women’s 
perspective, that influenced adherence to aspirin in pregnancy were; (1) pill burden and 
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non-intention omission (2) communication and relationship with their health care 
provider (HCP) (Figure 17)(131).  
 
 
Figure 19: Patient reported factors that influenced adherence with aspirin in pregnancy. 
* indicates factors that statistically correlated with adherence 
 
Pill burden and its associated non-intentional omission both strongly correlated with 
reduced adherence (Φ=0.8, p=0.02,Φ=0.8, p<0.01) whilst the use of reminder strategies 
were found to strongly minimize accidental omission and improve adherence (Φ=0.9, 
p<0.01)(131).  Consistent communication amongst HCPs and good patient-HCP 
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relationship were found to correlate with improved adherence (Φ=0.7, p=0.04, Φ=0.9, 
p=<0.01) and were found to play an important role in alleviating factors that had 
potentials to negatively influence adherence to aspirin in pregnancy (131). The findings 
of this study highlights the importance in recognizing the impact of pill burden in 
pregnancy and the need to counsel women on the utility of reminder strategies to 
minimize non-intentional omission. This study also emphasizes the importance a positive 
patient-HCP relationship through effective and consistent communication to achieve 
better maternal and fetal outcomes in high-risk pregnancies. 
 
7.3 Strengths and limitations of this study 
At the time of this thesis, a mixed methods study in analysing factors that influences 
adherence to aspirin in pregnancy, from a patient’s perspective had never been 
undertaken. Additionally, the patient population in this study consist of women from a   
multicultural background with variation in education and socio-economic background.  
 
This study, however, has several limitations. Given the nature of both the quantitative 
and qualitative study, non-English speaking women were excluded given the inability to 
access multilingual translational service for research. However, language barrier has 
been significantly demonstrated as a factor that influences adherence mainly due 
breakdown in communication (130). This is often overcome with the use of a medical 
interpreter, however, the use of an interpreter may hamper forming a therapeutic 
relationship with HCPs and reduce the potential for patients to discuss their concerns 
(132). Additionally, studies using electronic questionnaires carry a risk of selection bias 
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towards the more literate population. Further mixed methodology analysis on the 
influence of medical literacy and language barrier, particularly in the migrant population 
will be instrumental. This study may also be confounded by recall bias given that women 
participated, on an average of 12.4 (± 7.4) months post-partum in the qualitative study, 
and 14.8 (± 2.8 months) post-partum in the quantitative study. Whilst it would have been 
ideal to unblind the participant’s adherence in the quantitative study, women were 
allowed to participate in the quantitative study anonymously to allow and encourage 
them to provide honest and unbiased response to better understand their experience on 
the use of aspirin in pregnancy.  
 
7.4 Conclusion 
This study demonstrates factors within two themes that influences the use of aspirin 
amongst high-risk pregnant women; (1) pill burden and accidental omission (2) 
communication and relationship with HCPs. It highlights the need for clinicians to be 
aware of the consequences of pill burden in pregnancy and the importance of counselling 
patients on the utility of reminder strategies whilst applying repeated re-enforcement to 
minimize non-intentional omission of essential medications. This study also 
demonstrates the need for HCPs to recognize the importance of building a positive 
relationship with their patients to achieve the desired maternal and fetal outcomes. 
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Non-adherence with medications in pregnancy is increasingly recognized and often results
in a higher rate of preventable maternal and fetal morbidity and mortality. Non-adherence
with prophylactic aspirin amongst high-risk pregnant women is associated with higher inci-
dence of preeclampsia, preterm delivery and intrauterine growth restriction. Yet, the factors
that influences adherence with aspirin in pregnancy, from the women’s perspective, remains
poorly understood.
Objective
The study is aimed at understanding the factors, from the women’s perspective, that influ-
enced adherence with prophylactic aspirin in their pregnancy.
Study design
A sequential-exploratory designed mixed methods quantitative (n = 122) and qualitative (n =
6) survey of women with recent high-risk pregnancy necessitating antenatal prophylactic
aspirin was utilized. Women recruited underwent their antenatal care in one of three high-
risk pregnancy clinics within the South Western Sydney Local Health District, Australia. The
quantitative study was done through an electronic anonymous survey and the qualitative
study was conducted through a face-to-face interview. Data obtained was analysed against
women’s adherence with aspirin utilizing phi correlation (φ) with significance set at <0.05.
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Results
Two key themes, from the women’s perspective, that influenced their adherence with aspirin
in pregnancy were identified; (1) pill burden and non-intention omission (2) communication
and relationship with health care provider (HCP). Pill burden and its associated non-inten-
tional omission, both strongly corelated with reduced adherence (Φ = 0.8, p = 0.02, Φ = 0.8,
p<0.01) whilst the use of reminder strategies minimized accidental omission and improved
adherence (Φ = 0.9, p<0.01). Consistent communication between HCPs and a good
patient-HCP relationship was strongly associated with improved adherence (Φ = 0.7, p =
0.04,Φ = 0.9, p = <0.01) and more importantly was found to play an important role in allevi-
ating factors that had potentials to negatively influence adherence with aspirin in pregnancy.
Conclusion
This study identified factors that both positively and negatively influenced adherence with
aspirin amongst high-risk pregnant women. Is highlights the importance in recognizing the
impact of pill burden in pregnancy and the need to counsel women on the utility of reminder
strategies to minimize non-intentional omission. Importantly, it emphasizes on the impor-
tance of a positive patient-HCP relationship through effective and consistent communication
to achieve the desired maternal and fetal outcomes.
Introduction
Medication adherence in a health care setting is defined as the extent to which an individual
takes medications and executes lifestyle changes in accordance to the recommendations from
a health care provider [1, 2]. Non-adherence with medications, either by delayed or omitted
doses, is reported in up to 50% of non-pregnant patients with chronic illness [3, 4] and is asso-
ciated with higher morbidity and mortality [2, 4]. Non-adherence to medications during preg-
nancy is reported to occur in 40–60% patients and is associated with both significant maternal
and fetal co-morbidities [5–7]. Pregnant women view prescribed medications differently and
adherence with medications has been found to vary with the state of disease in pregnancy,
uncertainty of the benefit of the medication, expected side effects and fear of teratogenic effects
of medications [8–10]. This issue is particularly prominent with the use of prophylactic and
maintenance therapy in managing maternal comorbidities, especially when the acuity of the
maternal medical issue is not present [5, 11, 12].
Prophylactic use of aspirin is recommended in women who are at risk of developing pre-
eclampsia and has been shown to have a risk reduction of 60–80% [13–15]. However, recent
data suggest that the prophylactic benefit is best observed with�90% adherence with aspirin
[16]. The problem, however, lies in adherence with aspirin therapy in pregnancy [17–19]. Our
observational cohort study, which assessed for adherence quantitatively through plasma sali-
cyclic acid detection and platelet function analyser-100 (PFA-100) assessment, demonstrated
that 44% of high-risk women were <90% adherent with aspirin therapy [20]. Women with
inadequate adherence demonstrated aa higher rate of both early and late onset preeclampsia
with a higher rate of intrauterine fetal growth restriction (IUGR) and preterm delivery in com-
parison to women who were�90% adherent with aspirin therapy [20, 21]. This demonstrated
that non-adherence to prophylactic aspirin increases the risk of potentially avoidable maternal
and fetal complications in pregnancy.
Patient reported factors that influences aspirin adherence in pregnancy
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Multiple factors are known to contribute towards both intentional and non-intentional
non-adherence with medications in pregnancy [9, 10, 22]. However, an assessment on influen-
cers of non-adherence, particularly with the use of prophylactic aspirin in pregnancy, has not
been undertaken. Our study was aimed at examining the factors, from a patient’s perspective,
that influences adherence with prophylactic aspirin in pregnancy and identifying factors that
may enhance adherence and thus improve pregnancy outcomes.
Method
We utilized an sequential-exploratory designed mixed methods approach, combining both
quantitative and qualitative analysis [23]. Ethics approval for this study was obtained from the
Ethics and Research Committee of South Western Sydney Local Health District NSW, Austra-
lia (HE 16/184). Women provided written informed consent to participate.
High-risk pregnant women who were on aspirin as part of a multi-centre longitudinal
cohort study [20] within the South Western Sydney Local Health District (SWSLHD), NSW,
Australia, were invited to participate in an online survey (SurveyMonkey1). Women included
in this study were risk stratified as high-risk for preeclampsia based on the current guidelines
[24, 25] and were prescribed aspirin (100mgs or 150mgs) by their treating clinicians. Women
who were of non-English speaking background and who were unable to provide written
informed consent were excluded.
Electronic invitations, via email, were sent out to 154 women, from October 2018 –June
2019, to participate in this anonymous, non-compulsory survey that consisted mainly of multi-
choice responses with additional free text boxes for additional responses. As part of the quanti-
tative questionnaire, women were required to specify the extend of adherence (self-reported)
with prescribed aspirin during their recent pregnancy. Anonymous response was utilized to
facilitate honest and non-biased responses. Questions for the quantitative study were gener-
ated based on the validated adherence barrier questionnaire (ABQ) [26] and factors that are
known to influence adherence with medications in pregnancy (S1 Table) [27, 28].
Women were also invited to express their interest in participating in a one-to-one, face-to-
face interview for the qualitative assessment. Purposeful selection of the interview participants
was done based on the participant’s obstetric history and biochemically observed adherence to
aspirin [20, 21] to gain maximum variation in the sample. The qualitative study was designed
based on the quantitative data with the aim of further exploring the data obtain. Open ended
questions for the qualitative interview were generated based on the current literature on medi-
cation adherence in pregnancy in addition to the data obtained from the quantitative survey
(S2 Table). The semi-structured interviews were conducted by a single experienced co-investi-
gator who was not involved with the clinical care of these women during their pregnancy. The
interviews were conducted on an average of 12 months post-partum and were audio-recorded
with short key notes taken during interviews to allow for member checking at the end of the
interview. Participants were provided with a verbal summary of the interview and the opportu-
nity to request amendments to the interpretations. The duration of the interviews ranged from
45 to 75 minutes. Interviews were ceased at the point of data saturation, which was set at the
point at which no new data emerged from interviews.
Adherence for the purposes of the later thematic analysis was defined based on graded self-
reported adherence with aspirin of�90% for the duration of the pregnancy as specified in the
quantitative survey. A value of�90% was based on current data [16]. Audio recorded inter-
views were transcribed verbatim. No preconceived codes or categories were used. A six-stage
sequential qualitative analysis was undertaken in analysing the transcription with the use of
NVivo1 (v.12 QRS International Pty Ltd) [29]. Transcripts were re-coded by a second
Patient reported factors that influences aspirin adherence in pregnancy
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investigator to ensure agreement. Results of the quantitative and qualitative studies were com-
bined through a process of triangulation that enabled the investigators to connect and inter-
pret both data sets simultaneously through convergence and corroboration with the use of
NVivo1 [30, 31]. Phi correlation(φ) of data was done through SPSS (v.25 Chicago, IL, USA).
Data was analysed using the appropriate test based on the data distribution and statistical sig-
nificance was set at 0.05. A φ value of 0.7–1 is representative of a strong correlation, 0.3–0.69
of a moderate correlation and values of<0.3 are representative of a weak correlation.
Results
Of the 154 invitations sent out, 122 women (79%) completed the survey. Thirty-six women
expressed interest in participating in the qualitative study, of whom, 18 were identified
through purposeful selection to attend the interviews that were conducted at Liverpool Hospi-
tal, NSW, Australia. Interviews were ceased at point of qualitative data saturation which was
achieved after the sixth interview. Three of these 6 women in the qualitative study were noted
to have>90% adherence in the longitudinal study [20] with<90% adherence in the remaining
three women. Characteristics of the women invited to participate in the quantitative study and
those in the qualitative study are described in Tables 1 and 2 respectively. The quantitative sur-
vey demonstrated that 65 (53%) of the women reported�90% adherence with aspirin in their
pregnancy.
Table 1. Characteristics of participants invited to participate in quantitative study (�).
Characteristics Quantitative study invitations (n = 154)
Age (years) �� 33 (± 5.6)
Duration in months since delivery (months)�� 12.4 (± 7.4)
Primigravity 28 (17%)
Secondary education level 19 (12%)
Tertiary education level (Higher and Vocational) 135 (88%)
Smoking in pregnancy 8 (5%)
Ethnicity
Caucasian 78 (51%)
Middle Eastern 24 (16%)
South Asian 22 (14%)
South East Asian 19 (12%)
African 6 (4%)
Polynesian 3 (2%)
Australian Aboriginal 2 (1%)
Indication for aspirin in most recent pregnancy§
Chronic hypertension 90 (53%)
Previous pre-eclampsia 74 (44%)
Renal disease 35 (21%)
Type 1 or Type 2 Diabetes 13 (8%)
Based on first trimester screening only 8 (5%)
Systemic lupus erythematoses 5 (3%)
Anonymously self-reported adherence of�90% with aspirin 65 (53%)#
�Given the anonymous nature of this survey the characteristics of the women who participated (79% of total women
invited) could not be isolated. Presented here are the characteristics of all women invited to participate except for #,
which is based on the response from women who participated in the survey.
��Mean with standard deviation (± SD). §Some women had more than one medical condition.
https://doi.org/10.1371/journal.pone.0229622.t001
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Based on the combined analysis, we identified factors that influenced women’s adherence
with aspirin therapy in pregnancy. Results are present thematically: (1) Pill burden and non-
intentional omission (2) Communication and relationship with health care providers (HCPs)
(Table 3)
Pill burden and non-intentional omission: “I had so many pills and aspirin
was another pill..it was a struggle”
On average, women in our study were on 3.5 (range 2–6) medications at any one time in their
pregnancy with repeated dosing over 24 hours (average: 12 hourly). Of the women who missed
Table 2. Characteristics of participants in qualitative study.
Characteristics Qualitative study participants (n = 6)
Age (years)� 30.3 (±3.7)
Duration since delivery (months)� 14.8 (±2.5)
Primigravity 1 (17%)
Secondary education level 2 (33%)
Tertiary education level (Higher and Vocational) 4 (67%)
Smoking in pregnancy 0 (0%)
Ethnicity
Caucasian 4 (67%)
South Asian 1 (17%)
Middle Eastern 1 (17%)
Indication for aspirin in pregnancy��
Chronic hypertension 2 (33%)
Type 1 or Type 2 Diabetes 1 (17%)
Renal disease 1 (17%)
Previous pre-eclampsia 4 (67%)
�Mean with standard deviation (±SD).
�� Some women had more than one medical condition.
https://doi.org/10.1371/journal.pone.0229622.t002
Table 3. Summary of factors that influenced adherence with prophylactic aspirin.
Themes Factors Effect on adherence with
aspirin
P value�
Pill burden and non-intentional omission Pill burden Reduced F = 0.8,
p = 0.02
Non-intentional omission Reduced F = 0.8,
p<0.01
Strategizes to minimize non-intentional
omission
Improved F = 0.9,
p<0.01
Communication and relationship with Health Care Providers
(HCPs)
Consistent messaging between HCPs Improved F = 0.7,
p = 0.04
Repeated re-enforcement by HCPs Improved F = 0.8,
p = 0.02
Influence of social media and women support
group
Improved F = 0.7,
p = 0.03
Positive relationship with HCPs Improved F = 0.9,
p<0.01
�Based on phi coefficient relationship (φ)
https://doi.org/10.1371/journal.pone.0229622.t003
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more than 1 dose of aspirin (<90% adherent) in pregnancy, 42 (74%) reported pill burden as
an issue (φ = 0.8, p = 0.02) and this was associated with a higher rate of patient reported non-
intentional omission of aspirin (φ = 0.8, p<0.01). This was further evident in the qualitative
data where women who reported non-intentional omission were on an average of 6 pills a day
in comparison to women with good adherence with aspirin (average of 2 pills a day):
“I was taking lots of other vitamins and things, so yeah, I don’t think I fully grasped how
important it was to take aspirin every day. It was definitely not something I prioritized. I didn’t
like taking medications in general. I feel like there was a lot towards the end. I got a little bit hys-
terical.” (Interview participant 1, aspirin non-adherent group, 29 yo)
“To be honest with you, I was taking a lot. There was a time where I was taking eight per day; that
included things like Elevit, Vitamin D, my blood pressure medication and aspirin, yeah, so a lot. I had
to take my diabetic medication, Aspirin, Macrolide, Folate and Vitamin D and Calcium so yeah it
was hard to keep track of all of it.” (Interview participant 4, aspirin non-adherent group, 32 yo)
Non-intentional omission was also strongly related to difficulty with taking aspirin at night
as instructed by their doctor in 20 (35%) of women (φ = 0.8, p<0.01). The qualitative study
further indicated that the need to adhere to specified timing of aspirin ingestion (bedtime dos-
ing), along with pill burden was associated with increased non-intentional omission of aspirin:
“I had all my medications besides my diabetes medication and aspirin cause I had to take that
at specific times especially at night. When I got into bed and forgot to take all my medications, I
went ‘I’m not getting back out of bed. I’m exhausted. Yeah I’m in bed for the night now. I know
later on I’m going to get out of bed a million times. No I’m not getting out just to take medica-
tion’.” (Interview participant 4, aspirin non-adherent group, 32 yo)
A total of 65 (53%) women reported good adherence with aspirin either with no omission
45(37%) or only 1 omitted dose 20(16%) through the duration of their pregnancy. The strate-
gies utilized to minimize accidental omission included the use of a mobile phone reminder
application in 42(65%), pill box in 19(29%) and a medication routine 9(14%). The use of these
strategies strongly correlated with aspirin adherence (φ = 0.9, p<0.01) and was supported by
the qualitative responses in which women elaborated on the reminder strategies they utilized
to overcome issues in relation to bedtime dosing of aspirin:
“I had a reminder strategy. So usually I would take it when I brush my teeth, as a reminder.
So I just made sure that they were there and when I went to brush my teeth, I would see it and
take it.” (Interview participant 3, aspirin adherent group, 34 yo)
“I put all my medications in my room in my drawer so I knew when I went to bed I pulled out
the drawer and get all my medications out ready and yeah go to bed. I knew where all my medi-
cation was, and I had to take it.” (Interview participant 6, aspirin adherent group, 30 yo)
Therefore, whilst pill burden and non-intentional omission of medications were key factors
that negatively influenced adherence, the use of reminder strategies was an effective influencer
in overcoming this.
Communication and relationship with Health Care Providers (HCPs): “I
had a good rapport with my doctor early on which helped me trust the
healthcare system”
Consistent communication between the women’s HCP positively impacted their uptake of
aspirin. Most women, 101(83%), were first advised to take aspirin by their renal/obstetric phy-
sician, 33 (27%) by an obstetrician or midwives and 20 (16%) by general practitioners or based
on previous recommendation. Of these women, 59 (48%) discussed the use of aspirin with a
second HCP. Consistent message from HCPs on the indication of aspirin in pregnancy
strongly correlated to women’s uptake and adherence with aspirin (φ = 0.7, p = 0.04). The
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importance of consistent messaging and the negative impact of inconsistent messaging
between HCPs was evident through the qualitative data in which women elaborated on how to
information they obtained from multiple HCPs influenced their adherence with aspirin (both
positively and negatively):
“When I was told by the first doctor, I was still a bit sceptical and it’s only when I saw the sec-
ond and third doctor, it sunk in and I thought, it must be important as they are all saying the
same thing. It then made sense. It works well when doctors communicate the same thing, it gives
us confidence.” (Interview participant 2, aspirin adherent group, 34 yo)
“The chemist told me that I should not take aspirin while I was pregnant despite my doctor's
advice. This made my husband very concerned and discouraged me from taking the aspirin
(Interview participant 1, aspirin non-adherent group, 29 yo)
Additionally, 52(43%) of women reported that repeated re-enforcement on adherence with
aspirin by HCPs emphasized on its importance. This strongly correlated with adherence (φ =
0.8, p = 0.02) and was supported by the qualitative data:
“I remember my doctor saying not to forget to take my medications, especially the aspirin, so
actually I do recall her saying that to me and made it think it must be important for her to say
that.” (Interview participant 6, aspirin adherent group, 30 yo)
Communication on the use of aspirin in pregnancy with other high-risk women via social
media and forums was found to strongly correlate with uptake and adherence with aspirin in
33(27%) of women (φ = 0.7, p = 0.03). This was also evident in the qualitative data in which
these women elaborated on the positive impact of social media in reassuring them on the use
of aspirin in pregnancy:
“Speaking to other women that have been through it (preeclampsia) and that are going
through it–you know finding friends who are on or who have taken aspirin in pregnancy, who
are going through similar things gave me comfort in taking it.” (Interview participant 6, aspirin
adherent group, 30 yo)
Women’s good relationship with their HCPs played an important role in alleviating factors
that had potentials to negatively influence adherence with aspirin in pregnancy. These factors
included inconsistent messaging among HCP, especially from pharmacist which was reported
in 36 (30%) of women, concerns regarding maternal and fetal side effects of aspirin 39 (32%)
and discouragement from family and friends 18 (15%). However, none of these factors signifi-
cantly correlated with adherence (φ = 0.1–0.4) as 111 (91%) of women reported having a good
relationship with their primary HCPs and were happy to discuss their concerns on the use of
aspirin in pregnancy (φ = 0.9, p<0.01). This was further corroborated by women who partici-
pated in the interviews:
“The chemist kept telling me that I should not take aspirin while I was pregnant despite my doc-
tor's advice. This made my husband and mother very concerned and they discouraged me from
taking the aspirin. My husband was unhappy and came with me to my appointment to talk about
this with my doctor. My doctor spent a lot of time to talk to us about it and put our mind at ease.
She also called the chemist after we left.” (Interview participant 6, aspirin adherent group,30 yo)
“My previous pregnancy was horrible because I never had that connection with my doctor. So
you know, there was a difference this time, the relationship that I had with my doctor made a
huge difference. They had time to listen and answer my question. I knew I was under better care.
I had trust in them.” (Interview participant 3, aspirin adherent group, 34)
Discussion
Our study identified two key themes, from a patient’s perspective, that influenced adherence
with prophylactic aspirin in pregnancy: 1) Pill burden and non-intentional omission and 2)
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Communication and positive relationship with HCPs (Table 3). We previously demonstrated
that, from the women’s demographic characteristic perspective, women who had previous pre-
eclampsia and tertiary level education had a higher rate of adherence with aspirin [20, 21].
Pill burden and non-intentional omission of medications are commonly associated with
non-adherence in both pregnant and non-pregnant patients [2, 5, 25]. Our study demon-
strated that these two factors were strongly correlated with suboptimal aspirin adherence, par-
ticularly when women were put on a bedtime regimen. In keeping with this, other studies have
described restrictions around dosing requirements such as ‘take with food’, ‘take with an
empty stomach’, ‘take away from other medications’ and ‘take at night’ as common contribut-
ing factors towards non-intentional medication omission [32, 33]. However, the use of elec-
tronic reminders and pill boxes as reminders has been shown to minimize accidental
medication omission [34] and improve adherence [22]. Our study, similarly, demonstrated a
strong positive correlation between the use of reminder strategies and adherence with aspirin
therapy that can be used to overcome non-intentional omission with bedtime aspirin, particu-
lar given the growing recommendation for bedtime aspirin [13, 32].
Importantly, our study reflects the importance of communication and a positive relation-
ship between the woman and her HCPs in achieving the desired level of aspirin adherence and
clinical outcomes. Pregnant women view the use of medications in pregnancy differently com-
pared to when they are not pregnant. They often question the need for medication in preg-
nancy, mainly due to concerns over potential teratogenic effects [8, 9]. Therefore,
unsurprisingly, a woman’s understanding of the need for her medications influences her atti-
tude towards the adherence in pregnancy and this is directly influenced by the way the need
for the medication was communicated by her HCP [8]. Specific to this study, the importance
of effective communication between HCPs and patients in discussing the need for aspirin and
to discuss concerns regarding its use, was evident. The current literature supports the impor-
tance of a strong therapeutic relationship and trust in HCPs and patient’s behaviour towards
therapy [33, 34]. This relationship is often found to be closely related to the clinician’s interper-
sonal skill, ability to provide clear explanation of correlation between therapy and disease, abil-
ity to inspire patient’s trust and adequately address patient’s concerns [35–38]. In our study,
the relationship and interaction between the women and their HCP not only helped them
understand the need for aspirin but also allowed for discussions on their concerns with regards
to the use of aspirin and provide them with assurance, allowing for an improvement with
adherence with prophylactic aspirin.
Similarly, re-enforcing the importance of medications and checking for adherence with
therapy have been also shown to improve patient’s adherence [37] and in keeping with the lit-
erature, women in our study resonated this association. Additionally, the use of social media
as a domain of support network with other women has been shown to provide reassurance
and help improve women’s understanding on the need for therapy in pregnancy [39, 40]. This
has been shown to improve adherence with the recommended therapy in pregnancy [39]. In
keeping with this, our study demonstrated a positive influence of social media and support
group in facilitating adherence with aspirin in pregnancy.
To our knowledge, a mixed method study in analysing factors that influences adherence
with aspirin in pregnancy, from a patient’s perspective has never been undertaken, hence,
making this a novel study. Additionally, our patient population is vastly multicultural (Tables
1 and 2) with variation in education and socio-economic background. Our study, however,
consist of a few limitations. Given the nature of both the quantitative and qualitative study, we
excluded non-English speaking women given the inability to access a multilingual translational
service for research. However, language barrier has been significantly demonstrated as a factor
that influences adherence mainly due breakdown in communication [41]. This is often
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overcome with the use of a medical interpreter, however, the use of an interpreter may hamper
forming a therapeutic relationship with HCPs and reduce the potential for patients to discuss
their concerns [42]. Additionally, studies using electronic questionnaires carries a risk of selec-
tion bias towards the more literate population. Further mixed methodology analysis on the
influence of medical literacy and language barrier, particularly in the migrant population will
be instrumental. Our data may also be confounded by re-call bias given that the women partic-
ipated with an average of 12.4 (± 7.4) months post-partum in the qualitative study and 14.8 (±
2.8 months) post-partum in the quantitative study. Additionally, whist it would have been
ideal to unblind the participants in the quantitative study to use their data against their estab-
lished biochemical evidence of adherence with aspirin from our longitudinal cohort study
[20], we chose to allow for women to participate in the quantitative study anonymously to
allow and encourage them to provide honest and unbiased response to better understand their
experience on the use of aspirin in pregnancy. In doing so, we found that women’s self-
reported adherence in this study matched what we observed biochemically in the longitudinal
study. A non-anonymous patient-reported adherence assessment which we conducted as part
of the longitudinal study however demonstrated that patient-reported adherence (in a non-
anonymous form of qualitative assessment) only moderately correlated with their actual bio-
chemical adherence, therefore indicating that patient-reported adherence is likely more accu-
rate in an anonymous setting.
Conclusion
Multiple clinical, psycho-social and health care related factors are known to influence adher-
ence in pregnancy. Our study demonstrates factors within two key themes that influences the
use of aspirin in the prevention of preeclampsia amongst high-risk pregnant women; (1) pill
burden and accidental omission (2) communication and relationship with HCPs. It highlights
the need for clinicians to be aware of the consequence of pill burden in pregnancy and impor-
tance of counselling patients on the utility of reminder strategies whilst applying repeated re-
enforcement to minimize non-intentional omission of essential medications. Our study also
demonstrates the crucial need for HCPs to recognize the importance of building a positive
relationship with their patients through effective and consistent communication to achieve the
desired maternal and fetal outcomes in pregnancy.
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This thesis aimed to examine for a potential alternative mechanism of action of 
prophylactic aspirin, through the ATL pathway, in the prevention of preeclampsia 
(Scholarly research Paper 1, Chapter 4) and factors that are likely to influence the rate of 
risk reduction of preeclampsia with the use of aspirin. The two main aspirin factors of 
interest in this thesis were (1) aspirin dose (Scholarly research paper 2, Chapter 5) and 
(2) adherence to aspirin (Scholarly research paper 3, Chapter 6). Given the observations 
made relating to adherence (101), this thesis also examined for factors that both 
positively and negatively influenced adherence to prophylactic aspirin in pregnancy 
(Scholarly research paper 4, Chapter 7). This chapter will discuss the findings from this 
thesis and suggest future research to build on the results presented.  
 
The findings from this study will allow for an increase in interest on alternative 
mechanism by which aspirin may demonstrate its prophylactic benefit in preeclampsia 
and help optimize the clinical utility of aspirin in improving the risk reduction rate of 
preeclampsia. 
 
8.1 Mechanism of action of aspirin in the prevention of 
preeclampsia – an assessment of the ATL anti-inflammatory 
pathway 
To date, the mechanism by which aspirin prevents preeclampsia remains unclear. 
Regulation of the TXA/PGI2 ratio, with its resulting maternal anti-thrombotic effect has 
been previously proposed as a mechanism by which aspirin potentially reduces placental 
CLINICAL AND PROTEIN CORRELATIONS OF PROPHYLACTIC TREATMENTS FOR PREECLAMPSIA 
 
  Page 109 of 137 
 
dysfunction in the prevention of preeclampsia (47, 48). However, recent data on the lack 
of benefit of aspirin when commenced after 16 weeks of gestation (42) and greater 
prophylactic on early onset preeclampsia in comparison to late onset preeclampsia (29) 
suggest other potential mechanisms of action of aspirin that are specific to placental 
development.  
 
In examining the potential anti-inflammatory effect of aspirin on placental development, 
this thesis examined the influence of ATL on selected maternal cytokines (IL-10, 1L-8, 
TNF-α, IFN-γ and IL-1β) based on previous cell studies that examined the effect of ATL 
on placentation (67, 68). This work was undertaken by performing a longitudinal cohort 
study of high-risk pregnant women (Chapter 2.1 and Chapter 3). In exploring the 
influence of ATL, this thesis first examined for the difference in En-Lipoxin-A4, an 
endogenous anti-inflammatory lipoxin that is an epimer of ATL, between high-risk and 
low-risk pregnancy. Whilst studies have demonstrated an association between low 
maternal first trimester En-Lipoxin-A4 and placental dysfunction related fetal growth 
impairment (66), the study in Chapter 4 (Scholarly research paper 1) is novel in 
demonstrating a significantly lower En-Lipoxin-A4 concentration (of up to 70%) in high-
risk pregnancy compared to low-risk pregnancy (116). Further novel findings included 
demonstrating a significant detection of plasma ATL in the high-risk group in response to 
adequate adherence to aspirin (116). Additionally, a lower plasma concentration of IL-8 
from 12-36 weeks of gestation (p <0.001), TNF-α from 24-36 weeks of gestation (P=0.02) 
and an increase in IL-10 plasma concentration from 16 – 28 weeks of gestation (p=0.03) 
were observed in the aspirin adherent high-risk (HR-AA) group compared to the non-
aspirin high-risk  (HR-NA) group (116). 
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Chapter 4 of this thesis also described an observed sustained rise in maternal plasma 
PlGF concentration in the HR-AA group compared to the HR-NA group, even after aspirin 
was ceased between 34-36 weeks of gestation (Figure 12). Therefore, supporting the 
possibility  that the increased PlGF plasma concentration in the HR-AA group is likely a 
surrogate marker of better placentation with adequate adherence to aspirin (115). This 
work also demonstrated that high-risk women who did not develop preeclampsia had 
higher plasma PlGF concentrations compared to high-risk women who developed 
preeclampsia (Figure 13).  
 
Based on the observations of the studies in Chapter 4, adequate adherence with aspirin 
was found to demonstrate a significant elevation in plasma ATL concentration and was 
observed to be associated with lower plasma IL-8 and higher plasma IL-10 and PlGF 
concentrations. This also corresponded clinically, where high-risk women who did not 
develop preeclampsia were found to have higher plasma concentration of  PlGF, IL-10 
and ATL with lower plasma concentration of IL-8 in comparison to high-risk women who 
developed preeclampsia. These observations propose a potential anti-inflammatory 
effect of prophylactic aspirin through the ATL pathway in regulating maternal IL-8 and 
IL-10 plasma concentration. These effects, which were observed from when aspirin was 
commenced (before 16 weeks of gestation) is likely to have allowed for better 
placentation in these women, resulting in higher maternal plasma PlGF concentration, a 
surrogate marker for placentation. This study, however, proposes this mechanism though 
observational correlation only.  
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Further studies should focus on examining the hypothesis above with in-vitro placental 
models. Advancement at the time of this thesis, has seen the development of a human 
cytotrophoblast organoid (CTB-ORG) cultures that mimics the in-vivo structure of human 
placenta, express markers of trophoblast identity and secrete pregnancy hormones (133, 
134). This three dimensional (3D) culture is developed from purified first-trimester 
cytotrophoblast preparations that are capable of self-renewal and expansion under 
defined culture conditions and allows for a 3D analysis of cell column formation, growth, 
and differentiation (133, 135). The utility of this model in examining the direct effect of 
ATL on extravillous trophoblast (EVT) invasion along with the local cellular expression 
of IL-8, 1L-10, PlGF and invasive markers such as VCAM-1 and VE-cadherin will help build 
on the understanding of the observations made in this study. At the time of this thesis, 
access, both logistically and financially, to the 3D CTB-ORGs model was limited. However, 
its use in the study of placental development is likely to grow in the future and replace 
the currently used two dimensional (2D) in-vitro placenta models. 
 
8.2  Influence of aspirin dosing in pregnancy 
Chapter 5 of this thesis described a novel pharmacokinetic assessment of 100 mg and 150 
mg of aspirin in both pregnant and non-pregnant women through assessment of plasma 
SA  (Scholarly research paper 2) (125). A difference in pharmacokinetic between EC and 
non-EC aspirin was also examined. The study demonstrated a reduced AUC(t-24) and 
Cmax along with an increase in CL in pregnant women (for both 100 and 150mg of 
aspirin) compared to non-pregnant women (125). This, therefore, suggest possible 
increased clearance of aspirin’s active metabolite, SA, in pregnancy. The reduced AUC(t-
24) in pregnant women compared to non-pregnant women with the commonly 
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prescribed 100mg of aspirin, however, was overcome when the dose of aspirin in 
pregnant women was adjusted to 150 mg (Figure 17). Therefore, suggesting a potential 
need to dose adjust aspirin in pregnancy to achieve similar AUC(t-24) with 100mg of 
aspirin in non-pregnant women. This is likely due to the altered pharmacokinetics of 
aspirin in pregnancy. 
 
The pharmacokinetics of medications in pregnancy is influenced by the maternal 
physiological changes that occurs through all three trimesters of pregnancy. These 
changes lead to an alteration in absorption, distribution and elimination of commonly 
used medications in pregnancy (117, 118) (Figure 20).   
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In pregnancy, there is a progesterone driven delay in gastrointestinal motility which 
results in a 30% increase in gastric emptying time and an approximately 40% reduction 
in gastric acidity (136, 137). These changes can result in ionization of weak acids such as 
aspirin and could potentially affect its absorption. A stronger influence on the alteration 
of pharmacokinetics in pregnancy is the variation in drug distribution and elimination. 
The physiological plasma expansion of 50% in pregnancy often results in altered drug Vd 
and is most prominent towards the end of the first trimester (138, 139). The total mean 
increase in maternal body volume is approximately 8L and the resulting volume 
expansion results in a decrease in Cmax particularly of hydrophilic agents, such as SA. 
The increased circulating estrogen and progesterone in pregnancy can either increase or 
decrease hepatic metabolism of drugs based on its stimulatory or inhibitory influence on 
cytochrome P450 isoenzymes and uridine 5’-diphospho-glucuronosyltransferase 
isoenzyme activity (138, 140, 141). Glucuronidation activity may be a critical 
determinant of aspirin efficacy, however, the enzymes responsible for this conjugation 
have yet to be identified and characterized (142). Therefore, the influence of pregnancy 
on the hepatic metabolism of salicylic acid remains subject to further research.  
 
The relationship between increased creatinine clearance and drug excretion in 
pregnancy is well recognised and have been demonstrated through various studies, 
including this thesis which demonstrated a 45% increase in clearance of SA (138, 143, 
144).  Renal drug excretion is dependent on the glomerular filtration rate (GFR), tubular 
secretion and resorption. In pregnancy, GFR is increased by 50% from the first trimester 
and continues to increase until the last week of pregnancy (138, 145). Therefore, the 
clearance of drugs and metabolites that are renally excreted, such as salicyluric acid and 
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SA, are thought to parallel the change in GFR in pregnancy, hence leading to lower Cmax 
and AUC(t-24) as demonstrated in this thesis (146). Plasma protein binding of drugs is 
known to reduce in pregnancy due to reduced albumin concentration and estrogen-
induced reduced protein-binding of drugs (143, 147). Decreased protein binding 
increases the concentration of free drug and consequently increases the clearance of 
drugs and metabolites such as salicylates via increased renal clearance in pregnancy. The 
net effect of reduced protein binding, however, is potentially counterbalanced by 
increased renal clearance of drugs and metabolites like SA. 
 
When comparing the effect of preparation (EC vs non-EC aspirin) and chronotherapy, this 
thesis did not demonstrate a difference in overall AUC(t-24) between EC and non-EC and 
chronotherapy variation of aspirin (126). The study in Chapter 4 (Scholarly research 
article 1) demonstrated higher plasma concentration of ATL with the use of 150 mg of 
aspirin compared to 100 mg of aspirin (116), however this study was underpowered to 
make a meaningful comparison of plasma concentration of IL-8, IL-10 and PlGF between 
100mg and 150mg of aspirin (116).  The PFA-100 marker that was used as part of the 
two-point adherence assessment (Chapter 6, Scholarly research article 3), was unable to 
provide a quantitative assessment of the CT when the reading was >300 seconds. Given 
that a CT of >300 seconds was consistently observed in the group of women who were on 
150 mg of aspirin, the PFA-100 value was used as a qualitative assessment of adherence 
along with the plasma SA detection. However, an observational difference between the 
average PFA-100 with 100 mg (average CT of 233 seconds) and 150 mg (>300 seconds), 
suggest a potential difference in the degree of platelet aggregation inhibitory effect 
between both doses.  
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Whilst the pharmacokinetic findings of this study supports the emerging 
recommendation of 150 mg of aspirin in the prevention of preeclampsia, future studies 
should focus on examining for differences in pharmacodynamic and clinical effects when 
comparing 100 mg and 150 mg of aspirin. Pharmacodynamic studies through assessment 
of the effect of aspirin on either the COX-1, COX-2 or both pathways would be useful in 
addressing this question. The COX-1 pathway assessment could be assessed through the 
gold standard quantitative marker, light transmission aggregometry (LTA), however, this 
method requires laboratory expertise with internal and external standardisation (148). 
PFA-100 and PFA-200 have been widely used in accredited clinical laboratories, however, 
as observed in our study, quantitative measures are limited by the inability to quantify a 
CT beyond 300 seconds. Non-obstetric studies have utilized plasma TXB2 and 6-keto 
prostaglandin F 1-alpha (6-keto-PGF1α) in examining pharmacodynamics of aspirin 
(120), however, the sensitivity of these markers have previously found to be variable 
given its short and unstable half-life . More recently, Multiplate® impedance platelet 
aggregometry (IPA) analyzer has been used as a rapid, comprehensive and sensitive 
platelet function analyzer (149), and has emerged as a potential marker in studying 
pharmacodynamics of anti-platelet therapy (150, 151). At the time of this thesis, access 
to the Multiplate® IPA was limited, however, with its growing use, its utility in obstetric 
aspirin pharmacodynamic studies would be of interest. 
In addition to pharmacodynamic studies, future clinical studies, preferably undertaken 
as randomized controlled trials (RCT), directly comparing the rate of preeclampsia, IUGR 
and pre-term delivery between 100mg and 150mg of aspirin will be beneficial in 
answering the question on the optimal dose of aspirin in pregnancy. A RCT of this nature, 
with a large sample size, will also allow for an assessment of maternal and fetal risk of 
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harm with the use of 150 mg of aspirin, which has not been adequately documented in 
the literature at the time of this thesis  
 
8.3  Influence of adherence to aspirin in pregnancy and factors 
that influences adherence to aspirin 
The high prevalence of non-adherence to medications in pregnancy is well documented  
(128, 129), yet, the prevalence of non-adherence to prophylactic aspirin in pregnancy and 
its impact on obstetric outcomes remains poorly studied at the time of the thesis. The 
study in Chapter 6 (Scholarly research paper 3) demonstrated that 44% of the high-risk 
women in the longitudinal cohort study (Chapters 2.1 and 3) did not meet the two-point 
biochemical aspirin adherence criteria (101) . Inadequate adherence to aspirin was found 
to be associated with higher rates of preeclampsia, preterm delivery (Figure 18) and 
IUGR. This study also demonstrated that self-reported adherence, which is the commonly 
used qualitative assessment of adherence, only moderately correlated with biochemical 
verification of adherence. This study was novel in assessing for adherence with aspirin in 
a systematic two-point biochemical assessment and corresponding the observed 
adherence to clinical outcomes. This study also examined the correlation of self-reported 
adherence to biochemically verified adherence, providing evidence for the appropriate 
method of assessing adherence.  
 
In examining for factors that influenced adherence to aspirin in pregnancy, participants 
from the longitudinal cohort study (Chapters 2.1 and 3) were invited to participate in a 
mixed methods study (Chapter 7, Scholarly research paper 4) (131). This study identified 
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both positive and negative factors that influenced adherence to aspirin in pregnancy, with 
two main themes: (1) Pill burden and accidental omission and (2) communication and 
relationship with HCPs. The findings of this study highlights the need for HCP to be aware 
of the impact of pill burden and the importance of effective and consistent 
communication with patient in improving adherence. Inconsistent messaging on the need 
and safety of aspirin in pregnancy amongst various HCP was identified as a recurring 
issue in this study. In identifying this, the investigators of this study (Scholarly research 
paper 7) along with other clinicians in SWSLHD, are currently working on initiatives to 
improve the uptake of aspirin in pregnancy. This includes:  
 
1) An interventional, longitudinal cohort study on the effectiveness of aspirin and 
preeclampsia education and counselling 
 
2) Education initiatives for aspirin prescribing (obstetricians, endocrinologist, 
nephrologist and general practitioners) and dispensing(pharmacist) HCPs to 
increase awareness on the use of prophylactic aspirin and emphasize on the 
importance of consistent messaging. 
 
8.3.1 Effectiveness of aspirin and preeclampsia education and 
counselling 
Based on the literate on the effectiveness of patient information sheet and other 
measures to improve adherence (152, 153), the team of HCPs involved in this thesis have 
developed an aspirin information brochure and summarized handout to improve 
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women’s understanding on preeclampsia and the need for aspirin in pregnancy (Figures 
21). The team will conduct an interventional longitudinal cohort study to assess the 
effectiveness of aspirin and preeclampsia education and counselling in improving the rate 
of adherence to aspirin in pregnancy. Enrolled high-risk women will participate in an 
electronic survey to establish their baseline understanding of preeclampsia and 
prophylactic aspirin prior to their education session with the clinician. The women will 
then undergo a standardized education session (based on a checklist for the prescribing 
clinicians) to ensure that key counselling points are discussed at the time of initiation of 
aspirin (Table 9), along with distribution of the aspirin information brochure (Figures 
21).  
 
Participating women will then undergo a second electronic survey 2-3 weeks following 
the education session to assess for effectiveness of the education session and utility of the 
aspirin information brochure. The second electronic survey will include an assessment of 
women’s satisfaction with the education session and aspirin information brochure used. 
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Figure 21: Aspirin information brochure 
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Aspirin initiation counselling checklist 
o What is preeclampsia 
o Why is the patient at a higher risk of preeclampsia (specific to patient) 
o Evidence on the use of aspirin to reduce her risk of preeclampsia 
o How to take aspirin 
o Dose              
o Timing                 
o When to stop 
o Side effects 
o What to do if side effects occur 
o Importance of adherence 
o Strategies to reduce risk of accidental omission (pill box, electronic reminder)  
Table 9: Aspirin counselling checklist 
 
Concurrent biochemical adherence with aspirin, with PFA-100 and plasma SA detection 
as outlined in Chapter 6 will be conducted to assess for adherence to aspirin. The 
assessment of adherence in the SWSLHD cohort through these interventions will be 
compared against rate of adherence in the same cohort population without these 
interventions (Chapter 7). At the end of the study period, a quantitative assessment of 
clinician’s satisfaction with the counselling intervention will be conducted. 
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8.3.2  Education initiatives for Health Care Providers (HCP) 
The candidate of this thesis, along with the supervisors of this thesis, have conducted 
education sessions to HCPs at district and national level meetings and publications to 
increase awareness of the use of prophylactic aspirin in the prevention of preeclampsia. 
This includes: 
1) Prophylactic use of aspirin in the prevention of preeclampsia.  
Invited speaker at the Annual Scientific Meeting, Australian Diabetes in Pregnancy 
Society (ADIPS), Sydney 2019. 
R. Shanmugalingam 
 
2) Tackling pre-eclampsia: getting ahead of the game.  
Invited authorship for How To Treat Edition of Australian Doctors  
(General Practitioner (GP) Continuing professional development (CPD) article) 
2019. 
R. Shanmugalingam, A. Makris, A. Hennessy 
 
3) The use of prophylactic aspirin in high-risk women with pre-existing Diabetes. 
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4) Prophylactic use of aspirin in the prevention of preeclampsia. 
Invited speaker at the SWSLHD Department of Obstetrics and Gynaecology 
Meeting, Liverpool Hospital 2018, 2019 and 2020. 
R. Shanmugalingam and A. Makris 
 
5) Tackling preeclampsia: Getting ahead of the game 
Invited speaker at the SWSLHD General Practitioner (GP) CPD Education Meeting, 





1) CPD article on the use of prophylactic aspirin in the prevention of preeclampsia 
for Australian Journal of Pharmacy, targeting pharmacist 
R.Shanmugalingam, A.Hennessy, A.Makris (manuscript in preparation) 
 
2) Presentation at the SWSLHD Department of Renal Medicine Meeting, 2020 
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8.4 Conclusions 
Aspirin is an effective prophylactic intervention for preeclampsia when adequate 
adherence is observed. In addition to its anti-platelet effect, aspirin is likely to play 
a role in placental development through its ATL mediated anti-inflammatory 
effect in reducing one’s risk of preeclampsia. In optimizing the rate of risk 
reduction of preeclampsia with prophylactic aspirin, there may be a need to dose 
adjust aspirin in pregnancy given its altered pharmacokinetic in pregnancy. 
However, further pharmacodynamic and randomized controlled studies will be 
required to further assess this finding. Aspirin adherence should be assessed in 
clinical practice and future aspirin studies as adequate adherence plays an 
important role on the observed risk reduction of preeclampsia. The growing 
research interest on the use prophylactic aspirin along with the advances in in-
vitro placental models and platelet aggregation analysis will allow for a greater 
understanding on ways clinicians, globally, can utilize aspirin in successfully 
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